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Summary 
Malaria is a lethal disease caused by the Plasmodium parasite. The current 
arsenal of antimalarial therapies targets the parasite, thereby selecting for 
mutant, resistant parasites. New antimalarials are desperately needed and a 
potential clue for a new therapeutic strategy has been provided by so-called 
"natural genetic antimalarials". Host genetic changes to red cell genes have 
offered millennia of stable protection to individuals living in endemic 
regions. By imitating natural resistance, this thesis proposes novel host-
directed antimalarial pharmacologic therapies through the targeting of 
erythrocyte molecules required by the parasite for growth and survival. 
Work in this thesis investigated several enzymes from the haem 
biosynthetic pathway as potential targets for a host-directed therapy (HDT). 
Here, multiple experimental approaches were used to investigate and 
validate d-aminolevulinate dehydratase (ALAD), ferrochelatase (FECH) and 
uroporphyrinogen-III synthase (UROS) as targets for a novel host-directed 
antimalarial therapy. Firstly, it was demonstrated that host ALAD, FECH and 
UROS were localised in Plasmodium during intraerythrocytic growth. 
Moreover, the host enzymes were demonstrated to be required for normal 
parasite development as Plasmodium growth in vitro was impaired in UROS 
and FECH deficient red cells. This was shown using genetic models of 
human and mouse haem synthetic enzyme deficiency. 
Finally, the HDT strategy was validated with several inhibitors of ALAD and 
FECH demonstrating in vitro and in vivo anti-plasmodial activity. Host ALAD 
was specifically inhibited with succinylacetone (SA), a non-competitive 
irreversible ALAD inhibitor, demonstrating parasite growth inhibition in a 
P. Jalciparum in vitro assay with an ICso of 2.5 µM. The antimalarial activity 
of SA was also demonstrated in vivo with SA treated mice demonstrating a 
significant reduction in P. chabaudi infection and increased survival 
compared to untreated controls. 
The competitive FECH inhibitor N-methylprotoporphyrin (NMPP) 
demonstrated anti-plasmodial activity in vitro with an ICso of 25 nM, a figure 
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comparable with many current antimalarials today. Griseofulvin, a second 
FECH inhibitor, is an antifungal agent, approved for use for over 50 years 
with an anti-FECH side effect, mediated through NMPP. Griseofulvin 
inhibited P. falciparum growth in an in vitro growth inhibition assay, with an 
ICso between 10 and 50 µM on both chloroquine resistant and susceptible 
parasites. As griseofulvin is FDA and TGA-approved for human use, work in 
this thesis investigated parasite growth capacity in red cells from 
individuals taking pharmacologic doses of griseofulvin. It was demonstrated 
that griseofulvin concentrates in red cells and that parasites were unable to 
grow in red cells collected from human volunteers eight-hours after taking a 
clinically relevant dose of griseofulvin. Together, this data suggests that 
griseofulvin may be a useful antimalarial drug with a novel mode of action, 
potentially avoiding parasite resistance. 
Overall, work in this thesis has demonstrated that the parasite requires 
several host haem enzymes for growth and has provided proof-of-principle 
that targeting these enzymes as a HDT is a potentially effective antimalarial 
strategy. As griseofulvin is FDA and TGA approved for human use, it is quite 
possible that griseofulvin may be an "off the shelf' next generation 
antimalarial. The ultimate outcome from this work is a new generation of 
antimalarial therapies that may target the host and not the parasite, 
potentially limiting the development of drug resistance. 
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Chapter 1 
Introduction 
Summary 
The current arsenal of antimalarial treatments is losing the battle with 
parasite resistance. A new therapeutic paradigm that avoids parasite 
resistance is desperately needed. A clue for a resistance-proof antimalarial 
strategy has been provided by the numerous red cell mutations known to 
protect the host from severe malaria. Can we mimic these so-called natural 
"genetic antimalarials" as a new host directed therapeutic strategy? Work in 
this thesis investigates this question by targeting red cell enzymes required 
by the parasite in a strategy coined host directed therapy. Host directed 
therapy may be a resistance-proof therapeutic strategy as the target is 
outside of the cellular milieu and genetic control of the parasite. 
Malaria is a lethal disease with no easy solution 
Malaria is a disease caused by the protozoan parasite Plasmodium, which 
infects over 200 million people worldwide every year. Of these infections, the 
latest World Health Organisation (WHO) malaria report estimates that that 
over seven hundred thousand people die from the disease annually, mostly 
young children and pregnant women (WHO, 2011). Over 40% of the world 
population lives in at-risk areas. This includes nearly 100 countries with the 
highest prevalence in sub-Saharan Africa (Breman et al., 2006). Malaria also 
has a profound economic impact, having a severe effect of the gross domestic 
product in countries that are already burdened with poverty (Sachs and 
Malaney, 2002). 
Despite the number of currently available antimalarials, the outlook for 
eliminating malaria remains daunting. The WHO set the goal of eliminating 
malaria in 1946; a task that has dismally failed and studies have suggested 
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that, if unchecked, the number of malaria cases may double in the next 20 
years (Sachs and Malaney, 2002). The failure of the eradication of malaria is 
due in part, to a variety of socioeconomic factors in at-risk communities but 
is also exacerbated by the increasing parasite resistance towards all 
antimalarials (Gallup and Sachs, 2001). An additional concern is the limited 
number of novel antimalarial compounds making their way through the long 
and arduous pipeline of drug discovery and clinical trials. If we are to ever 
make inroads into not only treating but also overcoming this lethal disease, 
there needs to be a concerted effort in identifying compounds with novel 
modes of action that may avoid parasite resistance common to the current 
generation of antimalarials. 
Plasmodial species and lifecycle 
There are a variety of Plasmodium species that infect vertebrates including 
rodents, birds, reptiles and primates. Five species of Plasmodium infect 
humans; falciparum, vivax, malariae, ovale (which is now characterized as 
two separate species P. ovale curtisi and P. ovale wallikeri) (Liu et al., 2010, 
Sutherland et al., 2010). Also included is knowlesi, a strain infecting long-
tailed macaques but field data has shown naturally acquired human 
infections in Malaysian Borneo (Cox-Singh et al., 2008, Singh et al., 2004, 
Sutherland et al., 2010). All result in serious and sometimes life-threatening 
symptoms, but P. falciparum is the most lethal, accounting for the majority of 
deaths (Snow et al., 2005). 
The lifecycle of all Plasmodium species include stages of sexual and asexual 
reproduction in the female Anopheles mosquito and the human host 
respectively (Figure 1.1). 
2 
I 
0 Hepatic stage 
Liver 
. 0 Blood stage 
Gametocytes 
" t5' Trophozoite 
Figure 1.1 Lifecycle of Plasmodium. The lifecycle of Plasmodium in the 
human host is initiated upon the bite of a female Anopheles mosquito, 
releasing sporozoites that make their way to the liver. Infection in the human 
host is made up of the asymptomatic hepatic stage (A) and the clinical blood 
stage (B) before some merozoites differentiate into gametocytes that get 
taken back up by the Anopheles mosquito. Within the mosquito, the gametes 
combine, undergo meiosis and subsequently differentiate into new and 
genetically unique sporozoites capable of infecting other people, thereby 
continuing the lifecycle of the parasite. 
Illustration drawn by Andy Greth, Menzies Research Institute, 2010 
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Sporozoites residing in the salivary glands of the female mosquito are 
injected during feeding into subcutaneous tissue of the host (Lasonder et al., 
2008). The majority of sporozoites travel to the liver but work in rodent 
models of malaria demonstrated that a proportion of sporozoites remain in 
the skin and have the capability to form infective merozoites (Gueirard et al., 
2010). Sporozoites that follow the normal infection progression enter the 
circulation and make their way to the liver where they migrate through 
several cells before ultimately invading a hepatocyte, initiating the clinically 
silent stage of infection (Mota et al., 2002, Mota et al., 2001). Sporozoites 
subsequently undergo asexual schizogeny within a parasitophorous vacuole 
to form schizonts that can release up to several thousand merozoites into the 
host's circulation (Graewe et al., 2011). Evidence suggests the parasite 
modifies the host hepatocyte during its development to avoid detection by 
host immune cells. A specific death and detachment process is induced by the 
parasites allowing movement towards the liver sinusoids and into circulation 
(Sturm et al., 2006). The parasite reaches the circulation still enclosed in a 
vacuole of host origin, named the merosome, thereby escaping detection 
from the host immune system, until the merozoites are released and invade 
the host red cells (Graewe et al., 2011). 
Merozoites invade red cells where they undergo successive, synchronised 
rounds of intracellular asexual reproduction and merozoite release, causing 
the characteristic periodic fevers that are a classic symptom of the disease 
(Hill, 2006). Merozoite invasion is a multi-step process including initial 
recognition, attachment and the formation of a tight or moving junction 
between the apical end of the merozoite and the red cell membrane (Richard 
et al., 2010). A parasite actin-myosin motor powers a series of events that 
include the movement of the moving junction from the apical to the posterior 
end of the parasite. This process is facilitated through several parasite-
derived proteins including rhoptry neck protein (RON) 2 and the apical 
membrane antigen 1 (AMAl), which form a complex (Tonkin et al., 2011). A 
parasitophorous vacuole (PV) is formed as the parasites traverse into the 
host red cell cytoplasm (Aikawa et al., 1978). 
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Once inside a red cell, the parasite develops through several stages, namely a 
ring stage, a larger trophozoite stage and a schizont stage. Schizont rupture 
releases 30-40 merozoites that infect other red cells (Millholland et al., 
2011). The parasite undergoes a complete cycle of invasion, replication and 
release every twenty-four, forty-eight or seventy-two hours depending on the 
Plasmodium species. 
Some merozoites differentiate into male or female gametocytes (precursors 
of gametes), initiating the sexual stage of the Plasmodium lifecycle (Hawking 
et al., 1971). The trigger of parasite differentiation into gametocytes 
(gametocytogenesis) is unknown but several Plasmodium-encoded genes are 
essential (Gardiner et al., 2005). Gametocytogenesis also involves a specific 
pattern of gene regulation and expression (Pace et al., 2006). Environmental 
factors such as stress, pH and temperature may also play a role in 
gametocytogenesis (Carter and Miller, 1979). The mosquito takes up the 
gametocyte-infected red cells during a blood meal. Fertilization and 
subsequent differentiation of the zygote into an ookinete occurs in the 
midgut lumen of the mosquito (Boisson et al., 2011). The ookinate is motile 
and crosses the midgut, differentiating into an oocyst that can release up to 
several thousand sporozoites. The sporozoites make their way to the salivary 
gland of the mosquito, ready for the next blood meal (Ghosh et al., 2011). 
Parasite-erythrocyte interactions 
The mature red cell is devoid of organelles and trafficking pathways; hence 
the parasite must remodel the red cell to create a habitable environment 
(Gormley et al., 1992). The parasitophorous vacuole (PV) forms an 
intermediate between the host and parasite and facilitates the exportation of 
parasite proteins. 
The induction of transport pathways and ion channels from the 
parasitophorous vacuole to the surface of the red cell allows Plasmodium to 
maintain osmotic integrity of the red cell and obtain vital nutrients, ions and 
amino acids that the red cell cannot supply (Cobbold et al., 2011, Kirk and 
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Horner, 1995, Kirk et al., 1994, Martin and Kirk, 2007, Saliba and Kirk, 2001). 
One of the main pathways described is the new permeation pathway (NPP), 
which is induced around 16 hours after invasion and allows the infected red 
cell (iRBC) increased permeability to nutrients and inorganic ions (Kirk and 
Horner, 1995, Martin and Kirk, 2007, Saliba et al., 1998b, Staines et al., 2000). 
Additional features of the intraerythrocytic parasite include the formation of 
a tubulovesicular network, which acts as an intermediary between the 
parasitophorous vacuole membrane and the outside of the red cell (Lauer et 
al., 1997). Maurer's clefts are membranous structures formed as part of the 
network and play an important role in sorting parasite proteins prior to 
presentation on the surface of the red cell (Aikawa et al., 1986, Hanssen et al., 
2008b ). The exportation of several parasite proteins is essential for 
membrane rigidity and parasite virulence, including knob-associated 
histidine-rich protein (KHARP) and P. falciparum erythrocyte membrane 
protein 1 (PjEMPl) (Maier et al., 2008). PJEMP1 is exported to the Maurer's 
clefts before being targeted to knob-like structures, which form under the red 
cell membrane (Kriek et al., 2003). Several parasite proteins are essential for 
this process including the ring exported protein-1 (REX1) (Dixon et al., 2011, 
Hanssen et al., 2008a), skeleton-binding protein 1 (SBP1) (Cooke et al., 2006) 
and the membrane-associated histidine-rich proteinl (MAHRP1) (Spycher et 
al., 2008). These structures and parasite receptors decrease red cell 
deformability and allow cytoadherance of the iRBC to host receptors on the 
endothelium, preventing splenic clearance (Wickham et al., 2001). The 
sequestration of infected cells to the endothelium can occlude blood vessels 
to the brain, contributing to the pathogenesis of severe malaria (Glenister et 
al., 2008). Another pathogenesis mechanism associated with severe malaria 
is the adherence of iRBCs to uninfected red cells, in a process called rosetting 
(Mercereau-Puijalon et al., 2008). This process is thought to be mediated by 
PjEMPl and the host red cell receptor complement receptor 1 (CR1) (Rowe 
et al., 1997, Fairhurst et al., 2005, Chen et al., 1998). 
The display of the parasite proteins on the surface of the iRBC means that 
they are exposed to the host's immune system and can be targeted for 
6 
immune destruction (Vigan-Womas et al., 2011). The parasite relies on a 
complicated system of antigenic variation to evade the immune system 
(Barfod et al., 2011). Parasite proteins (such as PjEMPl) encoded by the var 
gene family are able to switch and avoid immune detection (Janes et al., 2011, 
Mok et al., 2008). Other parasite variant surface antigens implicated in either 
altering the properties of the red cell for cytoadherance or antigenic variation 
include the STEVOR family of transmembrane proteins (Przyborski et al., 
2005, Sanyal et al., 2011, Niang et al., 2009) and RIFIN (repetitive 
interspersed family) (Joannin et al., 2011, Wang et al., 2009, Haeggstrom et 
al., 2004). 
A number of recent discoveries have shed light on how exported parasite 
effector proteins traverse the PV. A conserved secretory signal called a PEXEL 
motif or a vascular transport signal (VTS) was identified in the sequence of 
proteins that make it to the surface of the red cell (Marti et al., 2004, Hiller et 
al., 2004). The parasite machinery allowing proteins with this motif to be 
exported beyond the PV was subsequently identified, termed a translocon. 
The authors identified the ATP-driven Plasmodium translocon of exported 
proteins (PTEX) and found a range of proteins making up the PTEX 
machinery (de Koning-Ward et al., 2009). Furthermore, plasmepsin V, the 
parasite endoplasmic reticulum aspartic protease, cleaves proteins with a 
PEXEL motif thus allowing their exportation (Boddey et al., 2010, Russo et al., 
2010). The PTEX is required for the remodeling process of the host red cell, 
thus enabling growth and survival of the intraerythrocytic parasite (Boddey 
et al., 2009). 
Clinical outcome to malaria 
Malaria infections can range from asymptomatic through to lethal. 
Pathogenic consequences of infection by the malarial parasite include 
periodic fever, anaemia and severe malaria, which include cerebral malaria, 
severe anaemia and metabolic acidosis (Menendez et al., 2000). Fever is 
caused by a pro-inflammatory cytokine response, which corresponds to the 
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rupturing of erythrocytic schizonts (Magill, 1998). Anaemia is thought to be 
due to a combination of increased hemolysis of infected red cells (iRBCs), 
increased clearance of uninfected red cells and an impaired ability of the 
infected host to produce an adequate erythropoietic response (Lamikanra et 
al., 2007, Kai and Roberts, 2008). The development of severe malaria is a 
multi-system disorder, which is thought to result from a combination of host 
inflammatory factors such as adherence and sequestration in the vasculature 
(Mackintosh et al., 2004). The adherence of iRBCs is mediated by the binding 
of PjEMPl to endothelial cell surface receptors such as CD36, 
thrombospondin and intracellular adhesion molecule 1 (ICAM-1) (Baruch et 
al., 1996). Adherence of iRBCs to the endothelial cells of various organs such 
as the heart, liver and brain of the host often causes microvascular 
occlusions, therefore preventing tissue perfusion (MacPherson et al., 1985). 
Host immunity can also influence the clinical outcome to malaria. The host 
immune response to malaria is complex and varies depending on the age and 
genetic makeup of the host, species of Plasmodium, level of endemicity, the 
particular stage of infection, and the antigenic makeup of the parasite that 
produces the immunity (Lopez et al., 2010, Stevenson and Riley, 2004). 
Individuals who are repeatedly infected and continuously exposed to the 
parasite over their lifetime develop an acquired immunity, which protects 
against the clinical symptoms of the disease (Bull et al., 1998). Protection 
against the symptomatic stage of disease is thought to be due to a variety of 
innate and adaptive immune responses over the lifetime of the host, which 
can reduce the levels of circulating parasites but may also result in a 
persistent infection by low levels of parasites, and therefore continued 
transmittance of the disease to other individuals (Doolan et al., 2009, Smith 
et al., 2002). Some of the mechanisms thought to be involved in host 
immunity to malaria include the production of antibodies that block the 
invasion of sporozoites into liver cells and invasion of merozoites into 
circulating red cells (Mueller et al., 2007, Purcell et al., 2008). It is also 
thought that interferon-y plays a role with CDS+ T cells to inhibit parasite 
development in hepatocytes, as well as acting with CD4 + T cells to activate 
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macrophages, which are able to phagocytose free merozoites and iRBCs 
(Hirunpetcharat et al., 1999, Todryk et al., 2008, Langhorne et al., 2008). 
Platelets have also been implicated as an important immune-mediated 
defense, with platelets preferentially binding to iRBC over uninfected red 
cells and directly killing the parasite (McMorran et al., 2009). Other evidence 
suggests that platelets contribute to the development of cerebral malaria and 
may actually worsen the clinical outcome to severe disease (Martins et al., 
2009). 
Evidence for a genetic basis to the immune response to malaria has come 
from several epidemiological studies in West Africa, showing inter-ethnic 
differences in antibody titers against several malarial antigens. Despite 
similar infection levels, the Fulani showed lower parasite rates and fewer 
malarial attacks than their neighbors. This was hypothesized to be due to a 
more efficient immune response, as evidenced by a higher antibody titer 
(Verra et al., 2009). The immune response genetic variants will be discussed 
later in this literature review, along with red cell variants that confer 
resistance to severe malaria. 
The antimalarial story dates back to ancient times 
The history of antimalarials dates back many thousands of years where 
ancient cultures recognised the medicinal properties of herbs and other 
natural products. One of the earliest known antimalarials, quinine, was 
originally isolated from the bark of the cinchona tree and used by the Aztecs. 
It was introduced into European medicine in the 1630s and quinine was 
identified as the active ingredient in the cinchona bark in 1820. The synthesis 
of this compound became a priority in the 1940s when supplies to the pacific 
were cut by the onset on war (Ball, 2008). Quinine was reportedly fully 
synthesized in 1944 by Woodward and Doering, a fact debated over many 
years and only now has been validated (Smith and Williams, 2008). Quinine 
was the frontline treatment for severe disease until the synthesis of 
chloroquine, which was deployed in the 1950s. Other antimalarials include 
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the sulpha and pyrimethamine drugs, used in combination in an effort to halt 
the signs of resistance. 
The most recently released antimalarial, artemisinin and related compounds, 
are another example of a natural product whose medicinal properties have 
been recognised for several thousand years. Artemisinin is derived from the 
extracts of sweet wormwood (Artemiaia annua L) and derivatives include 
dihydroartemisinin, artmether and artesuante, which were first prepared in a 
collaborative effort by Chinese scientists in the 1970s (Krishna et al., 2008). 
Current antimalarials are loosing the battle with parasite resistance 
Drugs in the current antimalarial arsenal inhibit a range of enzymatic and 
biologic processes specific to the parasite. Despite the range of compounds 
available in the fight against malaria, a cause for concern is that only one new 
synthetic antimalarial has been released in the last 30 years (mefloquine). 
The limited time needed for the parasite to develop resistance to 
antimalarials in the field is cause for concern. For example, chloroquine was 
synthesized in 1934 and was an important antimalarial used in the malaria 
eradication campaign in the 1950s but resistance was observed in Thailand 
by 1962. The emergence of resistance to chloroquine rapidly extended and 
by 1988 resistance had spread to essentially all of sub-Saharan Africa where 
chloroquine is no longer effective (Hyde, 2007). It is a similar story with the 
remaining antimalarials including the latest addition to the market, 
artemisinin, showing delayed parasite clearance and increasing resistance 
throughout Asia (Dondorp et al., 2011). 
One problem with these therapies is that they target the parasite, which has a 
rapid lifecycle in the human host and is under intense selective pressure. 
Additionally, gametocytes undergo meiosis in the mosquito vector, giving rise 
to genetic variation. These factors lead to the development of drug resistant 
parasites that can rapidly become the dominant strain within a geographical 
area (Vangapandu et al., 2007). There are several ways that resistance to 
antimalarials can occur. Firstly, mutations to transporters alter the activity 
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and/or expression of parasite transporters, preventing drug accumulation or 
increased transportation out of the infected cell (Chinappi et al., 2010, Martin 
et al., 2009). Alternatively, mutations in the target enzyme can reduce the 
drug affinity for the target molecule (Cowman et al., 1988, Foote et al., 1989). 
Several examples of this are illustrated below. 
Chloroquine mechanism of action and resistance models 
The internalisation of host cytosol is initiated at the mid-ring stage of 
intraerythrocytic growth and the imported host haemoglobin (Hb) is 
concentrated into acidic peripheral structures that form a digestive vacuole 
(Abu Bakar et al., 2010). Here, the imported haemoglobin is degraded and 
polymerized to the inert malarial pigment hemozoin (Slater and Cerami, 
1992). Chloroquine accumulates in the digestive vacuole and prevents the 
formation of hemozoin, allowing the buildup of toxic byproducts that damage 
the parasite (Homewood et al., 1972, Sullivan et al., 1996). Chloroquine 
resistance arises by mutations in parasite genes that encode drug 
transporters, in particular the Plasmodium Jalciparum chloroquine resistance 
transporter (PJCRT) (Vangapandu et al., 2007). The PjCRT is an integral 
membrane protein of the digestive vacuole and a variety of mutations have 
been shown to alter chloroquine transport (Saliba et al., 1998a). Compared to 
the wild-type protein, mutant PjCRT readily transports chloroquine, thus 
allowing chloroquine to be readily taken away from the site of action in the 
food vacuole (Martin et al., 2009). 
Another gene identified is the P. Jalciparum multiple drug resistance gene 1 
(PfMDRl), which is a parasite homologue of the mammalian multi-drug 
resistance (MDR) gene in tumour cells (Foote et al., 1990, Foote et al., 1989). 
Mutations in the PfMDRl gene confer chloroquine resistance through 
decreased accumulation of the drug (Reed et al., 2000). Additionally 
amplification of PfMDRl copy number is thought to contribute to both 
chloroquine and mefloquine resistance (Wilson et al., 1989, Cowman et al., 
1994). 
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Antifolate mechanism of action and resistance 
Folate is required for the pyrimidine, purine and amino acid biosynthetic 
pathways. Humans obtain folic acid from dietary sources, while the parasite 
cannot utilise exogenous folic acid, and instead employs a unique de nova 
synthetic pathway (Vangapandu et al., 2007). The sulphonamides and 
pyrimethamine are often used in combination, each targeting specific 
enzymes in the folate biosynthetic pathway in the parasite. The 
sulphonamides target dihydropteroate synthetase (Zhang and Meshnick, 
1991), whereas pyrimethamine and cycloguanil target dihydrofolate 
reductase (Gregson and Plowe, 2005). The genetic basis of resistance to anti-
folates is largely due to single point mutations in the genes of the target 
enzymes dihydrofolate reductase and dihydropteroate synthetase (Cowman 
et al., 1988). 
Artemisinin mechanism of action and resistance 
The artemisinins play an important role in current antimalarial strategies, 
with artemisinin combination therapy the first-line treatment worldwide 
(Dondorp et al., 2009). The mechanism of action is not completely 
understood with haemoglobin, iron and calcium ATPase processes being 
implicated as the targets of artemisinin (Coghi et al., 2009, Haynes et al., 
2011, Krishna et al., 2008, Krishna et al., 2010). Recent evidence 
demonstrates that artemisinin inhibits the uptake of host haemoglobin with 
subsequent parasite growth inhibition (Klonis et al., 2011). Artemisinin has a 
short half-life but is routinely coupled with other longer-lasting antimalarial 
compounds (Eastman and Fidock, 2009). However, artemisinin resistance 
has emerged on the Thai-Cambodian border, with demonstrated in vivo 
delayed parasite clearance (Dondorp et al., 2009), meaning that the future 
use of this drug may be limited. Work in vitro recently demonstrated several 
mutations in PJMDR1 were associated with parasite resistance in field 
isolates from the Thai-Myanmar border (Veiga et al., 2011). 
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Novel antimalarial targets 
With the current antimalarial drugs suffering from parasite resistance, there 
is a need for new compounds that are effective. One of these routes is the 
identification of new parasite targets, helped by the recent advances in 
parasite biology and the completion of the P. falciparum genome. While any 
new antimalarial compound needs to show efficacy against the parasite, 
bioavailability and limited side effects; another important trait is the cheap 
production cost. As such, the commercial opportunities of a new antimalarial 
are limited. Nevertheless, a range of parasite biochemical pathways are being 
viewed for potential targets, including parasite proteases, membrane 
biosynthesis, shikimate pathway, isoprenoid biosynthesis, purine 
metabolism, pyrimidine metabolism, cyclin-dependant proteases and the 
redox and mitochondrial systems (Grimberg and Mehlotra, 2011). Several 
large-scale drug screens have also revealed a large range of potential new 
candidate drugs (Garno et al., 2010, Guiguemde et al., 2010). 
A problem with any newly discovered antimalarial therapeutic candidates is 
that there is still the potential for parasite resistance to develop, as they are 
still parasite-directed. Another point to consider is that the above targets are 
still at the beginning of the drug development pipeline, with many millions of 
dollars needing to be spent and on clinical testing to evaluate their safety as 
antimalarials. Is there value in pushing these parasite-directed targets 
through the long and expensive road of clinical trials, only to see the parasite 
rapidly develop resistance once deployed in the field? From the multitude of 
evidence of the failure of the current antimalarial strategy presented above, 
there is a clear demand for the development of antimalarials for which the 
parasite cannot develop resistance. This necessitates that not only are new 
targets needed but also that a new therapeutic strategy is required. 
Vaccine prospects 
The prospect of a vaccine to protect against malaria is based on evidence that 
individuals repeatedly exposed to Plasmodium develop an acquired immunity 
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(Hommel, 1981 ). However, immunity occurs over the lifetime of an 
individual and is incomplete (Cohen, 1977). There are several potential 
strategies for vaccine targeting, including exoerythrocytic (liver stage) or 
intraerythrocytic. Out of over 4 7 new vaccine candidates, only one (The RTS,S 
vaccine) has reached phase III clinical trials (Langhorne et al., 2008). The 
RTS,S vaccine targets the circumsporozoite protein and recent preliminary 
results from a phase III clinical trial demonstrate between 35-50 percent 
efficacy (Agnandji et al., 2011). Important factors that must be considered 
include the low level of efficacy, length of protection and potential cost of the 
vaccine (White, 2011, Duncan and Hill, 2011). Overall, much is unknown 
about the actual mechanisms of natural immunity to malaria and future work 
in this area may provide novel insights into eliciting a sustained immune 
response. 
Vector control 
With widespread antimalarial resistance and no vaccine on the market, 
currently the most effective means of controlling malaria is by way of 
insecticide treated bed nets. The efficacy of bed-nets is dependent on several 
factors including mosquito sensitivity to insecticides, high malaria incidence 
and rate of community participation (Gu and Novak, 2009). A recent concern 
is the emergence of mosquito resistance to the insecticides used to treat bed 
nets (Fane et al., 2011, Garno et al., 2010). As mosquito resistance spreads, 
this important control method is at risk of becoming ineffective, just as 
antimalarials have done. With a fully protective vaccine unlikely in addition 
to increasing mosquito resistance to insecticides and widespread parasite 
resistance to drugs, a novel strategy is required to lessen the impact of this 
disease. 
Natural host resistance 
Malaria has coexisted with humans for many millennia, a recent study 
suggesting that the human and Plasmodium genomes have been evolving 
14 
together as Homo sapiens migrated out of Africa nearly 80,000 years ago 
(Tanabe et al., 2010). Given the high mortality rate it causes, malaria has had 
a profound impact on the human genome. A variety of mutations that protect 
against malarial infection and the symptoms of the disease have arisen in 
human populations living in malaria-endemic regions of the world 
(Weatherall et al., 2002). These include many polymorphisms affecting the 
red cell. Considering that the parasite spends a large proportion of its 
lifecycle in a red cell, it is not surprising that an ongoing evolutionary battle 
has been fought between the host and parasite genomes for thousands of 
years, the battleground being the red cell; the outcome ultimately deciding 
the result of infection for the human host and the continuing cycle of the 
parasite. 
Haldane (1949) first recognized the importance of host genetics in malaria 
resistance when he postulated that the high rates of thalassemia in 
Mediterranean populations were due to a heterozygous advantage afforded 
to carriers (Haldane, 1949). According to Haldane's malaria hypothesis, the 
heterozygous resistance to malaria balances the homozygote hematological 
disadvantage. Since this initial observation, numerous other mutations that 
have an impact on the host resistance to malaria have been identified. These 
mutations affect red cell proteins, factors involved in the sequestration of 
parasites or the host immune response. These have often been initially 
suggested through coincidence of malarial endemicity (Hill et al., 1987). 
Hemoglobin S (HbS) is one of the best-characterised mutations influencing 
infection but studies suggest there are many genes yet not identified, each 
resulting in small population effects (Mackinnon et al., 2005). New tools 
including genome-wide association studies may help identify other traits and 
increase our understanding of protective immunity (Verra et al., 2009). With 
the current drug regime failing due to profound parasite resistance, can we 
instead use what we know about host resistance to infection to discover 
novel antimalarials that avoid the problem of parasite resistance? 
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The host immune response variants 
There are several variants of immune response genes that confer resistance 
to malarial infection. The major histocompatibility complex (referred to as 
the human leukocyte antigen; HLA) and is comprised of many polymorphic 
genes, and subdivided into 3 main groups (Class I, II and III) (Verra et al., 
2009). Several studies have previously shown that carriers of certain HLA 
class I and II alleles have different susceptibility to malaria (Hill et al., 1991, 
Hill et al., 1992). Furthermore, carriers of the Class I HLA antigen HLA-Bw53 
were protected against severe malaria, an antigen that frequently occurs in 
sub-Saharan Africa (Hill et al., 1991, Hill et al., 1992, Gilbert et al., 1998). 
Complement receptor 1 (CR1) is a red cell surface protein responsible for 
complement-regulatory processes and for the removal of immune complexes 
(Stoute, 2011, Reinagel et al., 1997). CR1 has been implicated in the process 
of rosetting by interacting with P_fEMPl (Rowe et al., 1997). Polymorphic 
variants of CR1 confer reduced expression of CR1 on the red cell surface, a 
feature hypothesised to reduce the ability to rosette and therefore reduce 
severe malaria complications. One study by Thathy et al (2005) confirmed 
that low CR1 phenotype protects against cerebral malaria but not against 
malaria-associated anaemia (Thathy et al., 2005). These results have been 
contradicted by several studies showing no association between the low-
expression of CR1 and reduced severe malaria (Nagayasu et al., 2001, 
Zimmerman et al., 2003, Sinha et al., 2009). Recent evidence has 
demonstrated that CR1 is a host red cell receptor required for P. falciparum 
invasion (Tham et al., 2011, Tham et al., 2010, Awandare et al., 2011). 
Nitric oxide synthase 2 (NOS2) is an enzyme that produces nitric oxide, a free 
radical important in several immune-mediated responses (Lopez et al., 
2010). It has been suggested that polymorphisms in the NOS2 promoter may 
increase nitric oxide production and provide the host with some protection 
against severe malaria (Perkins et al., 1999). The effect of NOS2 
polymorphisms on severe malaria is not fully supported; with one study 
finding that increased nitric oxide production had a detrimental effect on 
disease (Kremsner et al., 1996). Levesque and colleagues also recently found 
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no association between polymorphisms in the NOS2 promoter and malarial 
severity in a cohort of Tanzanian children (Levesque et al., 2010). 
Tumor necrosis factor-a (TNF-a) is a cytokine produced by monocytes, 
macrophages and T- and B-cells and is important for the presentation of pro-
inflammatory events (Wilson et al., 1997). TNF-a has been implicated in 
severe malaria, including cerebral malaria, severe anaemia and lactic acidosis 
(Odeh, 2001). High levels of TNF-a were also shown to disrupt 
erythropoiesis and red cell proliferation (Tchinda et al., 2007). Several 
studies have identified TNF-a polymorphisms that are independently 
associated with cerebral malaria in infant populations in Africa (Knight et al., 
1999, McGuire et al., 1994). 
Haemoglobinopathies 
The haemoglobinopathies are a group of inherited disorders affecting 
haemoglobin structure and production. They are amongst the most common 
monogenic diseases worldwide (Weatherall et al., 2002). This group includes 
haemoglobin variants and the thalassemias, which have high population 
frequencies correlating with the historic incidence of malaria (Hill et al., 
1988). Haemoglobinopathies themselves are a worldwide health burden, 
with a recent minimum estimate suggesting in excess of 300,000 children 
each year born with a haemoglobin disorder (Weatherall, 2011). 
There are hundreds of known low-prevalence Hb variants but only 3 
structural variants are observed at polymorphic frequency, being 
Haemoglobin C (HbC), Haemoglobin E (HbE) and Haemoglobin S (HbS). The 
sickle cell trait (HbS) has one of the highest frequencies of these variants with 
carriers reaching 15-20% in some areas of sub-Saharan Africa (Weatherall et 
al., 2002, Hardison et al., 2002). HbS is caused by a point mutation in the 
haemoglobin j3-chain leading to an altered red cell shape. The most common 
resulting amino acid change is the substitution of valine for glutamic acid in 
the j3-globin subunit (j36Glu-Val) (Wood and Granger, 2007). Upon 
deoxygenation, this change induces polymer formation leading to the classic 
"sickle" shape (Lopez et al., 2010). Findings from studies suggest that while 
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the homozygous HbSS suffer a severe hemolytic syndrome, the heterozygous 
HbAS are healthy and protected from severe malaria (Williams et al., 2005a). 
Case control studies demonstrated heterozygous carriers were at least 70 
percent protected against severe malaria (Allison, 1954, Flint et al., 1986). 
HbC is another protective variant, but unlike HbS where selection for the 
heterozygous state has occurred, the protective advantage of HbC is greatest 
in homozygotes. This was demonstrated in a large study by Modiano and 
colleagues (2001) who showed a 90 percent protection rate of clinical 
malaria in homozygotes and 30 percent in the heterozygote carriers 
(Modiano et al., 2001). Prior to this report, there were contrasting results in 
the protective capability of this variant (Guinet et al., 1997, Mockenhaupt et 
al., 2004a, Rihet et al., 2004). Unlike the severe condition of the HbS variant, 
individuals homozygous for HbC are characterized by mild haematological 
symptoms (Agarwal et al., 2000). The mechanism for the protective effect of 
both HbS and HbC is not fully elucidated with several hypotheses postulated. 
Parasite entry into the red cell may be impaired by the altered exterior 
membrane structure of the red cell and additionally, low oxygen conditions 
and the altered red cell structure may impair subsequent parasite growth 
(Fairhurst et al., 2005, Cooke et al., 2001, Williams, 2006). Additionally, HbC 
heterozygotes and homozygotes have been shown to display an abnormal 
P_fEMPl, resulting in reduced cytoadhesion and impaired rosetting in vitro 
(Cholera et al., 2008). This mechanism would hinder the pathogenesis of 
disease and may prevent the onset of severe disease exacerbated by due to 
the sequestration of parasites in the microvasculature. 
HbE is the third haemoglobin variant thought to afford host protection 
against malaria. It is most widely distributed in South East Asia, with Laos, 
Cambodia and Thailand recording the highest carrier frequency of 55 percent 
(Flatz, 1967). Homozygotes have less efficient production of haemoglobin, 
resulting in red cells with a lower haemoglobin concentration and are 
microcytic (low mean corpuscular volume) (Bunyaratvej et al., 1992a). It has 
also been observed in vitro that HbE red cells show reduced plasticity and 
deformability (Bunyaratvej et al., 1992b ). Clinical presentation of 
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homozygotes is similar to (3-thalassemia, while heterozygous carriers are 
asymptomatic. A case-control study in Thailand suggested that the HbE 
variant affords protection only against severe malaria, due to reduced 
invasion efficiency at high parasitaemias (Hutagalung et al., 1999, 
Chotivanich et al., 2002). 
Thalassemias are caused by mutations in the promoters of either the a or f3 
globin genes, causing a-thalassemia or (3-thalassemia respectively (Williams, 
2006). A mutation in either one of the globin genes results in the reduced 
expression and formation of abnormal haemoglobin molecules 
(Mockenhaupt et al., 2004b ), of which there are over 180 known mutations 
(Lopez et al., 2010). The population frequencies of both of these conditions 
are unexpectedly high in countries where malaria is ( or previously was) 
endemic, including the southwest Pacific, sub Saharan Africa and the 
Mediterranean (Flint et al., 1986). Individuals homozygous for a+ thalassemia 
suffer from anaemia with hyperchromic red cells while heterozygotes are 
clinically normal (Fowkes et al., 2008). a 0 thalassemia occurs when both 
linked alpha globin genes are lost and is lethal in the homozygous state (Hill 
et al., 1987). Evidence for a protective role comes from a+ thalassemia but the 
mechanism of protection is unclear, with no evidence of reduced rate of 
invasion or parasite growth (Flint et al., 1986). An immune-mediated 
protection has instead been postulated, with a+ thalassemic iRBCs binding 
more antibody from immune plasma compared to control iRBCs (Luzzi et al., 
1991, Williams et al., 2002). Alternatively, the increased red cell number and 
decreased red cell size seen in homozygotes may offset anemia during severe 
disease (Fowkes et al., 2008). The protective effect of a+ thalassaemia has 
only repeatedly been observed in severe malarial anemia, while the observed 
effect on mild malaria has not been consistent between studies (Williams et 
al., 2005b, Mockenhaupt et al., 2004b, Wambua et al., 2006, Oppenheimer et 
al., 1987, Allen et al., 1997). The reproducibility of these studies may be 
affected by the finding of a negative epistatic effect between HbAS and a+ 
thalassaemia. When these two conditions are inherited together, the 
protective effect of either trait is lost (Williams et al., 2005a). 
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f3-thalassemia is usually caused by mutations affecting the promoter region of 
HbB, which causes a premature termination or a change in the correct 
splicing (Hill et al., 1988). This leads to a decreased synthesis of f3-globin and 
a subsequent excess of a-globin, which promotes oxidative membrane 
destruction and mechanical damage to precursors (Weatherall, 2000). 
Individuals heterozygous for the mutation display mild anemia and a lower 
erythropoiesis due to red cell morphological changes, while homozygous 
individuals display severe anemia and regular blood transfusions are 
required (Weatherall, 1997, Galanello and Origa, 2010). A variety of 
resistance mechanisms for malarial protection have been suggested: that 
fetal haemoglobin is sustained for longer in newborn carriers (Pasvol et al., 
1976); a higher phagocytosis rate in f3-thalassaemic iRBCs (Ayi et al., 2004 ); 
and that antibodies bind at a higher rate to f3-thalassaemic red cells 
compared to normal red cells (Smith et al., 2002). 
Glucose-6-phosphate dehydrogenase deficiency 
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked 
disease, which affects over 400 million people worldwide and is mainly found 
in tropical regions with the highest frequencies observed in Africa, Asia, 
Papua New Guinea and the Mediterranean (Ruwende et al., 1995). Glucose-6-
phosphate dehydrogenase catalyses the first step of the pentose phosphate 
pathway, providing NADPH, which is required to protect red cells from 
oxidative damage (Clarke et al., 2001, Frank, 2005). A G6PD deficient red cell 
is more susceptible to oxidative stress, as NADPH is not being produced in 
sufficient quantity to fully protect the cell. Although most affected individuals 
are asymptomatic, the clinical manifestations can include episodes of red cell 
hemolysis, which is associated with exposure to certain drugs ( such as 
primaquine), chemicals (such as naphthalene) or other redox compounds 
(Piomelli, 1981 ). In the literature, there is conflicting in vitro evidence of the 
protective mechanism of G6PD deficiency, with invasion thought to be 
normal but the growth of parasites in G6PD deficient red cells being impaired 
and a higher rate of phagocytosis (Roth et al., 1983, Cappadoro et al., 1998). 
Upon P. falciparum invasion, there is a higher level of oxidative stress in 
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G6PD deficient red cells, leading to the accumulation of toxic oxidised 
substances in the host red cell that impairs parasite development (Wajcman 
and Galacteros, 2004, Beutler, 1996). It is also hypothesized that due to 
parasitic infection, the extra oxidative stress put on the host red cells can also 
lead to the premature lysis of infected G6PD deficient red cells (Ruwende and 
Hill, 1998). A third proposal is that parasitaemia is limited in G6PD deficient 
red cells due to the earlier onset of phagocytosis (Gallo et al., 2009). 
Pyruvate kinase deficiency 
Pyruvate kinase (PK) is an enzyme in the glycolysis pathway, a pathway 
required in the red cell to maintain cellular energy (Chan and Sim, 2005). A 
deficiency in this enzyme causes hereditary non-spherocytic hemolytic 
anemia, which has a worldwide distribution pattern (Wang et al., 2001). PK 
deficiency was initially suggested to confer host resistance to malaria from 
mouse studies. Min Oo and colleagues (2003) showed that mice homozygous 
for a PK deficiency were resistant to P. chabaudi, a rodent model of infection 
(Min-Oo et al., 2003). This prompted suggestions that a similar protective 
effect might be seen in human populations and has been confirmed by in vitro 
studies with PK deficient human blood (Durand and Coetzer, 2008). Further 
work by Ayi and colleagues (2008) suggested that blood from homozygous 
patients was resistant to P. falciparum invasion (Ayi et al., 2008). This 
supported previous work demonstrating PK deficient red cells have altered 
membrane rigidity impairing parasite invasion (Min-Oo et al., 2003). 
Furthermore Ayi and colleagues (2008) suggested that infected red cells at 
the ring stage were preferentially cleared by macrophages (Ayi et al., 2008). 
Duffy antigen 
The Duffy antigen ( also known as DARC; Duffy antigen receptor for 
chemokines) is normally expressed on the surface of red cells and functions 
as a chemokine receptor (Mallinson et al., 1995). The receptor is also used by 
P. vivax to obtain entry into the host red cell (Singh et al., 2006). Certain 
populations, especially those in West Africa, do not express the Duffy antigen 
on their red cells due to a mutation in the promoter preventing erythrocytic 
expression (Tournamille et al., 1995). People who are Duffy negative are 
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resistant to infection by P. vivax (Miller et al., 1976), which probably explains 
the absence of P. vivax in West Africa today. A recent study in Madagascar 
identified Duffy negative individuals infected with P. vivax (Menard et al., 
2010). This is the first report of Plasmodium adaptation to host genetic 
variants but may be influenced by the unique Madagascan population that 
contains many diverse ethnic groups, as well as the high rate of co-infection 
with P. falciparum. 
Ovalocytosis 
Ovalocytosis is a disease caused by a 27 base-pair deletion in the gene 
encoding band 3, a red cell membrane protein (Liu et al., 1990, Jarolim et al., 
1991). The band 3 variant is endemic throughout Malaysia, Papua New 
Guinea and the Philippines, sometimes referred to as Melanesian or south-
east Asian ovalocytosis (Liu et al., 1990). It is a homozygous embryonic lethal 
disease, while heterozygotes are asymptomatic but have red cells with a 
distinctive elliptical shape (Amato and Booth, 1977). Carriers are susceptible 
to infection by the parasite but the mutation appears to offer strong 
protection against the development of cerebral malaria (Allen et al., 1999). 
Individuals with ovalocytosis may be protected from cerebral malaria due to 
an altered interaction between the infected red cell and the vascular 
endothelium (Genton et al., 1995). 
Sequestration variants 
The sequestration of infected blood cells is also a major cause of malarial 
pathogenesis. Several parasite antigens (PfEMPl) are known to bind and 
sequester to a number of host endothelial surface receptors such as ICAM-1, 
CD36 and CD31 (Baruch et al., 1996, Janes et al., 2011). Polymorphisms of 
these host receptors is thought to impact on severity of malarial infection, 
with several studies showing associations between decreased expression of 
host receptors and protection from malaria (Kun et al., 1999, Bellamy et al., 
1998, Amodu et al., 2005). 
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Red cell polymorphisms are still effective as "natural antimalarials'' 
Some of these red cell polymorphisms, such as sickle cell, were discovered in 
the 1840s but are thought to have been present in human populations for 
thousands of years (Lell et al., 1999). Thus, although the parasite has had 
ample time to change and overcome these protective mechanisms, this has 
not happened ( excluding the possible recent exception of Duffy-negative 
individuals being infected with P. vivax on Madagascar (Menard et al., 2010)) 
and contrasts with the resistance that has rapidly developed to parasite-
directed chemotherapy. Consequently populations with high frequencies of 
these red cell polymorphisms are able to avoid many of the serious 
complications associated with malarial infection. Therefore the host red cell 
variations can be regarded as "resistance-proof natural antimalarials" (Foote, 
2004). 
Host-directed therapy, a novel antimalarial strategy based on genetic 
resistance to malaria 
Evidence from the above described host genetics implies that red cell 
variants are an effective means of controlling malarial infection. Unlike 
current antimalarials that are parasite-directed, targeting host proteins could 
be a way of escaping parasite resistance that has hampered the current range 
of antimalarials. This thesis focuses on investigating and validating a novel 
host-directed therapy (HDT), targeting host proteins in the mature red cell 
that the parasite relies on for survival. A HDT is based on the evidence that 
red cell polymorphisms have a detrimental effect on invasion, growth or 
egress of the parasite. 
HDT: a way forward for infectious disease treatment? 
A host-directed therapy is a new and emerging field for treating not only 
malaria but also other infectious diseases caused by bacteria, viruses and 
other parasites. The role of the host in pathogenic infection has long been 
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investigated; in the late 1870s Louis Pasteur recognized the importance of 
the host as a "culture vessel" (Brown et al., 2008). Furthermore, Garber 
(1960) described the host's role as a growth medium, alluding that this may 
be exploited for therapeutic advantage (Garber, 1960). As our knowledge of 
host-pathogen interactions increases, identifying novel host factors required 
by pathogenic organisms has become a feasible approach to novel treatment 
avenues. Several examples below demonstrate the benefit of targeting host 
molecules needed by the pathogen for growth. 
Human immunodeficiency virus (HIV) is an example of a virus where 
therapies that previously targeted the causative agent have begun to fail. 
There has been a rapid emergence of resistance to available therapies due to 
the high viral mutation rate (Pingen et al., 2011). HIV drugs have classically 
targeted the viral replication machinery and proteases used for viral 
production in the host cell (Lewin et al., 2011). Along with poxvirus, HIV uses 
host chemokine receptors to enter the host cell, namely CCRS and CXCR4 
(Oppermann, 2004, Lalani et al., 1999). One of the most recent drugs 
Maraviroc (Trade names Selzentry /Celsentri, FDA approved in 2007) makes 
use of this phenomenon and targets CCRS on the host cell membrane. CCRS 
inhibition prevents the interaction with the viral protein gp120, necessary 
for viral entry (Ferain et al., 2011). A downside to this therapy is Maraviroc is 
only effective against strains that use the CCRS receptor for host cell entry 
(Lederman et al., 2006). Other host chemokine receptor inhibitors are being 
developed and are at various stages through pre-clinical and clinical trials. 
Large-scale screens using short interfering RNA (siRNA) libraries have been 
used to great effect to identify other host factors needed by viruses. One such 
study identified over 250 host factors required by HIV-1 (Brass et al., 2008), 
the challenge being to identify inhibitors of these novel targets. This 
technique has also been used to identify several novel host factors needed in 
bacterial infections. Chlamydia caviae infection in mammalian cells was 
reduced when the host Tim-tom multiprotein complex was knocked down. 
This complex is used by the bacterium to recognize and import nuclear-
encoded proteins into the mitochondria (Derre et al., 2007). Additionally, 
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several host kinases have been identified that support the growth of 
Salmonella and Mycobacterium (Kuijl et al., 2007). These host kinases could 
provide novel targets for future drug targeting. 
Celgosivir is another host-directed drug currently in phase II clinical trials, 
this time for Hepatitis C infection. Celgosivir inhibits host endoplasmic 
reticulum glycosidase, an enzyme important for the folding of the virus 
envelope proteins. Inhibition of this enzyme results in damaged viral 
assembly and release (Durante! et al., 2007). 
The host nutrient status has previously been investigated as a potential line 
of therapeutic targeting. Host cholesterol is needed by certain pathogens to 
establish infection (Riethmuller et al., 2006, Lafont and van der Goat, 2005). 
Drugs that reduce cholesterol such as statins have shown therapeutic 
promise against HIV infections by reducing viral load ( de! Real et al., 2004 ). 
Other pathogens thought to rely on host cholesterol include Leishmania spp. 
and Staphylococcus aureus, using cholesterol for binding or activity of 
virulence factors (Pucadyil and Chattopadhyay, 2007). 
Another host factor influenced by nutrition is iron, which is thought to play 
an important role in the onset of infection as many pathogens utilize host 
iron for growth (Weinberg, 1974). Animal studies have shown iron chelator 
treatment decreases the growth of M. tuberculosis (Gordeuk et al., 1996, 
Gangaidzo et al., 2001). Iron chelator therapy has also shown some success in 
human malarial infection (Mabeza et al., 1999). 
Finally, along with the increase in knowledge of host-pathogen interactions, 
the technological advances in target selection from genomic and proteomic 
techniques may lead the way for the rapid identification of further host 
targets. The examples described in this thesis demonstrate that host-directed 
therapies are emerging as a novel avenue for therapeutic intervention in the 
fight against pathogenic infection. Next, this review focuses on the literature 
surrounding host factors required for malarial infection. 
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Potential host-directed antimalarial targets 
Numerous host factors have been identified that Plasmodium either 
scavenges or requires to invade red cells, replicate or egress. As previously 
discussed, therapeutic targeting of these factors could be an important new 
class of antimalarials. Several examples are illustrated below. 
Host proteins necessary for parasite invasion 
Parasite invasion of the red cell is vital for the intraerythrocytic infection to 
begin. Several host proteins are required for this process, including the Duffy 
antigen receptor for P. vivax invasion, previously described in this review. 
Murphy and colleagues used an erythrocyte guanine nucleotide regulatory 
protein Gs antagonist to show that this protein was necessary for parasite 
invasion into red cell ghosts (Murphy et al., 2006). Additionally, Bei and 
colleagues used shRNA to knock down gene expression of glycophorin A in 
red cells isolated from haemopoietic stem cells and subsequently terminally 
differentiated into mature red cells in vitro (Bei et al., 2010) This knock-down 
showed that glycophorin A was required for strain-specific invasion. Most 
recently basigin (the Ok blood group antigen) was shown to be to be essential 
for P. falciparum invasion, through both knock-down and inhibition of the 
host protein (Crosnier et al., 2011). If novel drugs can target host proteins 
that the parasite requires for invasion, the ensuring parasitaemia levels may 
be decreased and severe malaria may be prevented. 
Host proteins in parasite egress 
An important step in the intraerythrocytic lifecycle of the parasite is when 
multiple new merozoites must escape the encompassing parasitophorus 
vacuole and red cell to enter into the blood stream. The process of 
parasitophorous vacuole and red cell rupture is referred to as egress. 
Without efficient egress, new merozoites are unable to continue the asexual 
lifecycle of the parasite. Calpain-1 has been demonstrated as an essential host 
factor for parasite egress, as Plasmodium was unable to egress from calpain-1 
immunodepleted red cells, instead remaining arrested in the schizont stage 
(Chandramohanadas et al., 2009). 
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Host protein kinases 
Host kinases have been a recent area of interest, with several studies 
investigating their efficacy as novel drug targets (Doerig et al., 2009). One 
study used the power of a large-scale RNAi screen of the 727 known kinase-
related genes to identify five host kinases influencing the liver stage of P. 
berghei infection. When the expression of any of these five host kinases was 
knocked down, the level of infection was severely reduced (Prudencio et al., 
2008). Recently host protein kinases have been implicated in malarial 
infection with the finding that host red cell protein kinases PAK-1 and MEK-1 
are upregulated in iRBCs and may be used in the parasite's protein kinase-
mediated signaling pathway (Sicard et al., 2011). 
Red cell eryptosis 
Another suggestion for new therapeutic targeting is to increase the rate of 
suicide death of iRBCs (also called eryptosis). Upon parasite invasion a 
cascade of events is induced that leads to high levels of oxidative stress on 
that cell, eventually causing it to undergo eryptosis (Foller et al., 2008). These 
cells display phosphatidylserine residues on the surface that act as flags for 
macrophages to engulf and destroy the dying cell. Foller and colleagues 
(2009) suggest using this strategy to therapeutically induce eryptosis in an 
effort to decrease parasitaemia and have a positive impact of the clinical 
course of disease (Foller et al., 2009). This idea builds on the observation that 
red cells with a haemoglobinopathy or that are deficient in G6PD are prone to 
early eryptosis once infected (Lang et al., 2002, Ayi et al., 2004). 
Host nutrients 
Another avenue for potential host targets is that of the nutrients and 
cofactors the parasite relies on scavenging from the host. The importation of 
host nutrients by the parasite is well established, initially from studies 
revealing that malarial parasites endocytose and digest host haemoglobin 
(Sherman, 1977). The parasite makes use of the abundance of host 
haemoglobin (Hb) in the red cell, digesting it for amino acids prior to storage 
in the digestive vacuole as hemozoin (Esposito et al., 2008). Channels such as 
the new permeation pathway (NPP) are induced in the red cell membrane 
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12-15 h after invasion, allowing infected red cells to more readily take up 
anions (Kirk et al., 1994), sugars (Ginsburg et al., 1985), purines (Upston and 
Gero, 1995), organic cations (Staines et al., 2000) and pantothenate (the 
precursor of coenzyme A) (Saliba et al., 1998b) from the host serum. 
Methionine (an amino acid missing from adult haemoglobin) and isoleucine 
also enter the iRBC though the NPP (Cobbold et al., 2011, Martin and Kirk, 
2007) and are required for parasite growth. It has also been suggested that P. 
falciparum scavenges fatty acids from the host red cell that are used in 
numerous parasite processes including phospholipid and triacylglycerol 
synthesis (Vial et al., 1982). 
Host enzymes 
One of the first studies to identify the acquisition of host red cell enzymes by 
the parasite was by Fairfield and meshnick (1983) who found that the 
parasite adopts host superoxide dismutase (Fairfield et al., 1983). This 
enzyme is vital to the oxidant defense system of cells, particularly important 
for the parasite in the lysis prone red cell (Fairfield et al., 1986). SOD activity 
in isolated P. berghei parasites was identified as being of host origin using 
enzyme activity assays, isoelectric focusing and polyacrylamide gel 
electrophoresis examining host and parasite enzymes. They surmised that 
the parasite lacked its own SOD therefore requiring the import of the host 
enzyme as part of its antioxidant defense (Fairfield et al., 1983). Another 
more recent study has shown that the human redox protein peroxiredoxin-2 
is scavenged and colocalised to the parasite cytosol and Maurer's clefts. The 
hijacked host protein was also found to have a functional role in the redox 
system of the parasite (Koncarevic et al., 2009). Enzymes of the haem 
biosynthetic pathway have also been of considerable interest as it has been 
suggested several host haem enzymes are scavenged by the parasite and 
used to fulfill its own haem synthetic requirements, namely aminolevulinate 
dehydratase (ALAD) and ferrochelatase (FECH) (Bonday et al., 2000, Bonday 
et al., 1997, Varadharajan et al., 2004). These enzymes are of interest to this 
thesis and are further discussed below. 
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The examples above display the wide-variety of potential novel host targets 
but it barely scrapes the surface of the many host proteins or transporters 
that may be utilized for a host-directed antimalarial therapeutic strategy. 
Proteomic studies have identified over 751 proteins in mature red cells, 
many of which may be scavenged or required by the parasite (Alvarez-
Llamas et al., 2009, Goodman et al., 2007, Kakhniashvili et al., 2004, Pasini et 
al., 2006, Zhang et al., 2008). Using the powerful and vast tools of the "-omics" 
generation, high throughput chemical screening libraries and traditional 
genetic techniques, the time is ripe to pursue a host-directed therapy as the 
antimalarial therapeutic strategy of the future. 
Identification of host targets using a bioinformatics approach 
Work done in my honours year examined potential host targets using 
microarray analysis on red cell precursors and bioinformatics methods to 
investigate parasite and host pathways. Firstly, host proteins present in the 
mature red cell were identified using microarray data from precursor red 
cells (unpublished data) as well as the red blood cell proteome database 
(Pasini et al., 2006). Parasite genome and pathway data was then analysed to 
investigate pathways that were vital to the parasite and corresponding 
protein homologs that may be absent in the parasite. It was hypothesised that 
the parasite may scavenge the host version to fulfill its own biochemical 
pathways. Several potential targets were identified including 
Uroporphyrinogen-III synthase (UROS), an enzyme in the haem biosynthetic 
pathway (Smith, 2007). The parasite has a complete repertoire of genes 
coding for all of the enzymes in this pathway, with the exception of UROS 
(Gardner et al., 2002). As the parasite lacks a gene coding for UROS, it was 
hypothesised that the host version may be imported by the parasite to 
supplement its UROS requirements for haem synthesis. Additionally, 
previous data suggests that other haem biosynthetic enzymes, ALAD and 
FECH, may be scavenged by the parasite (Bonday et al., 2000, Bonday et al., 
1997, Varadharajan et al., 2004). Considering the numerous potential targets 
in this pathway, enzymes in the haem biosynthetic pathway have 
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subsequently been the focus of my current investigation into host-directed 
therapeutics. 
Haem synthesis in red cells 
Haem is required by all organisms as a prosthetic group or cofactor for a 
variety of proteins including haemoglobin (Hb), myoglobin, cytochrome C, 
cytochrome p450, catalase, peroxidase and 812 (Heinemann et al., 2008, 
Layer et al., 2010). Haem synthesis occurs in high levels in liver and 
progenitor red cells (Ponka, 1999). The haem biosynthetic pathway is 
comprised of eight enzymes (Figure 1.2) and in red cells, this pathway occurs 
in the cytosol and mitochondria (Sassa, 1990). The terminal enzyme, 
ferrochelatase, is mitochondrially located, and hence the mitochondria are 
the ultimate site of haem formation (Wu et al., 2001, Chen et al., 2010). 
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Figure 1.2 The mammalian haem biosynthetic pathway. In black are 
substrates/products and in yellow boxes are the haem synthetic enzymes. ALAS, 
aminolevulinate synthase; ALA, aminolevulinate; ALAD, aminolevulinate 
dehydratase; PBG, porphobilinogen; HMBS, hydroxymethylbilane synthase; HMB, 
hydroxymethylbilane; UROS, uroporphyrinogen III synthase; Urogen III, 
uroporphyrinogen III; UROD, uroporphyrinogen decarboxylase; Coprogen III, 
coproporphyrinogen III; CPO, coproporphyrinogen oxidase; Protogen III, 
protoporphyrinogen III; PPO, protoporphyrinogen oxidase; PPIX, protoporphyin IX; 
FECH, ferrochelatase 
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As progenitor red cells undergo maturation, haem supplies the prosthetic 
group for Hb assembly (Thorell, 194 7). At the reticulocyte stage of red cell 
development, organelles and cell components are eliminated from the cell via 
exosomes (Carayon et al., 2011). This process completes the final transition 
into a mature circulating red cell. The final mature red cell form is devoid of a 
nucleus and organelles and therefore unable to transcribe and translate new 
proteins. The mature red cell is therefore also unable to synthesise haem. The 
red cell cytosol is comprised mostly of haemoglobin (98%) but a variety of 
proteomic studies have revealed the presence of over 700 other proteins 
(Alvarez-Llamas et al., 2009, Goodman et al., 2007, Kakhniashvili et al., 2004, 
Pasini et al., 2006, Zhang et al., 2008). The three haem synthetic enzymes, 
ALAD, FECH and UROS, currently under investigation in this thesis were 
identified in one of these studies (Pasini et al., 2006). A range of technical 
difficulties, including sample preparation and the detection limit, may have 
precluded their identification in the other studies. A question therefore 
remains if the haem biosynthetic enzymes are present in mature red cells, 
which are no longer undergoing haem synthesis. 
Plasmodium haem synthesis 
The parasite also has an active haem biosynthetic pathway that is 
compartmentalised between the mitochondria, apicoplast and cytosol 
(Figure 1.3) (van Dooren et al., 2006, Sato et al., 2004). Plasmodium haem 
synthesis begins in the mitochondrion with the first enzyme of the pathway, 
aminolevulinate synthase (ALAS) localised to this organelle (Varadharajan et 
al., 2002). The second enzyme, ALAD is targeted to the apicoplast 
(Dhanasekaran et al., 2004, Sato and Wilson, 2002). Transporters have not 
been identified that take the substrate aminolevulinic acid from the 
mitochondrion, across the cytosol and into the apicoplast, a process that 
must traverse several membranes. The next enzyme, hydroxymethylbilane 
synthase (HMBS) is also targeted to the apicoplast (Sato et al., 2004). 
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Figure 1.3 The hybrid haem biosynthetic pathway of Plasmodium. In bold black 
next to yellow boxes are the haem biosynthetic enzymes, which are 
compartmentalized between the cytosol, mitochondrion and apicoplast in 
Plasmodium. ALAS, aminolevulinate synthase; ALAD, aminolevulinate dehydratase; 
HMBS, hydroxym ethylbilane synthase; UROS, uroporphyrinogen III synthase; UROD, 
uroporphyrinogen deca rboxylase; CPO, coproporphyrinogen oxidase; PPO, 
protoporphyrinogen oxidase; FECH, ferrochelatase 
Hypothetically the following enzyme uroporphyrinogen-111 synthase (UROS) 
would also be targeted to the apicoplast, after HMBS but there is question 
over the presence of UROS, with no parasite-encoded genes having been 
annotated as UROS (Gardner et al., 2002). An orthologue of UROS has been 
identified in the genome of Toxoplasma gondii and is localised to the 
apicoplast (Ralph et al., 2004). The following enzyme in the pathway, 
uroporphyrinogen III decarboxylase (UROD) has been shown using 
bioinformatics to contain an apicoplast leader sequence, which was 
confirmed by immunohistochemistry studies (Nagaraj et al., 2009a). 
Interestingly, the pathway seems to continue into the cytosol with the next 
enzyme coporporphyrinogen III oxidase (CPO) being identified in this 
location using western blotting, immunohistchemistry and enzyme assay 
techniques (Nagaraj et al., 2010b). The next haem synthetic pathway enzyme, 
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protopophyrinogen IX oxidase (PPO), was cloned, expressed and localised to 
the mitochondrion using immunohistochemistry techniques (Nagaraj et al., 
2010a). These findings indicate the presence of further transporters involved 
in the shuttling of intermediates between the apicoplast, cytosol and 
mitochondria. The final enzyme in the pathway, ferrochelatase (FECH) has 
been surrounded by controversy regarding its location. Initially a study by 
Varadharajan and colleagues (2004) demonstrated an apicoplast location 
(Varadharajan et al., 2004) but evidence by Ralph and colleagues (2004) 
suggested a mitochondrial location (Ralph et al., 2004). Using the 
Plasmodium-trained mitochondrial transit peptide predictor tool PlasMit, 
FECH was shown to contain a short N-terminal extension that may function 
as a mitochondrial transit peptide. Recent work by Bonday and colleagues 
confirmed the mitochondrial location of FECH using immunohistochemical 
techniques (Nagaraj et al., 2009b ). Their prior mistake on its location was 
suggested to be due to an alternate promoter sequence used in their initial 
cloning experiments. A mitochondrial location of FECH makes sense as FECH 
is mitochondrially located in all other organisms and is therefore the ultimate 
site of haem production. It is unknown how the parasite coordinates this 
hybrid pathway, including the shuttling of enzymes or intermediates 
between the mitochondria, cytosol and apicoplast. 
A role for host haem enzymes in the Plasmodium haem synthetic 
pathway 
Interestingly, even though the parasite contains genes encoding ALAD and 
FECH, there is evidence that the parasite scavenges the host versions of these 
enzymes. Dhanasekaran and colleagues showed over 90% of the total 
parasite ALAD activity is derived from a host-encoded enzyme 
(Dhanasekaran et al., 2004). Similarly, over 80% of total parasite FECH 
activity is that of host origin (Varadharajan et al., 2004). The role of host 
haem enzymes in malarial infection has been unclear, considering the 
parasite contains genes encoding active ALAD and FECH enzymes (Sato and 
Wilson, 2002, Sato and Wilson, 2003). It has also been suggested that the 
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parasite contains a specific transporter for co-opting the host enzymes, as 
opposed to passive consumption when Hb is imported and proteolysed in the 
digestive vacuole (Sonday et al., 2000). It is unsure if the host enzymes are 
utilised in the cytosol or transported into the organelles of the parasite to 
supplement haem synthesis. Overall, the importation of the host haem 
enzymes ALAD and FECH has not been independently investigated. 
Furthermore, it is not known if the parasite requires the host enzymes for 
normal growth. These questions will be investigated in this study. 
A potential role for host UROS in Plasmodium haem synthesis? 
The absence of a Plasmodium-encoded UROS remains a question in parasite 
biology. UROS plays a vital role in the haem synthetic pathway, responsible 
for the inversion and closing of the linear hydroxymethylbilane into the 
uroporphyrinogen III porphyrin ring (Tsai et al., 1988). Without UROS, the 
substrate is unstable and non-enzymatically converts into the physiologically 
unusable uroporphyrinogen I isomer (Freesemann et al., 1998). With a 
parasite-encoded UROS yet to be identified, Nagaraj and colleagues (2008) 
provided evidence that the preceding haem biosynthetic enzyme, 
hydroxymethylbilane synthase (HMBS), acts as a dual function enzyme 
(Nagaraj et al., 2008). P. falciparum HMBS (PjHMBS) was cloned in a bacterial 
expression system and found to have limited UROS activity (Nagaraj et al., 
2008). However, it was noted that purified red cell UROS was catalytically 
more efficient than the PjHMBS activity. Considering the previously discussed 
evidence that the parasite scavenges other host haem synthetic enzymes and 
that the host enzyme is more efficient than the dual-function PjHMBS, it is 
possible that host UROS is also scavenged by the parasite. This is the case in 
other parasites such as Trypanosoma and Leishmania, which rely on 
scavenging haem enzymes due to the partial loss of their own pathways (Toh 
et al., 2010). This thesis proposes that Plasmodium does not require its own 
version of UROS with the availability of the host enzyme, which is scavenged 
like other haem enzymes. 
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Host directed therapy: a resistance proof therapeutic strategy? 
If the parasite relies on UROS, ALAD and FECH for essential metabolic 
functions, inhibitors of these host enzymes may be useful antimalarial 
compounds. Drugs against these host haem synthetic enzymes may be an 
important new class of antimalarial. This therapeutic strategy has been 
coined a "host directed therapy" (HDT). A HOT could be a potentially 
resistance-proof antimalarial strategy, as compounds targeting host enzymes 
would be acting outside the cellular milieu and genetic control of the parasite. 
An irreversible inhibitor of one of these targets could last the life of the 
mature red cell, about 120 days, thus creating a unique therapeutic window 
that may be useful in prophylactic as well as chemotherapeutic treatment. 
The red cell is the target cell of a HDT but potential side effects may be 
limited considering that other cells that rely on haem synthesis (such as 
hepatocytes) can easily overcome inhibition due to their transcriptional 
ability. 
Overall, current parasite-directed antimalarials are loosing the battle with 
resistance. Host genetics reveals that changes to the red cell disrupt parasite 
invasion or growth and may give us clues to a novel therapeutic strategy to 
overcome parasite resistance. Work in this thesis investigates the haem 
synthetic enzymes ALAD, FECH and UROS as targets for a novel host-directed 
antimalarial therapy. 
35 
Thesis aims 
All of the current chemotherapeutic antimalarial research is focused on 
identifying processes and targets unique to the parasite. The failure of this 
strategy is evidenced by both the field and in vitro data, which tells a story of 
parasite resistance to all current antimalarials. This thesis instead 
investigates a novel host-directed therapy, targeting host enzymes required 
by the parasite for growth and survival. The host targets are outside of both 
the cellular milieu and genetic control of the parasite, making it difficult for 
the parasite to develop resistance. 
Plasmodium requires haem for growth and several studies suggest that the 
parasite scavenges two host haem synthetic enzymes, ALAD and FECH. UROS, 
a third enzyme from this pathway is seemingly absent in the parasite. It is 
therefore hypothesised that Plasmodium also utilises the host enzyme to 
provide UROS activity for haem synthesis during intraerythrocytic growth. 
This thesis focused on investigating these three enzymes as potential targets 
for a host directed therapy using a variety of techniques including western 
blot and immunofluorescence; in vitro and ex vivo Plasmodium falciparum 
growth inhibition assays with specific inhibitors; knock-out mouse models; 
rodent studies using Plasmodium chabaudi and human studies with 
porphyria patient blood (haem enzyme deficiencies). 
Aim 1. To investigate the Plasmodium location of host haem enzymes. 
Previous evidence suggests host ALAD and FECH are scavenged by the 
parasite but this has not been independently investigated. The potential 
importation of host UROS has not previously been investigated. Here, 
western blot and immunofluorescence techniques were employed to verify 
whether the host proteins are located in Plasmodium during 
intraerythrocytic growth. 
An additional aim of this chapter was to further investigate the potential 
UROS activity provided by PJHMBS. Here, cloning and protein purification 
techniques were employed to investigate if PjHMBS can fulfill the enzymatic 
function of UROS. 
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Aim 2. Assess Plasmodium growth capacity in haem enzyme deficient red blood 
cells 
The requirement of host haem enzymes for parasite growth was investigated 
in this chapter through assessment of Plasmodium growth kinetics in human 
and mouse models of haem enzyme deficiency. The porphryias are a group of 
diseases caused by mutation(s) in the genes encoding haem enzymes, 
resulting in loss of its activity below a critical threshold. For this study, blood 
samples were obtained from patients with FECH (Erythropoietic 
protoporphryia) and UROS (Congenital Erythropoietic porphyria "Gunther's 
disease) deficiencies. P. falciparum growth was quantified in red cells 
deficient in UROS and FECH using an in vitro parasite culture system. 
Additionally, mice deficient in FECH (FechmlPas) were infected with the 
murine malaria parasite, P. chabaudi, to investigate the requirement of FECH 
during an in vivo malaria infection. 
Aim 3. Target host haem enzymes with chemical inhibitors as a novel 
antimalarial therapy 
The host haem synthetic enzymes ALAD and FECH were targeted with 
chemical inhibitors to determine their potential anti-plasmodial activity. 
Inhibitors were tested in an in vitro P. falciparum growth inhibition assay. 
Additionally, in vivo antimalarial effects were investigated in a murine model 
of malaria, P. chabaudi. One inhibitor that demonstrated in vitro effects is also 
FDA-approved for human use. In vitro Plasmodium growth was then 
examined in red cells collected from individuals taking pharmacologic doses 
of this compound. 
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Chapter 2 
Materials and methods 
2.1 Ethics 
Ethics approval for animal experiments was received from the University of 
Tasmania Animal Ethics Committee (A0001049). Ethics approval for the 
griseofulvin treatment and human blood studies was received from the 
Human Research Ethics Committee Networks of Tasmania (H0011444) and 
Melbourne Health (2011.013). 
This work was supported in part by a GlaxoSmithKline Australia Post-
graduate support grant. This grant was competitively obtained for work in 
this thesis involving validation of a high-throughput UROS assay for 
idenitfiying inhibitors. Synthesis of UROS inhibitors by collaborators in the 
UTAS School of Chemistry was ultimately unsuccessful. The postgraduate 
support grant obtained for the UROS work was completely unrelated and 
independent of other work in this thesis, which identified griseofulvin as a 
ferrochelatase inhibitor. Griseofulvin is made by several companies (one of 
which is GlaxoSmithKline) but is a drug that is off-patent and is therefore not 
a conflict of interest. 
2.2 Cloning, of human UROS and HMBS and Plasmodium falciparum 
HMBS 
2.2.1 PCR of cDNA and gel electrophoresis of PCR products 
Human Uros and Hmbs genes were amplified from cDNA derived from human 
PC-1 cells (A gift from Alison West). P. falciparum Hmbs was amplified from 
purified P. falciparum DNA (Table 2.1 for primers; all primers from 
Geneworks, South Australia, Australia). PCR products were analysed for 
correct product size using agarose gel electrophoresis, followed by 
purification using the Promega PCR clean-up kit (Promega, Wisconsin, USA). 
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2.2.2 Ligation of PCR products into pGEM-T Easy Vector system 
PCR fragments were ligated into the pGEM-T easy vector system (Promega) 
overnight at 4 °C, as per manufacturers instructions. A standard reaction 
contained 5 µl of rapid ligation buffer, 1 µl pGEM-T easy vector (50 ng), 1 µl 
T4 DNA ligase (3 Weiss units/µl) and 1-3 µl PCR product (to give a molar 
ratio of PCR product: vector of 3:1). The reaction volume was increased to 10 
µl with dHzO. A positive control was control insert DNA, instead of PCR 
product; background negative control was water instead of PCR product 
added to the reaction. 
2.2.3 Transformation using the pGEM-T easy vector ligation reactions 
2 µl of each ligation reaction was added to 50 µl of competent E. coli JM109 
cells (Promega) before being gently resuspended and placed on ice for 20 
min. The cells were heat shocked for 45 sec in a water bath at 42 °C before 
being returned to ice for 2 min. 950 µl room temp LB medium was added to 
the tubes containing cells transformed with ligation reactions. Cells were 
incubated at 37 °C for 1.5 h with shaking at 150 rpm. 100 µI of each 
transformation culture was plated onto duplicate LB plates with ampicillin (1 
µg/ml), IPTG (0.1 M) and X-GAL (50 mg/ml). Plates were incubated ON at 37 
oc. 
2.2.4 Colony selection and analysis for insert by PCR 
Upon growth of colonies, at least 8 white colonies ( containing the insert) 
were picked with a pipette tip, dipped into 10 µl dHzO before being added to 
2 ml LB both with ampicillin (1 µg/ml). Media with tips were incubated ON at 
37 °C with shaking and added 1:1 to 80 % glycerol before being placed at -80 
°C, as a backup of selected colonies. The water inoculated with a selected 
colony was subjected to PCR using the T7 and SP6 primers (Table 2.1) to 
determine if the correct sized insert was present. The PCR reaction consisted 
of 10 µl GoTaq Green (Promega), 1 µl T7 (10 µM), 1 µl SP6 (10 µM), 8 µl 
colony inoculated dHzO. PCR conditions consisted of 95 °C denaturation 5 
min; 95 °C 30 sec, 52 °C 30 sec, 72 °C 30 sec (35 cycles); 72 °C 10 min. PCR 
products were analysed using 1 % agarose gel electrophoresis. 
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2.2.5 Restriction enzyme digest on colonies with correct sized insert 
Colonies displaying the correct sized insert as determined by PCR analysis, 
were grown overnight in LB broth before being purified using a plasmid mini 
prep kit (Promega). Plasmid DNA was quantified on a spectrophotometer 
(Nano Drop Technologies, Delaware, USA). To ensure the correct insert was in 
the purified plasmid DNA, a restriction enzyme digest was performed using 
EcoRI (New England Biolabs, Massachusetts, USA). Reactions consisted of 
100 ng purified plasmid, 1 µl EcoRI, 2 µl lOx buffer and dH20 up to 10 µ1. An 
uncut plasmid control was run for each reaction, consisting of a reaction 
without EcoRI. Restriction enzyme digests were incubated at 37 °C for 4 h 
prior to analysis using 1 % gel agarose electrophoresis. 
2.2.6 Sequencing of recombinant plasmids 
Purified plasmids were sent to the Australian Genome Research Facility 
(AGRF; St Lucia, Qld) for sequencing using the SP6 and T7 primers. Reactions 
contained 150 ng purified plasmid, 2 µL of primer (3.3 µM) and brought up to 
10 µL with dH20. Sequences were analysed using VecterNTI to check for 
changes against the reference sequences (NCBI). 
2.2.7 Subcloning amplified and cloned genes in to pGEX expression vector. 
Clones with correct sequences and start sites were then digested from the 
pGEM-T easy vector with EcoRI restriction enzyme (New England Biolabs). 
Restriction digest reactions consisted of 500 ng purified plasmid, 1 µl EcoRI 
(12 units), 2 µl lOx buffer and dH20 up to 20 µI. Products were analysed on 
agarose gel electrophoresis for correct size insert, which was then cut from 
the gel and purified using a PCR and gel clean-up kit (Promega). The purified 
fragment was then quantified on the nanodrop spectrophotometer 
(NanoDrop Technologies, Delaware, USA) before being ligated into the pGEX-
6-P-3 expression vector (GE Healthcare, Wisconsin, USA). 
The pGEX plasmid was prepared for the subcloning by digestion with EcoRI 
(New England Biolabs) for 4 hat 37 °C. Reactions contained 10 µl pGEX DNA 
(500 ng), 10 µl lOX buffer, 1 µl EcoRI (12 u) and dH20 up to total volume of 
50 µ1. Digestion progress was monitored by agarose gel electrophoresis. The 
40 
linearized pGEX vector was dephosphorylated using RAPID alkaline 
phosphatase (Roche, New South Wales). Reaction contained 10 µI linearized 
pGEX DNA, 10x phosphatase buffer, 1 µI alkaline phosphatase and 7 µL dH20. 
Reaction was incubated for 30 min at 37 °C, followed by phosphatase 
inactivation for 2 min at 75 °C. 
Gel-purified insert sequences were then ligated into the linearized and 
dephosphorylated pGEX vector. The ligation reaction contained 2 µl 
linearized dephosphorylated pGEX DNA, 5 µl gel purified insert DNA, 2 µI 10x 
T4 ligase buffer, 1 µI T4 DNA ligase, dH20 up to 20 µI. Reactions were 
incubated for 2 h at 10 °C and terminated at 65 °C for 10 min. 
Purified recombinant plasmids were then transformed into competent E.coli 
BL21 cells (GE Healthcare) for expression of the fusion protein. BL21 cells 
were made competent using MgCl2 (Sigma; Missouri, USA). Briefly, a single 
BL21 colony was isolated from an LB plate and incubated at 37 °C until and 
optical density (600 nm wavelength; A6oo) of 0.4-0.5 was reached. Cells were 
sedimented at 2500 x g for 15 min at 4 °C, then gently resuspended in 1/10 
volume of ice-cold transformation and storage solution (1.0 g tryptone, 0.5 g 
yeast extract, 0.5 g NaCl, 10 g polyethylene glycol, 5 ml dimethylsulfoxide, 5 
ml MgCl2 (1 M) (All from Sigma) and dH20 up to 100 ml, pH 6.5) and placed 
on ice. 
For transformation, 20 µI of the ligation reaction or 1 ng uncut vector 
(positive control) or 20 µI dH20 (negative control) was added to 1 ml freshly 
prepared competent BL21 cells. Cells were incubated at 42 °C for 2 min 
before being returned to ice. 100 µI of transformed cells were added to 900 
µl warmed LB broth and incubated for 1 hat 37 °C with shaking (250 rpm). 
100 µl of diluted transformed cells from the samples were plated on LB/amp 
plates at 37 °C ON. Up to 50 colonies were selected and subjected to PCR 
analyses using the pGEX primers (Table 2.1) to determine if the recombinant 
plasmid was present. Several colonies were sequenced (as above) to check 
for correct insert and orientation. Colonies with correct recombinant 
plasmids were grown ON in LB broth with ampicillin. 500 µl of ON stock was 
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added to 500 µl of 100% glycerol and placed at -80 for future induction of 
fusion protein. 
Table 2.1 Oligonucleotide primer sequences. 
Oligonucleotide name Oligonucleotide sequence 
HsUROS-F ATGAAGGTTCTTTTACTGAAGGATGC 
HsUROS-R CAGGCTTGAGGCAGGAGTCTGAC 
HsHMBS-F ATGTCTGGTAACGGCAATGCGGCTG 
HsHMBS- R CCCTGCAGTTCAGTCTCCCGGGGTAA 
PfHMBS-F GGGCTGGCAAGCCACGTTTGGTG 
PfHMBS-R CCGGGAGCTGCATGTGTCAGAGG 
SP6 GATTTAGGTGACACTATAG 
T7 TAATACGACTCACTATAGGG 
pGEX-F GGGCTGGCAAGCCACGTTTGGTG 
pGEX-R CCGGGAGCTGCATGTGTCAGAGG 
F= forward primer, R= reverse primer; all primers from Geneworks 
2.3 Expression of recombinant proteins 
2.3.1 Screening pGEX recombinants for fusion protein expression 
2 ml warmed LB broth with ampicillin were inoculated from the frozen 
culture stocks and grown ON at 37 °C. For comparison, a control tube was 
inoculated with bacteria transformed with parental pGEX plasmid. ON 
cultures were diluted 1:100 into fresh LB and grown to an A6oo of 0.6-0.8 with 
vigorous agitation at 37 °C. Fusion protein expression was inducted with 2 µI 
of 100mM IPTG to give a final concentration of 1 mM. Incubation was 
continued for additional 1-2 h. Cultures were centrifuged in a 
microcentrifuge for five min at 500 x g and the supernatant was discarded. 
Each pellet was resuspended in 200 µI of ice-cold PBS. 10 µI of each cell 
42 
suspension was transferred into separate tube for SDS-PAGE analysis. 2 µl of 
lysozyme solution (Sigma) (at 10 mg/mL) was added to remaining cells and 
were then vortexed and incubated at room temperature for 5 min. Cells were 
then lysed by repeated cycle of freeze/thaw in dry-ice/warm water. The 
lysates was centrifuged in a microcentrifuge for 10 min to remove insoluble 
material. 10 µl of insoluble material was reserved for SDS-PAGE analysis. The 
supernatant (soluble material) was transferred to fresh tubes, with 10 µl 
being reserved for SDS-PAGE analysis. 
2.3.2 SOS-PAGE analysis of fusion protein expression 
The 10 µl samples previously saved from each induced recombinant pGEX 
colony were added to 2 µl of 6x SDS-PAGE loading buffer (0.35 M Tris-HCL, 
10.28 % SDS, 36 % glycerol, 0.6 M dithiothreitol, 0.012 % bromophenol blue). 
Samples were mixed and heated at 95 °C for 5 min before being placed on ice. 
Samples were loaded onto 12.5 % SDS-polyacrylamide gel and 
electrophoresed at 200 volts for 1 h. Gels were stained with BioSafe 
Coomassie stain (Biorad, California, USA) for 1 h, followed by 1 h of rinsing 
with dH20 to visualise fusion protein induction. 
2.3.3 Optimisation of fusion protein expression 
Colonies that did not express any fusion protein as indicated by SDS-PAGE 
analysis, were subjected to varying fusion protein induction conditions. 
These included varying IPTG amount (0.1-10 mM), length of induction (1-18 
h), A600 level (0.5-2), aeration level and induction temperature (18 to 37 °C). 
Each attempted induction was analysed by SDS-PAGE analysis (as above). 
2.3.4 Preparation of large-scale recombinant protein from bacterial lysates 
When the optimal induction condition for each fusion protein was identified, 
preparation of large-scale recombinant protein lysates for purification was 
attempted. A single colony of BL21 cells containing recombinant plasmid was 
used to inoculate 12 ml of LB medium with ampicillin. Inoculated cultures 
were grown at previously optimised conditions with the addition of IPTG to 
induce expression the fusion proteins. Induced cultures were treated as 
above to lyse cells and separate the soluble and insoluble fractions. 
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2.3.5 GST tagged protein purification 
The soluble protein was subjected to purification using the GST Spintrap 
purification columns, according to standard protocol (GE healthcare), with 
samples collected throughout the purification process for analysis by SDS-
PAGE. Briefly, resin was resuspended in column by vortexing briefly prior to 
use. Columns were centrifuged at 735 x g in a microcentrifuge and resulting 
buffer from each column was discarded. Up to 600 µl of supernatant from 
culture lysate was added to each column, before being mixed gently at room 
temperature for 10 min to ensure optimal binding of GST proteins to the 
glutathione sepahrose matrix. Columns were placed in a clean Eppendorf 
tube and spun in a microcentrifuge for 1 min at 735 x g to collect flow 
through. Columns were placed into clean Eppendorf tubes and 600 µl of PBS 
was added and spun as above to wash the matrix. This was repeated twice 
with 10 µl of each wash collected for SDS-PAGE analysis. 100 µl of 
glutathione elution buffer was added to each column and incubated at room 
temperature for 10 min. Columns were placed into clean Eppendorf tubes 
before being spun as above for 1 min at 735 x g to collect eluate. This was 
repeated to collect the second eluate with samples of both elutions collected 
for SDS-PAGE analysis. 
2.3.6 Cleavage of GST tag by PreScission protease 
On-column cleavage of the fusion protein was conducted when the fusion 
protein was bound to the glutathione sepharose column (as above). Upon 
binding of the GST-fusion protein to the matrix, the column was washed with 
1 ml of cleavage buffer at 4 °C. 40 µI of PreScission protease (80 units) (GE 
healthcare) was then added to 960 µl cleavage buffer (SO mM Tris-HCL, 150 
mM NaCl, 1 mM EDTA, 1 mM dithiothreitol) and added to the fusion protein-
bound column, followed by incubation at 4 °C for 4 h. Eluate was collected by 
centrifugation at 735 x g for 5 min. The eluate contained the protein of 
interest, while the GST portion of the fusion protein and the PreScission 
protease remain bound to the glutathione sepharose matrix. The eluates 
were subjected to SDS-PAGE analysis and immunoblotting to confirm 
cleavage of the GST moiety. 
44 
Samples were immunoblotted and visualised (as described in section 2.6); 
antibodies used were anti-human UROS (Santa Cruz; sc-100637), anti human 
HMBS (Sigma; HPA006114), anti-glutathione-S-Transferase (GST) (Sigma; 
G7781)(all at 1:500 dilutions) and goat anti-mouse HRP conjugated antibody 
(Sigma) (at 1:1000 dilution). 
2.4 Coupled enzyme assay to measure UROS activity 
The coupled enzyme assay to measure UROS activity was performed as 
described by Omata and colleagues (Omata et al., 2004). Briefly, HMBS 
generates the hydroxymethylbilane substrate for UROS from 
porphobilinogen and the ratio of uroporphyrinogen-1 and III are measured by 
ultra performance liquid chromatography-mass spectrometry (UPLC-MS). 
Initially, the units of purified recombinant HMBS were defined by optical 
quantification of the amount of urporphyrin produced, as described by 
Omata and colleagues. The standard assay mixture for the coupled-enzyme 
assay contained 0.2 M sodium phosphate buffer (pH 8.0), 0.6 mM EDTA, 100 
units HMBS, 0.5 mM porphobilinogen and UROS ( equivalent to 5 ng of 
purified enzyme per assay) in a total volume of 0. 75 ml. The reaction mixture 
without porphobilinogen was pre-incubated at 37 °C for 5 min prior to the 
addition of pre-warmed porphobilinogen to initiate the reaction. After 3 min, 
0.4 ml of 0.5% 12 in 1 % KI was added to terminate the reaction and oxidise 
the uroporphyrinogens to uroporphyrins. This also acted to convert the 
remaining HMBS to non-porphyrin products. Excess lz was quenched with 
0.1 ml of 1% sodium disulfite and proteins were precipitated with 1.75 ml of 
7.1 % TCA. Assay samples were analysed by UPLC-MS to separate the 
uroporphyrins I and III on a reversed-phased column attached to a waters 
600E HPLC system. Elution was carried out with a 1 mL/min isocratic flow of 
1 M ammonium acetate containing 0.27 mM EDTA and 12.5% acetonitrile. 
The eluate was monitored with a Waters 996 photodiode array detector and 
the Soret band maximum at 400 nM was extracted. One unit of activity was 
defined as the amount of enzyme that catalyses the formation of 1 µM 
uroporphyrin-III per hour under the reaction conditions used. 
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2.5 P. falciparum culture 
P. Jalciparum strain 3D7, Kl and W2 mef (a gift from R. Anders and L. Tilley, 
La Trobe University, Victoria) were maintained at between 0.5 and 10% 
parasitaemia in purified AB+ human erythrocytes in a 1 % 02/5 % CO2 
atmosphere according to the method of Trager and Jensen (Trager and 
Jensen, 1976). The cell culture medium (CCM) comprised of RPMI 1640 
supplemented with 1X Glutamax, 0.2 % Albumax (all from Gibco, new York, 
USA), 4 % pooled AB+ human serum (Invitrogen, New York, USA), 10 mM D-
glucose, 25 µg/ml gentamycin, 6 mM HEPES and 0.2 mM hypoxanthine (all 
from Sigma). 
2.6 lmmunoblotting 
Late-stage parasitised cells (trophozoites and schizonts) were harvested 
from P. Jalciparum cultures (at approximately -10% parasitaemia) using 
Percoll density gradient centrifugation (Rivadeneira et al., 1983); 80-90% of 
the harvested cells were infected. To isolate the parasites from their host red 
cells, the harvested parasites were treated with 10 volumes of saponin (0.15 
% w /v) for 10 minutes on ice. Following centrifugation, the resulting 
supernatant (containing the hemoglobin, red cell cytosol components and red 
cell plasma membranes) was removed and the parasite pellet was washed 
with RPMI and then resuspended in PBS containing protease inhibitors 
(Complete® protease cocktail from Roche). The parasites were then 
subjected to sonication (3 x 30 sec) and protein quantified using a Bradford 
protein assay (ThermoScientific, Illinois, United States). Purified parasites 
and equivalent numbers of uninfected red blood cells were lysed in equal 
volume of 2 x SDS loading buffer (containing 0.5 % ~-mercaptoethanol), 
heated at 95 °C for 5 min, and subjected to SDS-PAGE, 12 % gel from Biorad) 
(Laemmli, 1970), and then transferred to nitrocellulose membrane. 
Membranes, blocked in 1 % blocking reagent (Roche) overnight, were then 
blotted with antibodies (in 0.5 % blocking reagent); mouse monoclonal anti-
human FECH (Santa Cruz, sc-271434), mouse monoclonal anti-human ALAD 
(Santa Cruz; sc-271585), mouse monoclonal anti-human OROS (Santa Cruz; 
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sc-100637), mouse monoclonal anti-human hexokinase (Santa Cruz; 46695), 
all diluted at 1:100, followed by goat anti-mouse conjugated peroxidase 
(1:1000 dilution Sigma). Blotted membranes were visualised using enhanced 
chemiluminescence (ECL) reagents (Thermoscientific) using a Chemi-smart 
5000 (Vilber Lourmat, Marne-la-Vallee, France). 
2.7 lmmunofluorescence staining 
Thin blood smears prepared from P. falciparum cultures were air dried, fixed 
for 30 sec in 100 % methanol, and then fixed for 20 min in 1 % 
paraformaldehyde in PBS. Slides were washed in PBS and blocked with 1 % 
BSA/0.1 % Triton X100 in PBS (PBT). Slides were then incubated in the 
following primary antibodies (overnight at 4 °C, diluted in PBT); mouse 
monoclonal anti-human FECH (Santa Cruz, sc-271434) or mouse monoclonal 
anti-human ALAD (Santa Cruz; sc-271585) or mouse monoclonal anti-human 
UROS (Santa Cruz; sc-100637) (all 1:100 dilution) and rabbit anti-PjEXP2 
(1:1000; a gift from P. Gilson, Burnet Institute, Victoria). After washing, slides 
were incubated in donkey anti-mouse Alexa Fluor® 488 (1:1000) and goat 
anti-rabbit Alexa Fluor® 594 (1:1000; both from Invitrogen) for 90 min at 
room temperature in the dark. Slides were counter-stained with DAPI 
(1:5000), washed and mounted in Slowfade Gold (Invitrogen). Slides were 
viewed on a Nikon inverted microscope at 60x magnification with a water 
immersion lens. Images were obtained using an Evolve camera and NIS-
Elements software. 
2.8 Collection and preparation of purified human red blood cells 
Blood from individuals with porphyria and from individuals treated with 
griseofulvin was collected by venipuncture into 5 ml sodium citrate tubes. 
Blood samples collected at the Menzies Research Institute Tasmania were 
used immediately. Blood samples collected from EPP patients at the Royal 
Melbourne Hospital (by Prof Ingrid Winship) were shipped immediately to 
the Menzies Research Institute Tasmania at 4 °C prior to further processing. 
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XLOPP patient blood samples were collected at Centre Frarn;:ais des 
Porphyries, Hopital Louis Mourier, Colombes (France) by Herve Puy prior to 
immediate shipment to the Pasteur Institute, Paris. Blood was then 
centrifuged at 170 x g for 13 minutes and the plasma, platelet and white cell 
fractions removed. Blood was washed two times in RPMI and stored at 4 °C, 
and then washed further prior to use. 
2.9 P. falciparum growth inhibition assay 
For succinylaetone (SA) growth inhibition assays, two experimental 
approaches were taken. Firstly, synchronized trophozoite-stage P. falciparum 
(307) were incubated continuously with the inhibitor for 48 h. The second 
approach involved preincubating uninfected red cells with SA for 2 h, prior to 
repeated washing with RPMI to remove excess unbound SA. Aminolevulinic 
acid (2 mM) was then added to pre-treated red cells to non-enzymatically 
convert any unbound SA to a pyrrole (Ebert et al., 1979). Synchronised 
trophozoite-stage P. falciparum (307) parasites were then added to the pre-
treated red cells ( at a final percentage between 0.5-1 %) and cultured for a 
further 48 h prior to analysis. 
For N-methylprotoporphyrin (NMPP) in vitro growth inhibition assays, 
synchronized ring-stage P. falciparum (307) parasites were grown in the 
presence of increasing concentrations of NMPP (Frontier Scientific, Utah, 
USA) for 48 h prior to analysis of growth and subsequent comparison with an 
untreated control. 
For the growth assays involving in vitro griseofulvin treatment, uninfected 
red cells were incubated with griseofulvin for 3 days prior to the addition of 
synchronized ring-stage P. falciparum (307 and Kl) parasites, and then 
cultured for an additional 48 h prior to analysis. The medium and 
griseofulvin was replaced every 24 h during the preincubation and growth 
assay periods. 
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For ex vivo growth assays using the porphyric blood and blood from the 
griseofulvin-treated individuals, P. falciparum (3D7) parasites grown in 
normal untreated blood were harvested by Percoll density gradient 
centrifugation or MACS column (Ribaut et al., 2008, Rivadeneira et al., 1983) 
to collect trophozoite and schizont-stage parasites. All assays were conducted 
by infecting the red cells with 0.01 x volume of purified trophozoite- and 
schizont- stage infected cells at a final percentage parasitaemia of 
approximately 0.5 %. Parasites were grown in treated/porphyric blood and 
untreated/normal blood for up to 72 h, with samples collected for analysis at 
varying time-points. 
For all growth inhibition experiments, thin-blood smears were obtained after 
incubation of the parasites for up to 72 h, stained with 10% Giemsa stain and 
the percentage of infected parasites (% parasitaemia) was determined by 
counting cells under a light microscope. At least 1000 cells were counted on 
each slide. In some experiments parasite growth was also quantified by flow 
cytometric analysis using YOY0-1 dye (Invitrogen) (Li et al., 2007). 
Percentage parasite growth (parasitemia divided by the untreated or normal 
blood control parasitemia x 100) and percentage growth inhibition (the 
calculated % parasite growth of each sample subtracted from 100) were 
determined by comparison of growth in cultures treated without drug, or in 
blood from normal, untreated individuals. Each drug-treated sample, 
porphyria blood sample or control sample was completed in triplicate. Each 
entire experiment was indepenendly repeated at least twice. 
2.10 Experimental P. chabaudi infection 
There are several murine models of Plasmodium that replicate different 
aspects of P. falciparum infection. P. chabaudi was used in this study as it is 
most similar to P. falciparum blood stage of infection, with the exception that 
cerebral malaria does not occur. Upon intravenous injection with P. chabaudi, 
a 24-hour cycle of red cell invasion, growth and rupture occurs, resulting in 
increased proportions of infected red cells (% parasitaemia) over the ensuing 
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days. Upon peak parasitaemia, mice will either survive (with a resulting 
decrease in circulating infected red cells) or succumb to infection. Survival is 
also dependent on the sex and genetic background of the mice (Stevenson et 
al., 1982, Stevenson et al., 1990). 
2.10.1 P. chabaudi infection of FechmlPas mice 
FechmlPas mice, originally produced from an ENU-mutagenesis screen at the 
Pasteur Institute (Paris, France) were kindly provided by X. Montagutelli. 
Mice were genotyped as described by Abitbol (Abitbol et al., 2005). Female 
and male Fech+I+, Fech+I- and Fech-1- mice on an isogenic (C57BL/6) or mixed 
(C57BL/6 and BALB/c background were infected with the rodent malarial 
species Plasmodium chabaudi adami DS at 7-12 weeks of age. Female mice 
were routinely infected intravenously with 5 x 105 iRBC/ml and male mice 
were infected with 2.5 x 105 iRBC/ml. Blood stage parasitaemia (% infected 
red blood cells) for each mouse during infection was determined by counting 
cells on Giemsa-stained (10 % Giemsa solution) thin blood smears taken 
from tail bleeds of mice during the course of infection. Percentage 
parasitaemia was calculated by counting at least 500 cells per slide. 
2.10.2 P. chabaudi infection of SA-treated mice 
Male C57BL/6 mice between 7-12 weeks of age received an established dose 
of SA (in saline) the day prior to infection, the day of infection and everyday 
for eight days. Control mice received saline at the same time-points. All mice 
were infected with 2.5 x 105 iRBC/ml RBC. Blood stage parasitaemia (% 
infected red blood cells) for each mouse during infection was determined by 
counting cells on Giemsa-stained thin blood smears (as above). 
2.11 ALAD assay of peripheral mouse blood 
Blood samples were obtained from experimental mice and assayed for 
peripheral blood ALAD activity according to the method of Wigfield and 
Farant (Wigfield and Farant, 1981 ). ALAD activity was expressed as µM 
porphobilinogen produced per h at 37 °C, relative to the untreated control 
sample. 
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2.12 Haematological analysis of SA-treated mice 
Blood samples were obtained by mandibular bleeding from experimental 
mice (-250 uL collected) and complete blood analysis was performed using 
an Advia 2120 haematology system (Bayer Healthcare, New York, USA) using 
the CBC/D IFF /RETI C and CS 7BL/ 6 mouse settings. 
2.13 UPLC-MS analysis of griseofulvin levels in blood 
Quantification of griseofulvin in blood from griseofulvin treated volunteers 
or griseofulvin pre-incubated red cells was analysed by Ultra-Performance 
Liquid Chromatography-Mass Spectrometry (UPLC-MS) using a Waters 
Acquity H-series UPLC coupled to a Waters Xevo triple quadruple mass 
spectrometer as described previously (Mensch et al., 2007). 
2.14 Statistical Analysis 
P values were calculated in Microsoft Excel software using two-tailed t-tests 
assuming equal variance. P<0.05 was determined as significant. 
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2.15 General recipes 
LB broth 
12.5 g LB broth (Astral), with 500 ml distilled H20 (dHzO), autoclaved 
LB agar plates with ampicillin 
12.5g LB, 7.5g agar into 500mL dH20 
Autoclave then add 1uL ampicillin (1 µg/ml) per 100mL broth 
SDS PAGE electrophoresis buffer (10 X) 
30 g Tris base, 144 g glycine, 10 g SOS up to 1 L dH20, pH 8.3 
50mL of 10x stock was diluted with 450 mL dH20 for each electrophoresis 
run. 
Western transfer buffer 
25mM Tris, 182 mM glycine up to 1L dH20, pH 8.3 
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Chapter 3 
An investigation of the localisation of host haem enzymes 
during intraerythrocytic growth of the malarial parasite 
Introduction 
Host enzymes and proteins have been increasingly shown as important 
factors for intraerythrocytic malarial infection. Recently, several host factors 
have been implicated as essential requirements for parasite invasion, growth 
or egress. Further characterisation of essential host factors required for 
intraerythrocytic infection could pave the way for novel antimalarial 
therapeutic targets. 
It has been reported that two host haem synthetic enzymes aminolevulinate 
dehydratase (ALAD) and ferrochelatase (FECH) are scavenged by 
Plasmodium during intraerythrocytic infection (Bonday et al., 2000, Bonday 
et al., 1997, Varadharajan et al., 2004). However, these findings have been 
questioned because the presence of these enzymes in the mature red cell is 
unproven. It is also unclear why the parasite would need to scavenge host 
haem synthetic enzymes considering the parasite genome encodes a 
functional ALAD and FECH (Sato et al., 2004, Sato and Wilson, 2003, Sato and 
Wilson, 2002, Ralph et al., 2004). 
ALAD and FECH are abundant in progenitor red cells, which have a highly 
active haem synthetic pathway. Haem synthetic enzymes are distributed 
between the red cell cytosol and mitochondria. ALAD is a cytosolic enzyme, 
while FECH is located in the mitochondria where it inserts iron in 
protoporphyrin IX to form haem (Sellers et al., 2001). The mitochondria are 
therefore the ultimate site of mammalian haem synthesis. The current 
paradigm suggests that haem synthetic enzymes are expelled from the 
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developing red cell along with the mitochondria and other organelles. Recent 
proteomic studies have provided conflicting evidence, some confirmed ALAD 
and FECH were present in the mature red cell (Pasini et al., 2006), while 
others did not identify either enzyme (Alvarez-Llamas et al., 2009, Goodman 
et al., 2007, Kakhniashvili et al., 2004, Zhang et al., 2008). Therefore, the 
current study aimed to verify if ALAD and FECH are present in the mature 
red cell. 
If the mature red cell does contain residual ALAD and FECH, the parasite may 
indeed scavenge the host enzymes, as previously suggested (Bonday et al., 
2000, Bonday et al., 1997, Varadharajan et al., 2004). The parasite 
localisation of ALAD and FECH during intraerythrocytic infection remains to 
be independently confirmed and was therefore investigated in this chapter. 
A third host enzyme from the haem biosynthetic pathway, 
uroporphyrinogen-III synthase (UROS) is also of interest, considering there is 
no gene for Uros in the P. Jalciparum genome. The absence of a parasite UROS 
is an anomaly because UROS is an essential enzyme in the haem biosynthetic 
pathway and endogenous haem synthesis is essential for all cellular forms of 
life. Therefore, if UROS is present in the mature red cell, this enzyme may also 
be scavenged by the parasite to fulfill its UROS requirements for haem 
synthesis. A further aim of this chapter was to therefore investigate if host 
UROS is localised in the parasite during intraerythrocytic growth. 
An alternative explanation for the source of parasite UROS is that the enzyme 
in the haem synthesis pathway prior to UROS, hydroxymethylbilane synthase 
(HMBS; also known as porphobilinogen deaminase) may possess a dual 
HMBS and UROS function. Nagaraj and colleagues demonstrated parasite 
encoded HMBS (PjHMBS) contains UROS activity, although the activity was 
very low compared to the human version of the enzyme (Nagaraj et al., 
2008). A final aim of this chapter was therefore to further investigate the role 
of PjHMBS as a potential source of Plasmodium UROS. 
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Results 
The goals of this work were to initially investigate whether the host enzymes 
ALAD, FECH and UROS were present in the mature red cell and secondly if 
the host enzymes were localised in the parasite during intraerythrocytic 
infection. Two different approaches were used that took advantage of the 
availability of monoclonal antibodies specific to each of the human enzymes. 
These antibodies were used in Western blotting to probe protein extracts 
purified from cultures of saponin-lysed P. Jalciparum and uninfected red 
cells; and in immuno-staining of fixed P. Jalciparum-infected red blood cells. 
Analysis of the parasite-specific localisation of red cell ALAD 
Western blot analysis of uninfected human red cells was undertaken with a 
monoclonal anti-ALAD antibody against the amino acids 1-300 mapping at 
the N-terminus of ALAD of human origin. Results demonstrated the presence 
of ALAD in mature red cells (Figure 3.1 A). Furthermore, the same ALAD 
antibody was used to probe protein extracts purified from P. Jalciparum 
cultures, demonstrating a band at the same predicted size for that of the 
human ALAD (-37-39kDa) (Figure 3.1 A). It is unlikely that the band 
detected in the parasite fraction is anything other than host red cell ALAD. 
Firstly, host ALAD is not a membrane-associated protein; therefore it is 
unlikely the enzyme was adhering to the red cell membrane or 
parasitophorous vacuole membrane (PVM) of the saponin-lysed parasites. 
Secondly, the P. Jalciparum version of ALAD has a predicted size of 53kDa, 
distinct from the host protein at -37-39kDa. Finally, the human and 
Plasm odium ALAD share only 31 % amino acid sequence identity therefore it 
is unlikely that the host antibody cross-reacts with the parasite ALAD. 
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Figure 3.1 Host aminolevulinate dehydratase (ALAD) is present in uninfected 
red cells (uiRBC) and purified parasites 
(A and B) Western blot analyses of protein samples of uninfected red cells and 
purified saponin-lysed P. fa/ciparum parasites (parasites). Each lane was loaded 
with protein prepared from equal numbers of cells. Proteins were separated on 
denaturing SOS polyacrylamide gels, transferred to nitrocellulose membranes and 
immuno-blotted with anti-human ALAD antibody (A) and anti-human hexokinase 
antibody (8). 
(A) A band corresponding to the predicted size of human ALAD (37-39 kDa) is 
present in both the red cell and parasite samples. 
(B) A band corresponding to the predicted size of human hexokinase (130 kDa) is 
present in the red cell sample but not in the parasite sample, indicating that the 
parasite sample is free ofred cell cytosol. 
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Another possibility that may explain the presence of red cell ALAD in the 
parasite fraction was contamination with red cell cytosol. To rule this out, the 
presence of an additional and unrelated red cell cytosolic enzyme hexokinase 
was investigated as a control to provide evidence against the possibility of 
host red cell contamination. The same blots from the results above were 
analysed with an anti-hexokinase antibody. A band at the expected 120 kDa 
was observed in the uninfected red cell fraction but not the purified parasite 
fraction, indicating the purified parasite fraction is free of red cell 
contaminants (Figure 3.1 B). This data indicates the presence of host ALAD in 
the parasite fraction is unlikely a result of host red cell cytosolic 
contamination in the parasite lysate. However, it must be noted that the 
intensity of the host hexokinase band in the red cell fraction is very weak 
relative to that of the ALAD band in the same fraction. It is therefore possible 
that host hexokinase is present in the parasite fraction but is not abundant 
enough to be detected, given the weak signal in the red cell fraction. 
To further investigate the parasite localisation of host ALAD, a second 
approach involved immunostaining analysis of fixed preparations of cells 
from P. Jalciparum cultures. The same antibody as above, directed against 
human ALAD was used in conjunction with fluorescently labelled secondary 
antibodies and epi-fluorescence microscopy. An anti-EXP2 antibody, directed 
against the parasitophorous vacuole membrane (PVM), was used to delineate 
the boundary of the intracellular parasite and the DNA-specific dye DAPI was 
used to mark the parasite nucleus. 
Examples of uninfected red cells, ring, trophozoite and schizont iRBCs stained 
with these markers are shown in Figure 3.2. The host ALAD was evenly 
distributed in the uninfected red cells, consistent with a cytosolic location. 
This staining was distinct from that of the isotype control. The host ALAD 
staining was unchanged when an early ring-stage parasite (based on the 
absence of hemozoin pigment) was present. There was some concentration 
of host ALAD observed around the PVM marker at the late-ring and 
trophozoite stage, consistent with the growth stages of the parasite. 
57 
uiRBC 
Jsotpe 
control 
Ring 
Trophozoite 
Schizont 
DIC Nucleus Vacuole ALAD Merge 
Figure 3.2. Host aminolevulinate dehydratase (ALAD) is present in uninfected 
RBCs (uiRBC) and localised in the parasite during intraerythrocytic growth 
Representative images showing P. falciparum infected red blood cells immuno-
stained with anti-human ALAD and anti-EXP2 antibodies, and stained with the DNA-
specific dye DAPI (to detect parasite nuclei). Anti-EXP2 was used to detect the 
parasitophorous vacuole membrane (PVM). The images overlaid (merge) to show 
colocalisation (anti-ALAD in green, anti-EXP2 in red and DAPI in blue). Anti-ALAD 
staining is evident in uninfected red cells (uiRBC), this staining was distinct as 
compared to background levels of signal detected by isotype control antibodies. 
Different developmental stages of the parasite are depicted in early ring-stage, 
mature trophozoite stage, and schizont stage. ALAD staining is unchanged in ring-
stage iRBCs but starts to accumulate around the PVM at the trophozoite stage of 
infection. ALAD is almost entirely within the PVM by the schizont stage. 
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By the late-stage of development (schizont stage), the host stain was almost 
entirely within the PVM. Additional varying punctate ALAD staining was also 
observed within the parasite at this stage, possibly due to a specific sub-
cellular location or compartmentalisation of the host enzyme. These 
observations indicate that the host ALAD is progressively accumulated within 
the PV of the parasite, and is consistent with the uptake of this host enzyme 
during the growth of the parasite. This observation is consistent with 
previous published findings (Bonday et al., 2000, Bonday et al., 1997, 
Dhanasekaran et al., 2004). 
Analysis of the parasite-specific localisation of host red cell FECH enzyme. 
Western blot analysis of uninfected human red cells was undertaken with a 
monoclonal anti-FECH antibody raised against amino acids 124-243 mapping 
at the C-terminus of FECH of human origin. Results demonstrated the 
presence of FECH in mature red cells (Figure 3.3). This result indicates that 
there is still some residual FECH present in the mature red cell, even though 
FECH is a mitochondrial enzyme. Furthermore, the same FECH antibody was 
used to probe the same protein extracts purified from P. Jalciparum cultures 
( as used above) and previously shown to be free of red cell cytosol (Figure 
3.1 B). Results demonstrated a band at the same predicted size for that of the 
human FECH (-40-43 kDa) (Figure 3.3). While the parasite FECH is 
estimated at the same size as the human FECH, there is only 28% sequence 
identity between the amino acid sequences and therefore likely that the band 
detected in the parasite fraction is host red cell FECH. 
Fixed preparations of cells from P. Jalciparum cultures were then used for 
immunostaining analysis to further investigate the parasite localisation of 
host FECH (As for ALAD). The same antibody as above, directed against 
human FECH, was used in conjunction with fluorescently labelled secondary 
antibodies, anti-EXP2, DAPI and epi-fluorescence microscopy. Examples of 
uninfected red cells, ring, trophozoite and schizont iRBCs stained with these 
markers are shown in Figure 3.4. The host FECH was evenly distributed in 
the uninfected red cells, which is interesting considering the mitochondrial 
location of this enzyme in developing red cells. This staining was distinct 
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from that of the isotype control. The host FECH staining was mostly 
unchanged in early ring-stage parasites but some concentration of host FECH 
was observed (Figure 3.4; ring). By the late ring and trophozoite stage of 
infection, the host FECH staining was observed around the PVM and at the 
late-stage of development (schizont stage), the host stain was almost entirely 
within the PVM. Additionally, the host signal appeared comparatively weaker 
in the schizont stage, possibly due to metabolism or breakdown of the host 
enzyme inside the parasite. These results are similar to that observed for 
ALAD, in that the host FECH is progressively accumulating around or within 
the PVM during growth stages of the parasite. 
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Figure 3.3 Host ferrochelatase (FECH) is present in uninfected RBCs (uiRBC) 
and purified parasites 
Western blot analyses of protein samples prepared from uiRBC and purified 
saponin-lysed P. falciparum parasites (prepared from equal numbers of cells). 
Proteins were separated on denaturing SOS polyacrylamide gels, transferred to 
nitrocellulose membranes and immuno-blotted with anti-human FECH antibody. A 
band corresponding to the predicted size of human FECH ( 40-43 kDa) is present in 
both the red cell and parasite samples. 
The same parasite preparation was used, as previously shown to be free of red cell 
cytosol (Figure 18) 
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Figure 3.4. Host ferrochelatase (FECH) is present in uninfected RBCs (uiRBC) 
and localised in the parasite during intraerythrocytic growth 
Representative images showing P. falciparum infected red blood cells immuno-
stained with anti-human FECH and anti-EXP2 antibodies, and stained with the DNA-
specific dye DAPI (to detect parasite nuclei). Anti-EXP2 was used to detect the 
parasitophorous vacuole membrane. The images overlaid (merge) to show 
colocalisation (anti-FECH in green, anti-EXP2 in red and DAPI in blue). Disperse 
anti-FECH staining is evident in uninfected red cells (uiRBC), this staining was 
distinct as compared to background levels of signal detected by isotype control 
antibodies (Isotype control); Different developmental stages of the parasite are 
depicted in early ring-stage, mature trophozoite stage (Troph), and schizont stage. 
In ring-stage iRBCs the anti-FECH staining is distinct from that of uninfected red 
cells and this staining appears to be colocalisaing around the PYM by the 
trophozoite stage. By the schizont stage of infection, the host staining is entirely 
within the PVM. 
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Analysis of the parasite-specific localisation of host red cell UROS enzyme. 
Western blot analysis of uninfected human red cells was undertaken with a 
monoclonal anti-UROS antibody raised against recombinant UROS of human 
origin. Results demonstrated that host UROS is present in mature red cells 
(Figure 3.5); this was not unexpected considering the cytosolic location of 
this enzyme in progenitor red cells. Additionally, the same UROS antibody 
was used to probe the same protein extracts purified from P. falciparum 
cultures (as used above) and previously shown to be free of red cell cytosol 
(Figure 3.1 B). Results demonstrated a band at the same predicted size for 
that of the human UROS (-26 kDa) (Figure 3.5). The parasite does not 
contain its own UROS; hence the band detected in the parasite fraction is of 
host origin. 
To further investigate the parasite localisation of host UROS, immunostaining 
analysis of fixed preparations of cells from P. falciparum cultures was also 
utilised (As for ALAD and FECH). The same antibody as above, directed 
against human UROS, was used in conjunction with fluorescently labelled 
secondary antibodies, anti-EXP2, DAPI and epi-fluorescence microscopy. 
Examples of uninfected red cells, ring, trophozoite and schizont iRBCs stained 
with these markers are shown in Figure 3.6. The host UROS was evenly 
distributed in the uninfected red cells, consistent with its cytosolic location 
and the staining was distinct from the isotype control antibody. By the late 
ring and trophozoite stage of infection, the host UROS staining was 
concentrated around the PVM. At the schizont stage of infection, the host 
UROS was entirely within the PVM. The staining was not dispersed 
throughout the parasite, indicating there may be further 
compartmentalisation of the host enzyme within the parasite. These results 
are similar to that observed for ALAD and FECH, in that the host UROS is 
progressively accumulating within the PVM during growth stages of the 
parasite. Together, the Western blotting and immunofluorescence results 
demonstrate that host UROS is localised in the parasite during growth. 
Considering the parasite does not contain its own UROS, the host enzyme 
may play a functional role in the parasite. 
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Figure 3.5. Host Uroporphyrinogen-III synthase (UROS) is present in 
uninfected RBCs (uiRBC) and purified parasites 
Western blot analyses of protein samples prepared from uiRBC and purified 
saponin-lysed P. falciparum parasites (prepared from equal numbers of cells). 
Proteins were separated on denaturing SOS polyacrylamide gels, transferred to 
nitrocellulose membranes and immuno-blotted with anti-human UROS antibody. A 
band corresponding to the predicted size of human UROS (29 kDa) is present in both 
the red cell and parasite samples. 
The same parasite preparation was used, as previously shown to be free of red cell 
cytosol (Figure 1B). 
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Figure 3.6. Host Uroporphyrinogen-III synthase (UROS) is present in 
uninfected red cells and localised in the parasite during growth 
Representative images showing P. Jalciparum infected red blood cells immuno-
stained with anti-human UROS and anti-EXP2 antibodies, and stained with the DNA-
specific dye DAPI (to detect parasite nuclei). The images overlaid (merge) to show 
colocalisation (anti-UROS in green, anti-EXP2 in red and DAPI in blue) . Disperse 
anti-UROS staining is evident in uninfected red cells (uiRBC), this staining was 
distinct as compared to background levels of signal detected by isotype control 
antibodies. Different developmental stages of the parasite are depicted in early ring-
stage, mature trophozoite stage, and schizont stage. The UROS stain starts to 
concentrate and colocalise with the parasite vacuole at the trophozoite stage and by 
schizont stage, the host stain is entirely within the parasite vacuole and around the 
nucleus. 
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Can PfHMBS fulfill the enzymatic function of UROS? 
Results so far presented in this chapter indicate host UROS is localised in the 
parasite during intraerythrocytic growth and may act as the parasite's UROS 
source for haem synthesis. An alternative hypothesis suggests that 
Plasmodium-encoded HMBS (PjHMBS) has dual-functionality and possesses 
UROS activity (Nagaraj et al., 2008). Work here further investigated this 
reported finding, and aimed to assess the contribution of host UROS and 
PjHMBS towards overall UROS activity in the parasite. To do this, purified 
recombinant forms of both PjHMBS and human HMBS and UROS were 
produced to test and compare levels of UROS activity. 
Cloning and expression of PfHMBS 
PjHMBS was successfully amplified and cloned into the pGEX-3-P expression 
vector (Figure 3.7 A and B), via a sub-cloning using the pGEM-T easy plasmid. 
Clones with no sequence errors ( as determined by sequencing; figure 3. 7 C) 
were transformed into BL21 E. coli cells, a strain designed to maximize 
expression of full-length proteins. The PjHMBS fusion protein could not be 
induced in BL21 E. coli cells under a variety of trial induction conditions 
including varying IPTG amounts, temperature of induction and length of 
induction (Table 3.1). Several PjHMBS-pGEX clones were trialed under these 
conditions. Overall, the expression of PjHMBS as a fusion protein in this 
chapter was unsuccessful; hence the large-scale induction and purification of 
this protein was unable to be carried out. 
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Figure 3.7 Amplification, cloning and sequencing of PfHMBS 
(A) Amplification of the N-terminal truncated PjHMBS from purified parasite DNA 
using gradient PCR (Temperature range 55 to 65°C). Lane 1-4 show product 1.2 kb 
as compared to the no template control (NTC). 
(8) Restriction enzyme digest (using EcoRI restriction enzyme) of purified DNA from 
selected pGEX fusion protein clones transformed with positive control DNA (1), 
PjHMBS (2) or pGEX vector alone (3). The positive control demonstrates a product 
that is cut from the vector at the expected 700bp (1). The purified PjHMBS colony in 
(2) has a product at the expected 1.1kb as compared to the pGEX vector alone (3). 
(C) Selected segment from sequencing of the PjHMBS clone (from purified DNA of 
the correct clone above), demonstrating the start site of the PjHMBS-pGEX sequence, 
an additional T cloned in via PCR from the original sub-cloning into pGEM-T easy, 
the pGEX vector sequence and one of the EcoRI restriction enzyme sites. The 
PjHMBS sequence showed no base pair changes from the reference sequence 
(accession# XP _001350505, NCBJ). 
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Table 3.1 Summary of induction conditions trialed for PfHMBS fusion 
protein expression. 
Trial# IPTG Temperature Length of Induction of 
concentration (OC) induction fusion protein 
1 O.lmM 37 lh No 
2 0.lmM 37 2h No 
3 O.lmM 37 Overnight No 
4 O.lmM 20 lh No 
5 O.lmM 20 2h No 
6 O.lmM 20 Overnight No 
7 lmM 37 lh No 
8 lmM 37 2h No 
9 lmM 37 Overnight No 
10 lmM 20 lh No 
11 lmM 20 2h No 
12 lmM 20 Overnight No 
13 10mM 37 lh No 
14 10mM 37 2h No 
15 10mM 37 Overnight No 
16 10mM 20 lh No 
17 10mM 20 2h No 
18 10mM 20 Overnight No 
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Cloning, expression and purification of human HMBS and UROS as enzyme 
sources for the coupled-enzyme assay 
While the attempted expression of PjHMBS occurred, an assay system to test 
for UROS activity was concurrently developed. The hydroxymethylbilane 
substrate of UROS is highly unstable; as such the assay is a coupled-enzyme 
system requiring both UROS and HMBS sources, as based on the described 
method (Omata et al., 2004). Successful cloning of the full-length human 
UROS and HMBS into the expression vector pGEX was conducted as for 
PJHMBS. Several clones for each protein were sequenced prior to 
transformation into BL21 E.coli cells for induction of fusion protein 
expression. 
Proteins of the correct size for HMBS were induced with 1 mM IPTG at 37 °C 
for 1 hour with the subsequent large-scale expression and purification 
completed successfully (Figure 3.8 A and B). Proteins for the correct size for 
UROS were induced with 1 mM IPTG at 37 °C for 1 hour but the majority of 
protein was insoluble (Figure 3.9 A). Conditions were altered to try and 
increase the soluble yield without any success. The final purified UROS 
protein could not be detected on an SOS-PAGE gel using Coomassie stain but 
was present at the correct size upon western blot analysis, indicating there 
was some soluble protein able to be expressed and purified (Figure 3.9 A and 
B). 
The expressed and purified HMBS and UROS were initially tested in the 
couple-enzyme assay (as described in section 2.4) with no detectable 
product. Subsequently, the GST-tag was cleaved from each of the purified 
proteins to be trialed for activity in the assay. Due to the failure of PjHMBS to 
be expressed, subsequent development of the assay was put on hold and 
ultimately was not completed. Future work will aim to continue development 
of the coupled-enzyme assay using the UROS and HMBS sources purified in 
this study. 
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Figure 3.8 Expression and purification of Human HMBS-pGEX fusion protein 
6 
(A) Coomassie stained SOS-PAGE gel of protein lysate from a selected HMBS clone 
that was uninduced (1); induced with lmM IPTG for 1 hour at 37°C, with an arrow 
showing the induced protein band (2) ; insoluble HMBS protein from the induced 
clone (3); insoluble HMBS protein from bacterial lysate (4); soluble HMBS protein 
that was subsequently purified on a glutathione sepharose column; flow through of 
unbound protein from the column purification (5) and purified HMBS-pGEX protein 
at the estimated 66kDa (6). 
(B) Western blotting of purified HMBS using an anti-HM BS antibody after cleavage 
of the GST tag. The first elution after on column purification and cleavage 
demonstrates both uncleaved (66kDa) and cleaved (39kDa) HMBS (1), while the 
second elution (2) only contains pure HMBS with no residual GST tag. 
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Figure 3.9 Expression and purification of Human UROS-pGEX fusion protein 
(A) Coomassie stained SOS-PAGE gel of lysate from an uninduced UROS-pGEX clone 
(1); induced with lmM lPTG for 1 hour at 37°C, with an arrow showing the induced 
fusion protein band at 55 kDa (2); soluble UROS protein (3); insoluble UROS protein 
from the induced clone ( 4); flow-through eluate of unbound protein from the 
column purification (5) and a washing step (6). There was no visible band in the 
final elution product (7). 
(8) Western blotting of purified UROS with an anti-UROS antibody after cleavage of 
the GST tag. The first and second elutions off the column (1 and 2) show a band at 
the expected size of 26kDa but both have some residual uncleaved UROS-pGEX 
protein, as compared to RBC lysate run in (3). 
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Discussion 
This chapter investigated the intraerythrocytic parasite localisation of 
several host red cell enzymes from the haem biosynthetic pathway, namely 
ALAD, FECH and UROS. Host ALAD and FECH were previously demonstrated 
to be localised in the parasite (Dhanasekaran et al., 2004, Varadharajan et al., 
2004) and results in this chapter confirmed this. The P. falciparum genome 
does not contain a gene for UROS, therefore red cell UROS was hypothesised 
to be scavenged by the parasite. Results from this chapter demonstrated that 
host UROS is present in the mature red cell and is also located in Plasmodium 
during the growth-stages of parasite development. 
Haem synthetic enzymes are present in the mature red cell 
Results in this thesis demonstrated the host haem enzymes ALAD, FECH and 
UROS are present in the mature red cell. It was important to establish this, 
considering the mature red cell does not require an active biosynthetic 
pathway. If these enzymes were not present in the mature red cell, they 
obviously would not be available to be scavenged by the parasite as this 
chapter proposed. Results from Western blotting and immunofluorescence 
studies using antibodies against the host ALAD and UROS demonstrated that 
the enzymes were present throughout the uninfected red cell. These results 
were consistent with the cytosolic location of ALAD and UROS in progenitor 
red cells. FECH was also demonstrated to be present in the mature red cell, 
which was unexpected considering that it is located on the inner and outer 
membrane of the mitochondria in progenitor red cells (Chen et al., 2010). A 
possible explanation for the presence of this mitochondrial enzyme is that 
some FECH remains when the mitochondria are degraded in exosomes prior 
to removal from the red cell; or alternatively, after FECH is post-
translationally cleaved in the cytosol, not all of the enzyme may be 
translocated into the mitochondria for enzymatic function. As such, there 
may be some residual FECH remaining in the cytosol but this remains an 
unanswered question. 
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Host enzymes are localised in the parasite during growth 
Both western blotting and immunofluorescence techniques were employed 
in this chapter to investigate the localisation of the host haem enzymes ALAD, 
FECH and UROS during intraerythrocytic P. falciparum infection. Western 
blotting was conducted using monoclonal antibodies against the human 
proteins. All of these anti-host enzyme antibodies detected the human 
enzyme in both uninfected red cells and the purified parasite protein. These 
results indicate that the host enzymes are firstly present in the mature red 
cell and secondly, that they are localised inside the parasite. Parasites for 
Western blotting experiments were prepared by Percoll gradient density 
purification ( enabling the concentration of late-stage trophozoites and 
schizont parasites), followed by saponin treatment. Saponin is a detergent 
that lyses the red cell membrane and the parasitophorous vacuole membrane 
but not the parasite membrane (Hsiao et al., 1991). Serial washing steps then 
removed red cell cytosolic contaminants and parasitophorous vacuole (PV) 
contents. The removal of red cell contaminants from the parasite protein was 
confirmed with the use of an anti-hexokinase antibody, a red cell cytosolic 
enzyme. Therefore the host enzymes must be located inside the parasite 
plasma membrane, although the amount of each host protein was lower in 
the parasite preparation compared to the uninfected red cell preparation. 
Considering that equal cell numbers were loaded for SDS-PAGE analysis, the 
reduced host protein in the parasite may be due to the parasite metabolising 
the imported host protein. Alternatively, the percoll purification of parasites 
for Western blotting may have been yielded more trophozoites, which have 
not yet imported the host proteins (as evidenced by immunofluorescence 
studies below). 
Immunofluorescent analysis of thin blood smears of P. falciparum cultures, 
using the same human monoclonal antibodies, confirmed the western 
blotting results. ALAD, FECH and UROS staining were the same in uiRBCs and 
early ring-stage parasites but were concentrated around the PVM marker 
(EXP2) by late-ring and trophozoite stage of infection. By the schizont stage, 
the enzymes were mostly absent from the remaining red cell compartment 
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and instead entirely surrounded or were within the PVM marker. The host 
staining was not evenly distributed throughout the parasite, indicative of 
further sub-cellular compartmentalisation of the host enzymes. Further work 
utilising other parasite markers (particularly organelle and digestive vacuole 
markers) may provide further insight. An additional observation was that 
each of the host enzymes had dissipated by the late-schizont stage, possibly 
due to the host enzyme being metabolised by the parasite. Further analysis 
and quantification of this observation is required. 
One question arising from the western blotting and immunofluorescence 
work is if the host antibodies are also cross-reacting with the parasite 
enzymes. In the case of ALAD this is unlikely as the parasite and host ALAD 
amino acid sequence only share 31 % sequence identity. Additionally, 
parasite protein versions have a larger molecular weight than the host 
version (53 kDa for the parasite ALAD, 37 kDa for the host ALAD). In 
contrast, the human and parasite FECH proteins both have the same 
predicted molecular weight although cross-reaction between the parasite 
and human protein is unlikely as the amino acid sequence between the host 
and parasite FECH only share 26% sequence identity. In the case of UROS, the 
host anti-UROS antibody showed a protein band in the parasite fraction at 
the correct predicted size for the human protein (-29kDa), indicating the 
host protein is present in the parasite. Additionally, the monoclonal antibody 
against the human protein is unlikely to be cross-reacting with a plasmodial 
UROS, as there have been no genes coding for UROS annotated in the 
Plasmodium genome. Protein alignment tools have also not revealed any 
parasite proteins homologous to that of the human UROS. 
A role for host haem enzymes in parasite intraerythrocytic development 
ALAD and FECH were previously demonstrated to be scavenged by the 
parasite (Bonday et al., 1997, Dhanasekaran et al., 2004, Varadharajan et al., 
2004). It was also previously demonstrated that the host enzymes account 
for most of the total ALAD and FECH enzyme activity in the parasite 
(Dhanasekaran et al., 2004, Varadharajan et al., 2004). This finding has been 
received with considerable skepticism considering the parasite contains 
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genes encoding functional ALAD and FECH (Sato and Wilson, 2003, Sato and 
Wilson, 2002, van Dooren et al., 2006). Results presented here confirm that 
host ALAD, FECH and UROS are localised in the parasite during growth, with 
the host enzyme entirely within the parasite by the schizont stage of 
infection. Host UROS was also demonstrated to be localised within the 
parasite during intraerythrocytic growth, which has not been previously 
reported. Further questions remain regarding potential transport 
mechanisms and functional necessity of these host haem synthetic enzymes. 
The uptake of host haem synthetic enzymes may be a passive process with 
the endocytosis of haemoglobin and other red cell contents or through active 
transporters. One report by Bonday and colleagues identified a 65-kDa 
protein on the surface of P. berghei membrane that specifically bound host 
ALAD. They further identified that a truncated fragment of host ALAD 
competed with native red cell ALAD for binding to the parasite membrane, 
with parasite haem synthesis and subsequent growth impaired after the 
uptake of the truncated ALAD (Bonday et al., 2000). This work demonstrates 
the existence of transporters allowing the importation of host haem synthetic 
enzymes and also showed that the uptake of host ALAD is important for 
parasite haem synthesis. Equivalent transporters in P. Jalciparum have not 
been described and the specificity of the described transporter warrants 
further investigation. Future work could utilise live-cell imaging and further 
parasite organelle markers in conjunction with phase-contrast or confocal 
imaging to further investigate the uptake and final parasite colocalisation of 
these host haem synthetic enzymes. 
Regardless of how the host haem synthetic enzymes are transported into the 
parasite, a further question remains whether the host enzymes play a 
functional role in the parasite's own biosynthetic pathways. During 
intraerythrocytic growth the parasite has a high haem requirement, as haem 
is required for protein synthesis and as a cofactor for cytochrome c oxidase 
and cytochrome P450 (Surolia and Padmanaban, 1992). As these three host 
enzymes are localised in the parasite during growth, they may also play an 
essential role in supplementing the haem biosynthetic requirements of the 
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parasite during intraerythrocytic development. This remains to be 
confirmed; especially considering the parasite contains genes encoding active 
versions of FECH and ALAD (Sato et al., 2004, Sato and Wilson, 2003). Work 
in the next chapter aims to establish if these host enzymes are required by 
the parasite for normal intraerythrocytic growth. 
Investigation of the UROS activity of PfHMBS 
The absence of a gene coding for UROS in the P. falciparum genome has been 
a continuing question in parasite biology (Gardner et al., 2002, van Dooren et 
al., 2006). UROS is an essential enzyme in the haem pathway responsible for 
the cyclisation and inversion of the linear hydroxymethylbilane into the 
porphyrin ring, forming the basis of the haem molecule (Tsai et al., 1988). 
Work in this chapter has presented novel evidence that the host UROS is 
localised in the parasite during the late stages of intraerythrocytic infection. 
If Plasmodium can simply co-opt the host enzyme to maintain its metabolic 
haem requirements, it may in part explain the apparent absence of a parasite-
encoded UROS. 
Additional evidence has demonstrated that the parasite encoded HMBS 
(PjHMBS) is a dual function enzyme that also possesses UROS enzymatic 
activity. Nagaraj and colleagues expressed a N-terminus truncated PjHMBS 
and found it possessed a low level of UROS activity (Nagaraj et al., 2008). The 
PjHMBS protein was found to have extra residues that may be responsible for 
UROS activity. They also found that the UROS activity of PJHMBS was much 
lower than that of the host red cell enzyme. It may be possible that the 
parasite PjHMBS can yield enough UROS activity to keep minimal haem 
synthesis occurring while the parasite is not in a host red cell where it can 
feely scavenge the more efficient host enzyme. 
Work in this chapter attempted to further investigate the previous report 
that PjHMBS contained UROS activity. A coupled enzyme assay was being 
developed in conjunction with PfHMBS expression, in order to measure UROS 
activity. The assay development included cloning, expressing and purifying 
human UROS and HMBS, which was successful. PjHMBS was successfully 
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cloned into the expression vector but ultimately this protein was unable to be 
expressed; therefore the potential OROS activity could not be examined. 
Further work is needed to optimize induction of the fusion protein to verify 
the dual-enzyme activity of this enzyme and continue testing the coupled 
enzyme assay with purified OROS and HMBS cleaved from the GST-tag to 
allow activity. The contribution of the PJHMBS and host OROS for overall 
parasite OROS activity and ultimately haem synthesis may then be examined. 
Summary 
Overall this work verifies the previous reports that host ALAD and FECH are 
scavenged by the parasite (Bonday et al., 2000, Bonday et al., 1997, 
Varadharajan et al., 2004). The observations here also suggest that the 
import of these enzymes is dependent on the developmental stage of the 
parasite, with greater amounts present at later stages of parasite 
development. An additional finding of this chapter was that host OROS is also 
localised in the parasite during intraerythrocytic growth. This has not 
previously been demonstrated. If Plasmodium can scavenge the host enzyme, 
this may go some way toward explaining the absence of a parasite-encoded 
OROS. Work in the next chapter aims to establish if these host enzymes are 
required by the parasite for normal intraerythrocytic growth. 
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Chapter 4. 
Host haem enzyme deficiencies and Plasmodium growth 
Introduction 
Results in the previous chapter of this thesis support published data that the 
red cell haem enzymes ferrochelatase (FECH) and aminolevulinate 
dehydratase (ALAD) are localised in the parasite during intraerythrocytic 
growth. This was also demonstrated for additional host haem synthetic 
enzyme uroporphyrinogen-III synthase (UROS). These three host haem 
biosynthetic enzymes may be scavenged by Plasmodium as an essential 
growth requirement for parasite metabolism. This chapter proposes that 
parasite growth is impaired in red cells deficient in any of these haem 
enzymes. The requirement of host haem enzymes for sustenance of 
intraerythrocytic malarial infection was investigated in this chapter by 
examining parasite growth in red cells deficient in these enzymes, using both 
human and mouse models of haem enzyme deficiency. 
Porphyria is a rare disease caused by severe deficiencies in any one of the 
eight haem biosynthetic enzymes due to genetic or environmental factors 
(Puy et al., 2010). Each enzyme deficiency results in the accumulation of toxic 
porphyrin precursors, manifesting in different presentations of porphyria 
(Figure 4.1). The porphryias can be grouped into hepatic or erythropoietic, 
depending on the location of substrate porphyrin accumulation (Kauppinen, 
2005). 
This investigation focused on deficiencies involving the three haem enzymes 
that were previously determined to be localised in the intraerythrocytic 
parasite; ALAD, FECH and UROS. While all three deficiencies are rare, 
samples were available from UROS and FECH deficient patients (For 
overview of these porphyrias, see table 4.1). ALAD deficiency is particularly 
rare (with about six reported cases worldwide) and samples were not 
available for this study. 
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X-linked dominant 
protoporphyria 
Doss porphryia 
Acute intermittent 
porphryia 
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eryt hropoietic 
porphryia 
Porphyria cutanea 
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Figure 4.1. The haem biosynthetic pathway with corresponding enzymes and 
porphyria. In red are substrates, blue is haem synthetic enzymes and blue boxes the 
corresponding clinical porphyria syndrome manifesting as the deficiency or absence 
of each of the enzymes. ALAS, aminolevulinate synthase; ALAD, aminolevulinate 
dehydratase; HMBS, hydroxymethylbilane synthase; UROS, uroporphyrinogen Ill 
synthase; UROD, uroporphyrinogen decarboxylase; CPO, coproporphyrinogen 
oxidase; PPO, protoporphyrinogen oxidase; FECH, ferrochelatase 
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Table 4.1 Characteristics of each of the haem enzymes deficiencies used 
in this study 
Enzyme 
deficiency 
UROS 
FECH 
Porphyria 
Congenital 
erythropoietic 
porphyria 
(CEP), also 
called Gunther's 
disease 
Erthyro poietic 
protoporphryia 
(EPP) 
Mode of inheritance Prevalence Symptoms 
Autosomal recessive 1:1,000,000 Anemia, 
Hepatosplenomegaly, 
Erythrodontia, 
Cutaneous 
photosensitivity 
Predominantly 1:75,000 (The Cutaneous 
autosomal dominant Netherlands) photosensitivity, 
(requires mutant 1:200,000 Liver disease in 
allele co-inherited (Wales) severe cases 
with common 
hypermorphic 
allele); Also rarer 
autosomal recessive 
cases 
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In addition to the human EPP patient blood samples obtained for this 
investigation, the availability of a FECH deficient mouse provided an ideal model 
in which to further examine the role of host FECH in an in vivo malarial infection. 
The FechmlPas mice, generated from an ENU-mutagenesis screen, were kindly 
provided by X. Montagutelli (The Pasteur Institute, Paris, France). FechmlPas have 
an A to T substitution at nucleotide 293, which leads to a methionine to lysine 
substitution at position 98 (mutation M98K) in the murine Fech homolog 
(Boulechfar et al., 1993). The mutation results in 5% residual FECH activity in 
homozygotes and 45-65% FECH activity in heterozygotes (Tutois et al., 1991). 
The mice used in this study were maintained on an isogenic (C57BL/6) or mixed 
(C57BL/6 and BALB/c) background. 
Overall this chapter sought to determine whether haem enzyme deficient red 
cells were able to support malaria parasite growth. P. falciparum growth was 
quantified in red cells deficient in UROS and FECH using an in vitro parasite 
culture system. FechmlPas mice were infected with the murine malaria parasite, P. 
chabaudi, to investigate the requirement of FECH during an in vivo malaria 
infection. 
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Results 
Reduced Plasmodium growth in UROS-deficient human red cells 
Congenital erythropoetic porphyria (CEP; also known as Gunther's disease) is a 
rare condition, with only -150 cases reported worldwide to date (Wiederholt et 
al., 2006). One patient with confirmed CEP (Homozygous for a mutation in Uros), 
based in Australia, was recruited into the study (See table 4.2; CEP 001). Both 
CEP 001 and non-porphyria control blood were infected with synchronized late 
stage (trophozoite and schizont) P. falciparum (3D7 strain) and grown for a 
further 72 hours. Overall average parasite growth was significantly impaired in 
CEP 001 blood at each time point, after the addition of parasites, relative to the 
normal blood control (Figure 4.2 A). At T=24, parasites in UROS deficient blood 
had grown to only 45 % of the control blood levels. A reduction in new ring-stage 
parasites in the UROS deficient cells was also observed at this time-point, 
indicating that parasite invasion of new red cells may be impaired (Figure 4.28). 
The number of new rings at the second round of reinvasion (at T=72) was also 
lower in CEP blood than the control, confirming that overall reinvasion was 
impaired in CEP blood (Figure 4.28). Additionally, parasites grown in CEP blood 
did not have the same proportion of ring to trophozoite stage parasites as the 
control at T=48 and 72, indicating overall growth was also impaired in CEP blood 
(Figure 4.28). 
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Table 4.2 Overview of porphyria patient samples obtained for this study. 
Specific enzyme Porphyrins in RBC nmol/L Patient# Porphyria RBC (Normal 
activity* 
ref:<1.8nmol/L) 
CEP 001 CEP Unknown Not available 
EPP 001 EPP Unknown 37.6 
EPP 002 EPP Unknown 84.8 
EPP 003 EPP Unknown 43.9 
EPP 004 EPP Unknown 17.9 
XLDPP 001 XLDPP ALAS2: +200%*, 86.3 FECH: 4.1 * 
XLDPP 002 XLDPP ALAS2: +200%*, 51.2 FECH: 3.7* 
XLDPP 003 XLDPP ALAS2: +300%*, 25.6 FECH: 3.9* 
: -ALAS2 mutants were expressed as% of wild-type activity using prokaryotic expression vector as previously 
described(Cotter et al., 1994); N: 100% 
82 
120 
100 
~ 
.c. 80 
3 
e 
b.O 60 
.el 
"iii 
~ 40 
nl 
C. 
20 
0 
~-----t-----t-----1 
Oh 24 h 48 h 72 h 
Time after parasite addition (H) 
Figure 4.2 P. falciparum growth in UROS deficient blood. 
- .. _•Control 
..,.._CEPOOl 
Parasite growth is impaired when cultured in red cells from an individual with UROS 
deficiency ( congenital erythropoeitc porphyria; CEP 001 ). 
Average percent parasite growth was determined at different time points after in vitro 
infection of red blood cells purified from blood samples collected from one individual 
with CEP, and compared to similarly infected red cells from a non-porphyric control 
individual. Parasite growth relative to the normal control was significantly impaired in 
the UROS-deficient blood at all time-points (T=24 p=0.0093; T=48 p=0.0088; T=72 
p=0.0005). 
Data represents the mean of triplicate cultures at each time point; at least 900 cells were 
counted for each replicate. Error bars indicate SEM. 
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Figure 4.3 Individual growth stages of P. falciparum in UROS deficient blood. 
Parasite invasion and growth is impaired when cultured in red cells from an individual 
with UROS deficiency (congenital erythropoeitc porphyria; CEP 001). 
Average % infected red cells (% parasitaemia) including percent schizonts (S), 
trophozoites (T) and rings (R) at each time point for UROS deficient and control blood 
samples. Blood was infected at T=O with late stage parasites (Trophozoite-schizont). 
UROS deficient blood has a lower % of rings at T=24 and T=72, indicating invasion is 
impaired (p=O.OOland 0.004). Additionally, a lower proportion of trophozoites at T= 72, 
was observed in the UROS deficient blood, indicative of impaired growth (p= 0.004) . 
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Host FECH deficiencies impair normal parasite growth 
Human studies 
There are -20 known EPP cases in Australia. Four patients with laboratory 
confirmed FECH mutations were recruited into this study, all compound 
heterozygotes (inheriting one deleterious FECH mutation and the common low 
expression allele, IVS3-48 T /C) (Table 4.2). Collaborator Ingrid Winship 
confirmed the FECH mutations in each patient and conducted total RBC 
porphyrin analysis. The total RBC porphyrin levels were above the normal 
reference value in all four patients (> 1.8 nmol/L; table 4.2), a characteristic of 
EPP due to decreased FECH with subsequent substrate build-up. 
Purified red cells from EPP001-EPP004 and non-porphyria control bloods were 
infected with late stage (trophozoite and schizont) P.Jalciparum (3D7 strain) and 
grown for a further 72 hours. Erythrocytes from the four individuals with EPP 
displayed impaired P. Jalciparum growth in vitro compared to normal controls at 
all time-points (Figure 4.4 A, B, C and D). Further analysis of individual stages of 
parasite development in each EPP patient sample demonstrated a reduction in 
new ring-stage parasites compared to each control at T=24 (Figure 4.5 A, B, C 
and D). This was also observed at T=72, when a second round of reinvasion 
occurred in the control samples. Together, this data indicates that invasion is 
impaired in FECH deficient blood. The progression of parasites from the ring 
stage to trophozoite and schizont stage of development was variable between 
the four patients but generally parasites grown in the EPP patient blood did not 
demonstrate the same proportion of late-stage parasites as the control at T=48, 
indicating growth may also be impaired. Overall, results in the 4 EPP blood 
samples indicate that P. Jalciparum intraerythrocytic growth is severely 
compromised in FECH deficient blood. 
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Figure 4.4 P. falciparum growth in FECH deficient blood 
Parasite growth is impaired when cultured in red cells from individuals with FECH 
deficiency (Erythropoietic protoporphyria; EPP 001-004). 
- .._•Control 
--EPP002 
----·control 
--EPP004 
(A-0) Average percent parasite growth was determined at different time points after in 
vitro infection of red blood cells purified from blood samples collected from 4 individual 
with EPP, and compared to similarly infected red cells from four non-porphyric control 
individuals. Parasite growth was significantly impaired in the FECH-deficient blood 
compared to normal blood control by 72 h after parasite addition in all four EPP blood 
samples (P-values at T=72: EPP 001 p=0.00020; EPP 002 p=l.58708E-05, EPP 003 
p=0.0010; EPP 004 p=0.0011). 
Data represents the mean of triplicate cultures at each time point (EPP 002 and EPP 003 
were both independently repeated twice); at least 900 cells were counted for each 
replicate. Error bars indicate SEM. 
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Figure 4.5 Individual growth stages of P. falciparum in FECH deficient blood 
Parasite invasion is impaired when cultured in red cells from individuals with FECH 
deficiency (Erythropoietic protoporphyria; EPP 001-004). 
(A-D) Average % infected red cells (% parasitaemia) including percent schizonts (S), 
trophozoites (T) and rings (R) at each time point for each individual FECH deficient and 
control blood patient sample. Blood was infected at T=O with late stage parasites 
(Trophozoite-schizont). FECH deficient blood had a lower proportion of new rings at 
T=24 and 72 compared to control blood, indicating invasion is impaired in the EPP red 
cells (T =24 and T=72 p=< 0.05 for all EPP individuals) . 
Data represents the mean of triplicate cultures at each time point, from the same 
experiment as shown in figure 4.4 (note that results presented in the above graphs are 
from one of the independent repeats of EPP 002 and EPP 003). At least 900 cells were 
counted for each replicate. 
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Parasite growth impairment is independent of protoporphyrin 
A characteristic of EPP is a significant increase in red cell protoporphyrin 
additional to the FECH deficiency. To investigate if impaired parasite growth in 
EPP blood was due to FECH deficiencies or a direct inhibitory effect of 
protoporphyin, P. Jalciparum was additionally grown in blood samples from 
patients with X-linked dominant protoporphryia (XLDPP); a recently recognised 
porphyria caused by gain of function deletions in aminolevulinate synthase 
(ALAS2) (Whatley et al., 2008). ALAS2 is the major rate-limiting enzyme in the 
haem biosynthetic pathway, therefore gain of function deletions in the C-
terminus of the ALAS2 protein inhibit its ability to regulate the pathway. This 
leads to greatly increased substrate presentation to the remainder of the 
pathway (Whatley et al., 2008). The next rate-limiting enzyme is FECH; therefore 
XLDPP patients demonstrate a buildup of protoporphryin (with normal FECH). 
When grown in the XLDPP red cells, parasites showed the same growth kinetics 
as non-porphyria control blood (Figure 4.6 A, B and C; Figure 4.7 A, B and C), 
indicating that the growth inhibition seen in the EPP patient blood was due to 
host FECH deficiency and not increased protoporphryin. 
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Figure 4.6 Parasite growth is not impaired when cultured in XLDPP patient blood 
(A-C) Parasite growth is not significantly impaired when cultured in red cells from 
individuals with XLDPP (X-linked dominant protoporphyria; XLDPP 001-003). 
Average percent parasite growth was determined at different time points after in vitro 
infection of red blood cells purified from blood samples collected from three individuals 
with XLDPP, and compared to similarly infected red cells from a non-porphyric control 
individual. P. falciparum growth was not significantly impaired when cultured in blood 
from XLDPP individuals compared to a normal blood control. 
Data is an average of parasite growth from 3 XLDPP patients compared to 1 non-
porphyria control blood and represents the mean of triplicate cultures at each time 
point; at least 900 cells were counted for each replicate. Error bars indicate SEM. 
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Figure 4. 7 Individual stages of P. falciparum growth in XLDPP patient blood 
(A-C) Average % infected red cells (% parasitaemia) including percent schizonts (S), 
trophozoites (T) and rings (R) at each time point for each XLDPP patient and the control 
blood sample. Blood was infected at T=O with late stage parasites (Trophozoite-
schizont). There was no significant difference of parasitaemia or stage of development 
between XLDPP and control blood samples at any of the time points after parasite 
addition. 
Data represents the mean of triplicate cultures at each time point, from the same 
experiment as shown in figure 4.6. At least 900 cells were counted for each replicate. 
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Mouse studies 
Mice carrying the FechmlPas mutation were maintained on two different genetic 
backgrounds; inbred C57BL/6 and mixed (C57BL/6 and BALB/c). Mice 
homozygous for the FechmlPas mutation (Fech-1-), as well as heterozygous mice 
(Fech+I-) were infected with P. chabaudi and the course of infection compared to 
similarly infected wild-type littermates (Fech+I+). Parasite growth was 
monitored daily for each mouse over the course of infection. The dose of iRBCs 
was different for female and male mice, given that male mice are more 
susceptible to P. chabaudi infection (Stevenson et al., 1982, Stevenson et al., 
1990). 
In the isogenic background (C57BL/6) strain female Fech-1- mice had a significant 
difference in average percent parasitaemia at the peak of infection ( day 6) and a 
significant increase in survival compared to Fech+I+ and Fech+I- mice (Figure 4.8 A 
and B). Similar to the females, male Fech-1- mice also demonstrated a marked 
resistance to P. chabaudi infection, with a significant difference in average 
percent parasitaemia at the peak of infection (Day 8) and significantly increased 
survival compared to Fech+/+ and Fech-1-(Figure 4.9 A and B). 
In the mixed background strain, female Fech-1- mice had a significant difference in 
average percent parasitaemia at the peak of infection compared to Fech+I+ mice 
(Figure 4.10 A). Interestingly mice heterozygous (Fech+I-) for the Fech mutation 
(with -45-65% residual FECH activity) also displayed the same course of 
infection as the Fech-1- mice, with a significant decrease in percent parasitaemia 
at peak compared to wild-type mice. These results confirm that host FECH is 
important for malarial infection, regardless of the genetic background of the 
host. Male Fech mice on the mixed background were also challenged with P. 
chabaudi but continuing problems with frozen parasite stocks resulted in failed 
challenges (i.e. none of the control or mutant mice displayed evident 
parasitaemia ). 
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Figure 4.8 P. chabaudi infection kinetics and survival in female FechmtPas mice 
(Isogenic background). 
Homozygous female ferrochelatase deficient mice (C57BL/6 background) display a 
significantly lower infection and increased survival compared to mice with normal FECH 
levels when infected with a murine model of malaria, P. chabaudi. 
(A) Parasitaemia (% of iRBC) of P. chabaudi infected female mice. Data represent the 
mean percentage of infected red cells in mice on the indicated day following infection 
with P. chabaudi (Sxrns iRBC). The strains of mice used (all on a C57BL/6 genetic 
background) were: Fech+J+ (WT, n=22), Fech+J- (Het, n=l 7) and Fech-1- (Mut, n=12). 
There was a significant difference between Fech·I- mice and both the Fech+J+ and Fech+J-
strains at the day of peak infection (female, day 6, p <0.003). Error bars indicate SEM. 
(B) Survival of P. chabaudi infected female mice from the same experiment as (A). Mice 
were infected with P. chabaudi (as above) and monitored for survival over the time 
period indicated. There was a significant difference in survival between Fech-1- mice and 
both the Fech+J+ and Fech+J- strains (female, p < 0.01 using Mantel-cox Log-rank test of 
survival). 
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Figure 4.9 P. chabaudi infection kinetics and survival in male FechmtPas mice 
(lsogenic background). 
Homozygous male ferrochelatase deficient mice (C57BL/6 background) display a 
significantly lower infection and increased survival compared to mice with normal FECH 
levels when infected with a murine model of malaria, P. chabaudi. 
(A) Parasitaemia (% ofiRBC) of P. chabaudi infected male mice. Data represent the mean 
percentage of infected red cells in mice on the indicated day following infection with P. 
chabaudi (Male 2.Sx1os iRBC). The strains of mice used (all on a C57BL/6 genetic 
background) were: Fech+I+ (WT, n= 20), Fech+/- (Het, n= 23) and Fech-1- (Mut, n= 16). 
There was a significant difference between Fech-1- mice and both the Fech+/+ and Fech+/-
strains at the day of peak infection (male, day 8, p < 0.002). Error bars indicate SEM. 
(B) Survival of P. chabaudi infected male mice from the same experiment as (A). Mice 
were infected with P. chabaudi (as above) and monitored for survival over the time 
period indicated. There was a significant difference in survival between Fech-1- mice and 
both the Fech+/+ and Fech+I- strains (male p < 0.01 using Mantel-cox Log-rank test of 
survival). 
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Figure 4.10 P. chabaudi infection kinetics in female FechmtPas mice (mixed 
background) 
Mixed background Fech-1- and Fech+!- mice (C57BL/6 / BALB/c) display a significantly 
lower infection compared to Fech+/+ mice when infected with a murine model of malaria, 
P. chabaudi. 
Parasitaemia (% of iRBC) of P. chabaudi infected female mice. Data represent the mean 
percentage of infected red cells in mice normalised for the peak of infection from four 
independent challenges with P. chabaudi (Sx10s iRBC). The strains of mice used (on a 
mixed C57BL/6 and BALB/c genetic background) were: Fech+I+ (WT, n=16), Fech+I- (Het, 
n=14) and Fech-1- (Mut, n=14). The Fech-1- and Fech+/- mice both displayed a 
significantly lower % parasitaemia at the peak of infection, compared to Fech+I+ 
(p=<0.01). Error bars indicate SEM. 
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Discussion 
The previous chapter of this thesis investigated the intraerythrocytic localisation 
of the host haem synthetic enzymes ALAD, FECH and UROS but it is unknown 
whether these host enzymes are required for normal parasite growth. This 
chapter aimed to investigate the growth of parasites in haem synthetic enzyme 
deficient red cells, using genetic models of UROS and FECH deficiency. UROS and 
FECH deficient human red cells were infected in vitro with P. Jalciparum, while 
FECH deficient mice were infected with an in vivo murine model of malaria, P. 
chabaudi. Results in this chapter demonstrate dramatically reduced parasite 
growth in the UROS and FECH deficient models, indicating that the host enzymes 
are important for normal intraerythrocytic infection and may play a functional 
role in the parasite. 
Host FECH and UROS deficiencies inhibited parasite growth 
Haem enzyme deficiencies manifest as porphyrias in susceptible humans and 
mice. UROS deficiencies result in congenital erythropoietic porphyria (CEP) 
while severe FECH deficiencies lead to erythropoietic porphyria (EPP). This 
study utilised available blood samples from human patients with CEP and EPP, as 
well as a mouse model of FECH deficiency to investigate the importance of these 
host enzymes in malarial infection. Complete absence of enzyme activity is not 
compatible with life; therefore although these red cells have enzyme deficiencies, 
they contain some residual enzyme activity. Human red cells were infected with 
late stage Plasmodium Jalciparum parasites (trophozoites and schizonts) in vitro. 
Parasites in the enzyme-deficient red cells displayed overall lower growth 
relative to normal blood controls. Parasite growth was also impaired in the FECH 
deficient mice, with mice homozygous for the Fech mutation (and 5% residual 
FECH activity) displaying a significantly lower course of infection and increased 
survival compared to the wild-type mice (with normal FECH levels). 
The developmental stages of intraerythrocytic P. Jalciparum growth were 
analysed in the human haem synthetic enzyme deficient red cells. Results 
demonstrate that parasite invasion was impaired in both UROS and FECH 
deficient red cells, as evidenced by the lower percentage of new rings 24 and 72 
hours after parasite addition. It is difficult to conclude if invasion per se is 
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impaired or if this is due to impaired progression of late-stage parasites (trophs 
to schizonts), subsequently resulting in reduced ring-stage parasites. To further 
dissect the mechanism of impairment, whether invasion or growth, additional 
future studies could add purified merozoites to the haem enzyme deficient red 
cells in a specific invasion assay, recently described (Riglar et al., 2011). 
Additionally, TUNEL-staining could be used to investigate whether parasites are 
undergoing apoptosis in the UROS or FECH deficient red cells. 
Parasite growth inhibition in FECH-deficient red cells is independent of 
protoporphyin 
Results from this chapter demonstrate that the parasite growth impairment in 
EPP red cells is due to FECH deficiency, and not due to protoporphyrin substrate 
levels. It was important to make this distinction, to rule out the possibility that 
protoporphyrin itself was not directly inhibiting growth of the parasite, 
considering that EPP patient red cells contain high protoporphyrin (Table 4.2). 
Parasites grown in red cells from patients with XLDPP, with normal FECH but 
increased RBC protoporphyrin, showed the same rates of growth compared to 
normal control blood. This indicates that protoporphyrin does not affect parasite 
growth and confirms that the parasite impairment demonstrated in EPP patient 
cells is due to FECH deficiency. 
Host resistance to P. chabaudi infection is irrespective of genetic background 
The importance of host FECH was also demonstrated in FECH deficient mice 
infected with P. chabaudi. Fech-1- mice (with -5% residual FECH activity) 
displayed a lower peak of infection and increased survival compared to Fech+I+ 
mice (with normal FECH activity). The protective effect of the FECH deficiency 
was observed irrespective of the genetic background of the mouse. Since this 
factor is known to strongly influence the host response and resistance to 
infection (Stevenson et al., 1982, Stevenson et al., 1990), FECH deficiency must 
play an important role in the infection. The protective effect was also observed in 
both female and male mice. The lower peak parasitaemias can be explained by 
reduced rates of parasite growth and/or invasion, consistent with the parasite 
growth and invasion differences in the P. Jalciparum-infected EPP human cells. 
This therefore suggests that like its human-host-specific counterpart, P. chabaudi 
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also utilizes host red cell FECH for its own growth requirements. Interestingly, 
heterozygous mice on the mixed background exhibited the same course of 
infection as the resistant mutant mice, possibly due to the wide range of FECH 
activity in the heterozygous mice (-45-65% activity)(Tutois et al., 1991), or 
alternatively due to the effect of a modifier gene co-segregating with the mutant 
Fech allele in mixed background mice. Together these results demonstrate the 
importance of red cell FECH for normal malarial infection, regardless of the 
genetic background of the host. 
Contribution of parasite vs. host enzyme to overall parasite growth 
Results presented in this chapter demonstrate overall impaired parasite growth 
in FECH or UROS deficient host cells; however, parasite growth was not 
completely abolished in these red cells. This may be due to the small amount of 
residual host enzyme activity, as complete absence of these enzymes is not 
compatible with life. Alternatively, the parasite-encoded enzymes may provide 
sufficient enzyme activity to sustain limited infection. It has been demonstrated 
that P. Jalciparum encodes an active FECH that is localized to the mitochondria 
(Sato and Wilson, 2003, Nagaraj et al., 2009b) but additional studies found that 
the imported host version of FECH accounts for up to 80% of the parasite's FECH 
activity (Varadharajan et al., 2004). Work in this chapter provides additional 
evidence that the majority of FECH activity in the parasite is provided by the host 
enzyme, considering that parasites have impaired growth in FECH deficient red 
cells and FECH deficient mice. 
Unlike the case with FECH, the parasite does not contain a gene coding for UROS 
but previously published work has demonstrated that parasite encoded HMBS 
(PjHMBS) contains UROS activity, potentially alleviating the need for a separate 
functional UROS (Nagaraj et al., 2008). However, the host enzyme activity was 
25-30 fold higher than that of the dual function PjHMBS (Nagaraj et al., 2008). 
Considering the low UROS activity of the PjHMBS compared to that of the red cell 
enzyme, results in this chapter demonstrate that the parasite enzyme is 
insufficient to sustain growth. This indicates the parasite has an absolute 
requirement for host UROS for normal intraerythrocytic growth and replication. 
Overall, for both UROS and FECH it cannot be definitely concluded that the host 
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version of these enzymes are exclusively used by the parasite but results in this 
chapter indicate that it is likely they comprise a major source of the parasite's 
haem synthetic capacity. 
In order to further investigate the contribution of host or parasite encoded FECH 
for parasite haem synthesis; it would be useful to create a FECH and HMBS 
knockout line of P. falciparum. If FECH or HMBS deficient parasites were viable 
with normal growth kinetics, this would provide further evidence of the host 
enzyme as the major contributor to haem synthesis in the parasite. This work 
could also be extended to testing the knockout parasites in UROS and FECH 
deficient blood to more closely examine the contribution of host or parasite 
enzymes for overall haem synthesis in the parasite. 
Potential for haem enzyme deficiencies to protect the host against malarial 
infection 
Work in this chapter has shown that host UROS and FECH are required for 
intraerthrocytic growth, raising the possibility that people with these haem 
enzyme deficiencies may exhibit natural protection against blood stage malarial 
infection. While porphryias are rare, the global distribution of asymptomatic 
carriers of certain porphyria mutations may have wider implications in 
identifying new malaria protective red cell variants. In compound heterozygous 
EPP patients, the IVS3-48T /C common allele is co-inherited with a deleterious 
Fech mutation, acting in concert to decrease FECH activity below a critical 
threshold and therefore causing the porphyria phenotype (Gouya et al., 1996, 
Gouya et al., 1999, Gou ya et al., 2004). There is evidence that carriers of the IVS3-
48T /C common allele (without a deleterious Fech allele) also have reduced FECH 
activity without any porphyric symptoms (Gouya et al., 2006). The IVS3-48 T /C 
common allele is carried at a high rate in Japanese (54%), Chinese ( 43%), 
Mexican ( 44%) and South-East Asian (39%) populations (Hapmap data). It was 
also hypothesized that this allele was positively selected for in the Southeast 
Asian population (Gouya et al., 2006). These are areas where malaria has 
historically been present. It would be of interest to investigate Plasmodium 
growth kinetics in blood samples from asymptomatic carriers of the IVS3-48 T /C 
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common allele, as results from this chapter indicate that FECH deficiencies may 
also impair parasite growth. 
Future work 
A limiting factor in the investigation of parasite growth in haem enzyme deficient 
blood was the availability of small numbers of UROS and FECH deficient patients. 
Future work will continue investigating the role of host FECH in several other 
EPP patients in Australia and Europe, in collaboration with Ingrid Winship 
(Melbourne Royal hospital) and Herve Puy (Centre Franyais des Porphyries, 
H6pital Louis Mourier, France). As mentioned above, further study will also 
involve an investigation of the IVS3-48 T /C common allele and potential 
contribution towards host protection against malaria. 
In the case of UROS deficiency, there is one known CEP patient in Australia. This 
patient participated in the current study. Consent has been obtained from the 
offspring to also contribute blood samples to this study in the future. As UROS is 
inherited in an autosomal recessive fashion, the offspring are presumably 
heterozygous for the UROS mutation. The potential dose-response of residual 
enzyme activity and inhibition of parasite growth could be examined by 
correlating UROS activity and parasite growth in red cells from CEP001 and 
offspring. 
Additionally, considering the rarity of human patients with severe haem enzyme 
deficiencies, mouse models may provide a useful tool for investigating the role of 
other haem enzymes in an in vivo malarial infection. Additional to the FechmlPas 
mouse used in the present study, there are mouse models for both CEP and Doss 
porphyria (ALAD deficiency). Investigation of parasite growth in these haem 
enzyme deficient mice may provide further insight into the importance of host 
haem enzymes for parasite growth. 
Summary 
Overall, this chapter presents novel findings that genetic deficiency of the host 
haem enzymes UROS and FECH render the red cells resistant to Plasmodium 
growth. Data in the previous chapter supports the hypothesis that host enzymes 
are scavenged and data in this chapter confirms that the host enzymes play a 
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functional role in the intraerythrocytic parasite. This chapter has provided 
genetic validation that targeting host enzymes, required by the parasite for 
growth, may be a feasible host-directed therapeutic strategy. The next chapter in 
this thesis investigates the effects of pharmacologically inhibiting these host 
enzymes as a novel host-directed antimalarial therapy. 
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Chapter 5. 
Pharmacological targeting of host haem enzymes as a novel 
antimalarial therapy 
Introduction 
Work in this thesis has demonstrated that the host haem enzymes ALAD, UROS 
and FECH are localised in Plasmodium parasites during intraerythrocytic growth. 
Host UROS and FECH were then established as essential factors for parasite 
development, as parasite growth is impaired in UROS and FECH deficient red 
cells. The aim of this chapter was to determine if specific pharmacological 
inhibitors of these host enzymes can prevent parasite growth, and if they can 
thus act as novel host-directed antimalarial therapies. 
Here, chemical inhibitors of the haem enzymes aminolevulinate dehydratase 
(ALAD) and ferrochelatase (FECH) were tested for antimalarial activity. UROS 
inhibitors were not commercially available and were therefore unable to be 
tested. 
Several inhibitors were used in this section, including succinylacetone (SA), N-
methylprotoporphyrin (NMPP) and griseofulvin (Table 5.1). SA is a highly active 
non-competitive irreversible inhibitor of ALAD (Ki -0.03 µmol/1) (Ebert et al., 
1979, Sassa and Kappas, 1982, Tschudy et al., 1981, Berger et al., 1983). 
Evidence suggests that SA is a suicide substrate inhibitor, binding covalently to a 
conserved active site lysine in ALAD, (Erskine et al., 2001). NMPP is a potent 
FECH inhibitor (Ki -10 nM) (Shi and Ferreira, 2006, Cochran and Schultz, 1990). 
NMPP is a transition-state analogue of protoporphyin IX, the porphyrin substrate 
for FECH; NMPP competes with the substrate for FECH binding (Shi and Ferreira, 
2006). Griseofulvin is a FECH inhibitor, a pro-drug that reacts with the haem 
moiety of cytochrome P450 or haemoglobin to form the alkylated porphyrin 
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NMPP (Bellingham et al., 1995). Studies in this chapter investigated the potential 
anti-plasmodial activity of these three compounds. 
Table 5.1 Structures of inhibitors tested for anti-plasmodial activity 
Inhibitor 
Succinylacetone (SA) 
N-methylprotoporphyrin 
(NMPP) 
Griseofulvin 
Structure 
One of 4 
Isomers 
shown 
HO 
0 
0 
OH 
OCH3 o CH-' 
II 
C 
> () 
Cl OCH, ,l 
GRISUOfULVIN 
OH 
() 
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Results 
Inhibition of P. falciparum growth by succinylacetone 
The ALAD inhibitory capacity of succinylacetone (SA) was verified by 
measurement of ALAD activity in uninfected human red cells incubated with SA. 
ALAD activity decreased with increasing concentrations of SA, indicating SA is an 
effective ALAD inhibitor (Figure 5.1). 
The ability of SA to inhibit the growth of Plasmodium was tested in a direct P. 
falciparum growth inhibition assay, where parasites were cultured continuously 
in the presence of SA for 48 hr. There was a dose-dependant impairment of 
parasite growth, with an ICso of 12.5 µM (Figure 5.2 A). These results 
demonstrated that parasite growth is impeded by SA, which presumably acts 
through the inhibition of red cell ALAD. However, because Plasmodium also 
produces its own version of ALAD, SA could be targeting either host or parasite 
enzymes. The continuous culture assay used in the above experiments could 
therefore not distinguish if the antimalarial effect was due to inhibition of the 
host or parasite ALAD. 
SA is a non-competitive inhibitor that irreversibly binds to ALAD (Bourque et al., 
2010). This pharmacological feature of SA allowed direct targeting of the host 
enzyme. Uninfected red cells were pre-incubated with SA for two hours and then 
repeatedly washed to remove SA. Any remaining unbound SA was non-
enzymatically converted to a pyrrole by the addition of 2 mM of aminolevulinate 
(Ebert et al., 1979) prior to the addition of P. falciparum (3D7). When parasites 
were added to red cells preincubated with increasing concentrations of SA, again, 
a dose-dependant inhibition of parasite growth was demonstrated after 48 
hours, with an ICso of 2.5 µM (Figure 5.2 BJ. Closer examination of the individual 
growth stages at each time-point indicated invasion was affected, with less ring-
stage parasites in SA-treated cultures compared to the untreated control (Figure 
5.3). The parasite culture is seeded in untreated red cells. These parasites 
therefore are able to produce normal viable merozoites. The observed reduction 
in new ring-stage parasites 24 hours later is therefore due to impaired parasite 
invasion in the SA-pretreated red cells. There was also a dose-dependant 
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decrease in the proportion of parasites progressing from ring to trophozoite and 
schizont stage in the SA pre-treated red cells, indicating growth is also impaired. 
These results confirm that the anti-plasmodial activity of SA is due to specific 
inhibition of host red cell ALAD, and that levels of parasite-derived ALAD are not 
sufficient to compensate for this inhibition. 
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Figure 5.1 ALAD activity in uninfected red cells incubated with succinylacetone 
(SA) 
ALAD activity was measured in uninfected human red cells incubated with increasing 
concentrations of SA. ALAD activity is expressed as the amount of porphobilinogen (µM) 
produced per h at 37 °C relative to that of the untreated control activity; each SA 
concentration was replicated in triplicate; error bars are SEM. 
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Figure 5.2 Growth inhibition of P. falciparum infected human red cells by SA 
(A) Parasite growth inhibition (relative to untreated control) with increasing 
concentrations of SA. Assays were conducted using trophozoite-stage P. falciparum 3D7 
parasites and growth was determined after 48 h incubation. Data represent the mean of 
two independent assays (each concentration assayed in triplicate). Error bars indicate 
SEM. 
(B) Parasite growth inhibition (relative to untreated control) in red cells pretreated with 
SA. Red cells were pretreated in medium with SA for 2 h, prior to multiple washing steps 
to remove excess SA and the addition of 2 mM aminolevulinic acid (to non-enzymatically 
convert any unbound SA to a pyrrole) before infection with P. falciparum (3D7) 
parasites. Cells were infected with trophozoite-stage infected cells and parasite growth 
was determined after a further 48 h incubation. Data represent the mean of four 
independent assays ( each concentration assayed in triplicate). Error bars indicate SEM. 
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Figure 5.3 Individual growth stages of P. falciparum after incubation in red cells 
pretreated with SA 
Average percent parasitaemia (of one of the repeat experiments from above) including 
percent schizonts (S), trophozoites (T) and rings (R) at each time point after specific 
targeting of host ALAD with SA. Blood was infected at T=O with trophozoite-stage 
parasites. There is a dose-dependent decline in the percentage of new ring-stage 
parasites at T=24 (p=<0.05 for cultures pretreated with 0.25 µM SA and above) . 
Subsequently, there is also a lower proportion of ring-stage parasite progressing 
through to trophozoite and schizont stage parasites at T=48 in cultures pre-treated with 
0.25 µM SA and above (p=<0.05). 
106 
Red cell ALAD inhibition after SA administration in mice. 
The SA dose required to completely inhibit red cell ALAD in mice was 
determined by measuring ALAD enzyme activity. ALAD enzyme assays were 
conducted on red cells taken from mice 24 hours after receiving increasing 
amounts of SA delivered by intraperitoneal injection (i.p.). Results showed a dose 
of 160 mg/kg SA was required for near complete inhibition of red cell ALAD in 
C57BL/6 mice (Figure 5.4 A). This once-off dose inhibited red cell ALAD for 24 
hours, with ALAD levels back to control levels by four days (Figure 5.4 B). Red 
cell ALAD was fully inhibited in mice that received 160 mg/kg SA each day for 
seven days, with no significant differences in haematological cells due to the SA 
treatment compared to that of untreated mice (Table 5.2). Therefore to achieve 
sustained ALAD inhibition in the mouse, it was concluded that a daily dose of 160 
mg/kg was required. 
Effect of administration of SA in a murine model of malaria 
The antimalarial capacity of SA was then investigated in mice infected with a 
murine-specific species of malaria parasite, P. chabaudi. Based on the above-
demonstrated pharmacokinetic data, male C57BL/6 mice were given daily 
160mg/kg i.p. injections of SA (or saline treatment for controls) the day prior to 
and everyday for eight days during a P. chabaudi infection. The untreated control 
mice demonstrated a gradual increase in percentage of iRBCs (% parasitaemia), 
peaking at around 50% parasitaemia (Figure 5.5 A). At this point the adaptive 
immune system responds to plasmodial infection, killing parasites and resulting 
in a decline in infected red cells. C57BL/6 mice are known to be relatively 
resistant to P. chabaudi infection, and in these experiments, around 50% of 
saline-treated control mice survived infection (Figure 5.5 B). SA-treated mice 
had a lower overall % parasitaemia throughout infection, with a significant 48 
percent decrease in average parasitaemia than control mice at the peak of 
infection (Figure 5.5 A). Additionally, SA-treated mice were significantly more 
likely to survive infection than saline-treated controls (Figure 5.5 B). These 
results demonstrate that targeting ALAD with the specific inhibitor SA prevents 
severe in vivo malarial infection. 
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Figure 5.4. ALAD activity in red cells after treatment of mice with SA 
(A) ALAD activity in peripheral mouse blood 24 h after receiving varying doses of SA. 
ALAD activity was measured as the amount of porphobilinogen (µM) produced in one h 
at 3 7°C with data representing the average ALAD activity relative to control mice. Three 
mice per dose were injected i.p with SA; error bars are SEM. 
(B) Recovery of ALAD activity after a single 160 mg/kg i.p injection of SA (3 mice per 
time point). ALAD levels had returned to control ALAD activity by 4 days. Data 
represents the average ALAD activity (Porphobilinogen (µM) produced in one hat 37°C) 
relative to control mice; three mice per time-point were injected i.p with 160 mg/kg SA; 
error bars are SEM. 
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Table 5.2 Whole blood analysis of ALAD activity and haematological parameters of 
mice during SA treatment. Average ALAD activity (µM porphobilinogen produced, 
relative to the untreated control mice) was significantly impaired throughout the daily 
SA treatment of 160 mg/kg for seven days. Average haematological counts (±SD) 
showed no significant differences to that of untreated mice over the treatment period. 
Untreated Day1 DayS Day7 
ALAD activity 5.4 ± 6.1 1.44 ±4.9 10.49 ±4.95 (relative to control) 100 (negligible) (negligible) (negligible) 
Red blood cells 
(x1012 cells/L) 9.71 ±0.04 9.01 ±0.23 9.86 ±0.23 9.41 ±0.48 
Haemoglobin(g/L) 145.5 ±2.12 137 ±1.15 144 ±5.66 140.5 ±6.36 
Haematocrit(L/L) 0.49 ±0.01 0.46 ±0.01 0.49 ±0.01 0.47 ±0.03 
Mean corpuscular volume 
(fL) 50.3 ±0.99 51.35 ±0.06 49.7 ±0.42 49.55 ±0.35 
Mean corpuscular 
haemoglobin (pg) 15 ±0.14 15.25 ±0.29 14.4 ±0.57 14.95 ±0.07 
Mean corpuscular 
haemoglobin 298 ±2.83 296.3 ±6.35 294 ±8.49 300.5 ±3.54 
concentration (g/L) 
Corpuscular haemoglobin 
concentration mean (g/L) 283 ±2.83 280.5 ±1.73 283 ±5.66 280.5 ±0.71 
Corpuscular haemoglobin 
content (pg) 14.2 ±0.14 14.4 ±0.12 14 ±0.14 13.9 ±0.14 
Platelets (x109 cells/L) 1194 ±28.9 1022 ±123.5 1232 ±158.3 1391 ±265.1 
Percentage reticulocytes 
(%) 4±2 4 ±0.01 4 ±0.5 3 ±1 
109 
A B 
60 
so-
i 40 
·j 
CL 30. 
~ 
~ 
1 20 
JO 
,,, 
,' 
' 
,t 
, \ 
,,' \ 
, \ 
, \ 
J' \ , \ 
, \ 
,' \ 
,' 
,r'' 
, 
-3day -2day -1day peak +lday +2day 
Day of infection 
100 
90 
80 
60 
50 
-SA treated 
---·Control 40 
10 
10 
Lh I .__ __ _ 
I 
I 
I 
I 
I 
I 
.. , 
'--, 
.. , 
'-------· 
10 15 zo 
OayoflnfMtion 
Figure 5.5 P. chabaudi infection kinetics and survival in SA-treated mice 
(A) Parasitaemia of P. chabaudi infected male mice receiving once-daily SA treatment 
mice for 7 days compared to saline-treated controls. Data represents the mean 
percentage of infected red cells in mice infected with P. chabaudi (1x105 iRBC/mL) and 
normalised for the peak of infection. There was a significant difference between SA-
treated and untreated control mice at the day prior to peak (P= 2.62084E-06) and the 
peak (P= 5.60601E-06) of infection; n=19 SA-treated mice; n=l8 untreated controls; 
Results are the average of two independent experiments; Error bars indicate SEM. 
(B) Survival of P. chabaudi infected male mice from the same experiment as (A). Mice 
were infected with P. chabaudi (as above) and monitored for survival over the time 
period indicated. There was a significant difference in survival between SA-treated and 
untreated control mice (P=0.005 using Mantel-cox Log-rank test of survival). 
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In vitro analysis of P. falciparum growth after NMPP treatment 
N-methylprotoporphyrin (NMPP) is an analogue of protoporphyin IX and is a 
competitive FECH inhibitor. The anti-plasmodial activity of NMPP was 
investigated in a direct P. falciparum growth inhibition assay, where ring-stage P. 
falciparum (3D7) parasites were cultured continuously in the presence of NMPP 
for 48 hours. There was a dose-dependent impairment of parasite growth, with 
an ICso of around 25 nM (Figure 5.6), a figure comparable with many current 
antimalarials. Further investigation of the individual growth stages 
demonstrated a dose-dependent decrease in the proportion of rings (at T=O) 
progressing through to trophozoites and schizonts at T=24 (Figure 5.7), 
indicating parasite growth impairment. There was also a lower percentage of 
new ring-stage parasites in the NMPP-treated cultures at T=48, but it could not 
be determined if invasion was being impaired or if NMPP was killing the seed 
parasites prior to invasion. As NMPP is a competitive inhibitor of FECH, the 
specific targeting of host FECH by preincubation could not be investigated. It is 
therefore possible that NMPP is targeting both host and parasite FECH. However, 
NMPP demonstrated potent anti-plasmodial activity, for which the parasite FECH 
could not compensate for. 
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Figure 5.6 Anti-FECH mediated growth inhibition of P. falciparum infected human 
red cells by N-methylprotoporphyrin (NMPP). 
Parasite growth inhibition (relative to untreated control), with increasing 
concentrations of NMPP. Assays were conducted using P. falciparum (3D7) parasites and 
growth determined after 48 hours incubation. 
Data represent the mean of two independent assays ( each concentration assayed in 
triplicate). Error bars indicate SEM. 
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Figure 5. 7 Individual growth stages of P. falciparum after NMPP treatment 
Average percent infected red cells (percent parasitaemia) including percent schizonts 
(S), trophozoites (T) and rings (R) at each time point after growth of P. falciparum in the 
presence of NMPP. Blood was infected at T=O with ring-stage parasites (at -1 % 
parasitaemia) . 
At T=24, there was no significant difference in total parasitaemia between any of the 
NMPP treatments and control. 
At T=48 there was a lower percent parasitaemia in cultures treated with NMPP 
concentrations of 1 nM and above (P=<0.01). There was also a dose-dependent 
decrease in percentage of new ring-stage parasites in cultures treated with NMPP 
concentrations of 1 nM and above (P=<0.05). 
Results are the averages of percent parasitaemia from triplicate cultures in one 
experiment; error bars are SEM. 
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In vitro analysis of P. falciparum growth after griseofulvin treatment 
A search for additional FECH inhibitors revealed that griseofulvin has anti-FECH 
activity that is a side effect of its normal antifungal activity, precluding its use by 
porphyria patients (Holley et al., 1991, Bellingham et al., 1995). Griseofulvin has 
been used to treat dermatophytoses by oral administration in people for over 50 
years (De Carli and Larizza, 1988). The drug concentrates in the keratinous layer 
of the skin, and targets fungal mitotic spindles (Develoux, 2001). The fungicidal 
activity of griseofulvin is independent of its FECH inhibitory capacity. 
Initial experiments with griseofulvin using the co-incubation growth inhibition 
assay (As for NMPP) showed no effect on parasite growth at a range of doses. 
However, reports in the literature suggest that griseofulvin is a pro-drug, binding 
to the haem moiety of haemoglobin or cytochrome P450 to form the alkylated 
porphyrin, NMPP (Bellingham et al., 1995). This process may require the 
accumulation of griseofulvin. Subsequently, uninfected red cells were pre-
incubated with griseofulvin for several days prior to parasite addition, with cell 
media and drug replacement every 24 hours. Using this assay, there was a dose-
dependent inhibition of P. falciparum 3D7 strain (chloroquine sensitive) at 48 
hours (Figure 5.8). Parasite growth inhibition with a similar ICso was also 
observed in a chloroquine resistant P.Jalciparum strain (Kl) (Figure 5.8). 
Analysis of griseofulvin in uninfected red cells using ultra performance liquid 
chromatography-mass spectrometry (UPLC-MS) demonstrated that the drug 
accumulates in red cells over several days of pre-incubation and constant co-
incubation (Figure 5.9). This is consistent with the parasite inhibitory effect only 
being observed after three days of pre-treatment in red cells. 
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Figure 5.8. Anti-plasmodial activity of griseofulvin 
-•- K1 
~307 
Parasite growth inhibition (relative to untreated control) in cells pretreated with 
griseofulvin. Red cells were pretreated in medium with griseofulvin for three days with 
medium replaced every 24 h prior to infection with parasites. The medium and 
griseofulvin was replaced at the time of parasite addition and every 24 h during 
subsequent culturing. Parasite growth was determined 48 h after infection. Two strains 
of P. falciparum were tested, 3D7 (chloroquine sensitive), and Kl (chloroquine 
resistant). Data represent the mean of two independent assays ( each concentration 
assayed in triplicate). Error bars indicate SEM. 
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Figure 5.9 Accumulation of griseofulvin in red blood cells 
UPLC-MS analysis of griseofulvin in red cells treated with 10 µM griseofulvin for up to 
five days, and sampled each 24 h. Griseofulvin-containing medium was replaced each 24 
h. Griseofulvin levels were quantified by comparison to a standard curve of known 
griseofulvin amounts. Each sample contains equal cell numbers; data represent the 
mean of three independent assays; error bars indicate SEM. 
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Ex vivo analysis of Plasmodium growth in red cells from griseofulvin-treated 
human volunteers 
After demonstrating antimalarial properties in vitro, most experimental 
compounds progress to animal studies of infection for drug safety and 
tolerability testing. However griseofulvin is FDA and TGA-approved for use in 
humans to treat fungal skin infections, has very mild or no side effects, and has 
been used safely in the clinic for over 50 years. Griseofulvin could therefore be 
administered to human volunteers to further investigate its anti-plasmodial 
activity. 
Two different dose regimens were used. Firstly, volunteers took a clinically 
standard oral dose of griseofulvin (500 mg/day) for seven days. Blood samples 
were collected from each patient prior to and at the conclusion of the seven-day 
treatment period. Following blood collection, both blood samples were washed 
three-times in RPMI medium to remove white-blood cells, platelets and residual 
griseofulvin present in the serum. P. falciparum (3D7) parasites were seeded 
into the blood samples and cultured for 24 hours. Parasites grew normally in the 
blood taken before the griseofulvin treatment, but were unable to grow in the 
cell collected after the seven-day treatment regimen (Figure 5.10 A). The number 
of parasites measured in the blood after griseofulvin treatment was less than the 
original number of seed parasites added. This suggests that the parasites were 
being killed and as well as growth retarded. 
In a second set of experiments, red cells were obtained everyday over the seven-
day dosing regime from one volunteer, in order to examine when the parasite 
growth inhibitory effect occurred. P. falciparum (3D7) parasites were again 
seeded into the blood samples immediately after collection and cultured for 24 
hours. A time course showed that the antiplasmodial effect was observed three 
days after the onset of griseofulvin treatment and parasite growth was fully 
inhibited by four days of treatment (Figure 5.10 B). UPLC-MS analysis showed a 
gradual accumulation of red cell griseofulvin, with the level peaking at three to 
four days, explaining the delay in the onset of parasite inhibition (Figure 5.11). 
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Figure 5.10. Parasite growth in red cells from human volunteers receiving 500 
mg/ day griseofulvin 
(A) Percentage of parasite growth in red cells collected from seven different individuals 
(A-G) after taking griseofulvin for seven days (500 mg/day). p < 0.01 for all seven 
individuals, comparing parasite growth in cells before and after treatment. 
(B) Percentage of parasite growth in red cells collected each day from an individual 
taking a five-day course of griseofulvin (500 mg/day). * p < 0.01 comparing growth in 
cells before and after treatment. 
Mean (± SD) initial percentage parasitaemia in all the assays was 1 % (±0.5%). Growth 
was determined (after 24 h) by subtracting the starting parasitaemia, and expressed as 
a percentage of parasitaemia in cells collected before the griseofulvin treatment (initial 
levels subtracted). Negative values reflect the reduction in numbers of parasitised cells 
from initial levels. Data represent the mean of 3 replicate cultures for each griseofulvin 
treated individual. Error bars indicate SEM. 
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Figure 5.11 Griseofulvin accumulation in red cells from a griseofulvin-treated 
volunteer 
UPLC-MS analysis of griseofulvin in red cells from an individual taking griseofulvin for 
five days (500 mg/day). Blood samples were collected and analysed at the indicated 
times, and quantified by comparison to a standard curve of known griseofulvin amounts. 
Data represent the mean of two independent assays. Error bars indicate SEM. 
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The previous data demonstrating that several days of treatment was required to 
see an anti-plasmodial effect, suggested that the accumulation of griseofulvin in 
the red cell may be the rate-limiting step. A once-off two-gram loading dose of 
griseofulvin was then administered to test if a higher dose of griseofulvin may 
result in more rapid accumulation inside the red cell and a therefore more rapid 
anti-plasmodial effect. Analysis of blood samples taken eight hours post 
treatment, from three different individuals, consistently demonstrated that they 
could not support parasite growth (Figure 5.12). Red cells from samples 
collected from these individuals at later time points (24, 48 and 72 hours) 
showed a progressively reduced capacity to prevent parasite growth (Figure 
5.13 A). 
Griseofulvin levels were quantified in samples from one of the volunteers 
receiving a once-off two-gram dose. UPLC-MS analysis demonstrated a spike in 
red cell griseofulvin at eight hours with a progressive decline in griseofulvin 
levels over the subsequent time points (Figure 5.13 B). The griseofulvin levels 
measured are consistent with the anti-plasmodial effect occurring at eight hours 
after the two-gram dose. Griseofulvin levels were not detectable in human red 
cells one-week post griseofulvin treatment. These results show that the two-
gram loading dose accumulates more rapidly in red cells, causing the crucial 
threshold for parasite killing to be reached at an earlier time-point. The growth 
inhibition effect declines over time, the antiplasmodial activity is present for at 
least two days. Therefore at clinical doses, administration of griseofulvin may act 
as an effective therapy against malaria infection. 
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Figure 5.12 Parasite growth in red cells from human volunteers eight-hours after 
a once-off two-gram dose of griseofulvin 
Percentage of parasite growth in red cells collected from individuals eight-hours after 
taking a single 2000mg dose of griseofulvin, relative to the untreated control blood form 
each individual. 
Data represent the mean of three replicate cultures in blood from three individuals. 
Error bars indicate SEM. In all three individuals, p < 0.01 comparing growth in cells 
before and after treatment. 
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Figure 5.13 Parasite growth and griseofulvin levels in red cells from human 
volunteers up to 72 h after a once-off two-gram dose of griseofulvin 
(A) Percentage of parasite growth in red cells collected from individuals taking 
griseofulvin at indicated time-points after a single dose (2000 mg) of griseofulvin. Data 
represent the mean of 3 replicate cultures for three individual volunteers receiving a 
once-off 2000mg dose of griseofulvin. Error bars indicate SEM. * p < 0.01 comparing 
growth in cells before and after treatment. 
(B) UPLC-MS analysis of griseofulvin in red cells from one individual taking a once-off 
2000mg dose of griseofulvin. Blood samples were collected and analysed at the 
indicated times, and quantified by comparison to a standard curve of known griseofulvin 
amounts. Data represent the mean of three independent assays. Error bars indicate SEM. 
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Discussion 
Studies presented in chapters 3 and 4 of this thesis demonstrate that the host 
enzymes ALAD, FECH and UROS are localised in the intraerythrocytic parasite 
and that host FECH and UROS are required by the parasite for normal growth. It 
was therefore hypothesised that these host haem synthetic enzymes are 
essential growth factors for the parasite. To test this hypothesis further, and 
pave the way for the development of novel anti-malarial lead compounds, work 
in this chapter tested if pharmacological inhibitors of these enzymes could 
prevent parasite growth. The results showed that SA, a specific and irreversible 
inhibitor of ALAD, and NMPP, a substrate analog inhibitor of FECH were potent 
anti-plasmodial agents in a P. falciparum in vitro growth inhibition assay. The 
irreversible nature of SA provided a means to directly demonstrate that 
specifically targeting the red cell ALAD prevented parasite growth. SA was also 
administered to mice infected with P. chabaudi, and significantly improved 
outcome to infection (survival) and reduced parasite growth. Lastly, griseofulvin 
demonstrated novel anti-plasmodial properties in vitro and in red cells collected 
from human volunteers taking pharmacologic doses of griseofulvin. 
Specific inhibition of host ALAD with SA prevents parasite growth 
This chapter has established that the ALAD inhibitor SA blocks P. falciparum 
growth using in vitro and in vivo models. SA demonstrated antimalarial activity 
when directly added to P. falciparum cultures with an ICso of 12.5 µM. As the 
parasite contains a gene encoding ALAD, the anti-plasmodial effect of SA could be 
due to targeting the host, parasite or both species of enzymes. Subsequent 
experiments investigated parasite growth after specific inhibition of host ALAD. 
Uninfected red cells were preincubated with SA for several hours prior to 
removal of excess unbound SA and addition of parasites. Results demonstrate 
significant growth impairment 48 hours after the addition of parasites, 
suggesting that the antimalarial effect of SA is due to the specific inhibition of 
hostALAD. 
Closer analysis of the individual intraerythrocytic parasite stages demonstrated 
the progression from ring to late-stage parasites was impaired in a dose-
dependent manner by SA, indicating impaired growth. Results here also 
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indicated that invasion was reduced in drug-treated cultures, evidenced by the 
lower proportion of new rings in drug treated-cultures compared to the 
untreated control. The reduction in rings is likely to be due to impaired invasion, 
rather than direct killing of the seed parasites, as the trophozoite-infected red 
cells used to seed the culture are growing in SA untreated red cells and can 
therefore be presumed to have normal growth and merozoite formation. 
SA has previously demonstrated parasite growth inhibition in vitro 
(Dhanasekaran et al., 2004) the investigations in this chapter have shown the 
anti-plasmodial effect is due to targeting of the host enzyme, resulting in both 
impaired invasion and growth. The impaired invasion was a surprising finding 
and has not been previously been demonstrated but is consistent with findings 
from the previous chapter where parasite invasion was also impaired in FECH 
and UROS deficient red cells. An alternative explanation is that the impaired 
parasite invasion may be due to a direct effect of SA on the host red cell, making 
the red cell cell inhospitable for normal parasite development. This may be in 
addition to the parasite scavenging inhibited ALAD. Regardless of either 
proposed mechanism, the results indicate that invasion is impaired after SA 
treatment and any parasites that succefully invade the red cell are further 
impaired in their intraerythrocytic development. 
The anti-plasmodial activity of SA was also tested in vivo using P. chabaudi, a 
mouse model of malaria. Results demonstrated the SA-treated mice had a 
significantly lower course of infection and increased survival compared to the 
untreated controls. This effect may be due to inhibition of host or parasite ALAD. 
However the previous pre-incubation experiment specifically targeting host 
ALAD, demonstrated that the majority of antimalarial activity of SA comes from 
inhibition of the host ALAD. Considering the similarity of P. Jalciparum and P. 
chabaudi, the inhibition of parasite growth due to host ALAD targeting may also 
translate into the mouse model. 
In vitro parasite growth is impaired NMPP 
This chapter demonstrated that NMPP, a specific FECH inhibitor, blocks the 
intraerythrocytic development of P. falciparum in vitro. The drug was directly 
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incubated with ring-stage parasites and 48 hours later, there were significantly 
less new ring-stage parasites in drug-treated cultures incubated with NMPP (1 
nM and above) compared to the untreated control. This indicates invasion may 
be impaired, but this may also be a consequence of delayed parasite growth in 
the first 24 hours of incubation. Overall, NMPP significantly impaired parasite 
intraerythrocytic development in the growth inhibition assay with an ICso of 25 
nM, comparable with several current antimalarials. As NMPP is a competitive 
inhibitor, unlike SA, specific targeting of the host enzyme was unable to be 
investigated. Therefore NMPP may be targeting both host and parasite FECH. 
However, results from the previous chapter demonstrated that host FECH is 
required for normal Plasmodium intraerythrocytic infection, as parasites 
displayed impaired growth in EPP red cells. The main effect of NMPP-mediated 
FECH inhibition is therefore likely to be targeting of the human enzyme. Overall, 
regardless of the species of enzyme inhibition, this work has demonstrated that 
FECH is a potential antimalarial target and that NMPP possesses potent anti-
plasmodial activity in vitro. Future work will continue to investigate the anti-
plasmodial activity of NMPP in vivo, using the P. chabaudi murine model of 
infection, as for SA. 
Griseofulvin has both prophylactic and fast-acting treatment properties 
Griseofulvin is a pro-drug that forms the FECH inhibitory compound NMPP, 
independent of its normal antifungal activity. This drug is routinely used to treat 
human fungal skin infections caused by dermatophytes but is contraindicated in 
people with porphyria because of its FECH inhibitory side effect. This compound 
was initially tested in the standard Plasmodium co-incubation assay ( as 
performed for NMPP) with no demonstrable effect. Literature suggests that 
griseofulvin reacts with the haem moiety of cytochrome C or haemoglobin to 
form NMPP (Bellingham et al., 1995, Cole and Marks, 1984). The concentration 
and accumulation of griseofulvin may affect the rate of NMPP formation. 
Therefore in the co-incubation assay, griseofulvin may not have had time to 
accumulate and form the inhibitory compound NMPP, thus explaining why no 
growth inhibition was observed. 
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Subsequently, red cells were pre-incubated with griseofulvin for three days prior 
to the addition of parasites (to allow for maximal drug accumulation), resulting 
in marked anti-parasitic effects. Griseofulvin demonstrated an ICso between 10 
and 50 µM, with similar efficacy against chloroquine sensitive and resistant 
parasites. Furthermore, measurement of griseofulvin in red cells demonstrated 
that a minimum of three days of griseofulvin pretreatment is needed to achieve 
maximal loading in red cells. Parasite growth inhibition is therefore dependent 
on the accumulation on griseofulvin in red cells and may explain why 
griseofulvin has not been previously identified in large-scale screens for new 
antimalarial agents from currently FDA-approved drugs. 
As griseofulvin is FDA and TGA-approved for human use, its anti-plasmodial 
properties were further investigated in red cells from human volunteers 
receiving the drug. Parasites were not able to grow in red cells from human 
volunteers after seven days of daily griseofulvin (500 mg/day) and the anti-
parasitic effect was demonstratable from three days, coinciding with the peak in 
red cell griseofulvin level. These results indicate griseofulvin may be useful as a 
prophylactic agent. Griseofulvin is well tolerated, as evidenced by the extended 
period of time (months or longer) that human patients take griseofulvin to treat 
fungal skin infection. Therefore, griseofulvin could be taken at least three days 
prior to potential Plasmodium exposure and ongoing preventative treatment 
could be sustained for long periods oftime. 
Results from this chapter indicate that griseofulvin requires several days to 
accumulate in red cells to form the active FECH inhibitor NMPP. Considering the 
accumulation of griseofulvin may be the rate-limiting step, a higher loading dose 
of griseofulvin was investigated to see if there was also a more rapid 
accumulation of the drug and therefore more rapid antimalarial response. Red 
cells collected from volunteers eight hours after receiving a once-off two-gram 
oral dose of griseofulvin were resistant to parasite growth, with an observable 
effect sustained up to 48 hours after the once-off dose. This was explained by 
further griseofulvin quantification, demonstrating a peak in red cell griseofulvin 
levels at eight hours, followed by a subsequent decline corresponding to the 
decrease in anti-parasitic effect. Note that these parasite growth experiments 
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were performed in vitro on purified and washed erythrocytes from griseofulvin-
treated human volunteers in the absence of additional exogenous griseofulvin, 
therefore the growth inhibition is reliant on residual accumulated erythrocytic 
griseofulvin. 
This work demonstrates griseofulvin accumulates in the red cell prior to 
observable anti-parasitic effects in vitro, but attempts to measure NMPP 
formation in griseofulvin treated red cell were unsuccessful. A UPLC-MS method 
developed by Noel Davies (Central Science Laboratory, University of Tasmania) 
detected NMPP in uninfected red cells spiked with known NMPP quantities but 
was unable to detect NMPP formation in red cells pretreated with griseofulvin. A 
potential problem is that NMPP is likely bound in a haem complex in the red cells 
and future work will attempt to proteolyse the complex to measure NMPP. 
A host or parasite-targeted therapy? 
The aim of this thesis was to investigate targeting host enzymes that the parasite 
requires as a novel host-directed antimalarial therapy. Previous chapters of this 
thesis report that host ALAD, FECH and UROS are localised in the parasite during 
growth and additionally that host UROS and FECH are necessary for 
intraerythrocytic infection of red cells. Work in this chapter targeted ALAD and 
FECH with chemical inhibitors. In the case of ALAD, SA inhibition of the host 
enzyme resulted in parasite growth inhibition but SA treatment in the mouse 
model may have been targeting host or parasite ALAD. Additionally, FECH 
inhibition with NMPP and griseofulvin could not differentiate between host and 
parasite FECH. Therefore, this thesis cannot rule out the possibility that there is 
some parasite ALAD or FECH contributing to haem synthesis in the parasite and 
that these drugs may act through targeting both parasite and host enzymes. 
Additionally, it is theoretically possible for the parasite to develop resistance by 
increasing the expression of its own gene during blood-stage infection. However, 
it is likely that these drugs would still target the parasite enzyme as well, 
ensuring that the parasite would need to accumulate mutations in the parasite 
genes to overcome this type of therapy. Therefore although resistance is 
possible, it would likely take considerable time. 
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UROS was a third host target in the haem biosynthetic pathway that was 
localised in Plasmodium and required for normal parasite growth. As the parasite 
does not contain a gene coding for UROS, this enzyme is an ideal target for a 
host-directed therapy as resistance is unlikely. Unfortunately there were no 
commercially available inhibitors and collaboration with a chemistry team to 
make compounds also failed to yield any compounds. Recently, a compound 
called sampangine was identified as a UROS inhibitor (Huang et al., 2011), and 
future work will investigate its potential anti-plasmodial properties. 
Considering the widespread drug resistance to all current antimalarials and the 
lack of new antimalarial compounds in the drug-discovery pipeline, results in 
this thesis have demonstrated several novel targets for antimalarial therapeutic 
intervention. Additionally, as griseofulvin is already FDA-approved for human 
usage, phase I clinical trials can be bypassed enabling a more rapid and cost-
effective route for the introduction of a novel antimalarial agent. 
Summary 
Overall this chapter investigated pharmacological targeting of the host haem 
enzymes ALAD and FECH as a novel antimalarial treatment. Results 
demonstrated that chemical inhibition of host ALAD (with SA) or host FECH 
(with NMPP or griseofulvin) results in P.falciparum growth inhibition in vitro. SA 
also showed in vivo antimalarial activity in a murine model of malaria, protecting 
mice from severe infection. This chapter has also shown that clinical doses of 
oral griseofulvin render the red cells of a human volunteer resistant to parasite 
growth. This data indicates that griseofulvin has potential as both a prophylactic 
and an acute antimalarial treatment. Griseofulvin is already FDA and TGA-
approved for human use, paving the way for further investigations of the 
antimalarial treatment capacity of this compound in humans. An exciting future 
prospect of this work is a phase II B clinical trial of this compound, in 
collaboration with James McCarthy at the University of Queensland. This thesis 
has provided novel evidence that griseofulvin could also be a useful antimalarial 
drug; with a novel mode of action that potentially avoids parasite resistance. 
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Chapter 6 - Final discussion 
Malarial parasites have developed resistance to all current antimalarial 
therapies. All of these drugs target parasite enzymes or processes, thereby 
selecting for mutant, resistant parasites. New antimalarials are desperately 
needed and a potential clue for a new therapeutic strategy has been provided by 
so-called "natural genetic antimalarials". Host genetic changes to red cell genes 
have offered millennia of stable protection to individuals living in endemic 
regions. By imitating natural resistance, the work described in this thesis 
proposed a novel host-directed antimalarial therapy through the targeting of 
erythrocytic molecules required by Plasmodium for growth and survival. 
Here, multiple experimental approaches were used to investigate and validate 
several enzymes from the haem biosynthetic pathway as targets for a novel host-
directed antimalarial therapy. Firstly, it was demonstrated that the host haem 
synthetic enzymes ALAD, FECH and UROS are localised in Plasmodium during 
intraerythrocytic growth. Moreover, parasites showed impaired growth in red 
cells deficient in UROS and FECH, using both human and mouse genetic models 
of haem enzyme deficiency. Finally, the HDT strategy was validated with several 
inhibitors of ALAD and FECH demonstrating in vitro and in vivo antimalarial 
activity. One of these inhibitors, griseofulvin is of particular interest considering 
it is already FDA and TGA approved for human use. The anti-FECH activity of 
griseofulvin is a side effect additional to its normal antifungal activity. This drug 
has been used over the last 50 years to treat human skin infections caused by 
certain species of dermatophytes. Griseofulvin was demonstrated to have novel 
antimalarial activity in vitro ( on both chloroquine susceptible and resistant 
parasites) and additionally in red cells from human volunteers receiving 
pharmacological doses of griseofulvin. Parasites were unable to grow in red cells 
collected from human volunteers eight-hours after taking a clinically relevant 
dose of griseofulvin. Overall, this work has provided proof-of-concept that an 
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HDT is a feasible approach to antimalarial treatment and also demonstrated 
griseofulvin has potential clinical benefits as an antimalarial. 
Host haem enzymes are required for parasite growth 
Work in this thesis initially demonstrated that the host haem biosynthetic 
enzymes ALAD, FECH and UROS are localised in the intraerythrocytic parasite 
during the late stages of growth. This supports previously published work, 
demonstrating that host ALAD and FECH are scavenged by the parasite (Bonday 
et al., 2000, Dhanasekaran et al., 2004, Varadharajan et al., 2004). Questions 
remain about the mechanism of transport into the parasite, final parasite 
compartment localisation and the functional requirement of these host enzymes. 
Evidence presented in this thesis established that host FECH, UROS and ALAD 
are essential factors for normal parasite growth. This was demonstrated using 
genetic models of human and mouse haem synthetic enzyme deficiency for UROS 
and FECH. Human red cells deficient in UROS or FECH were unable to sustain 
normal parasite infection, with substantial Plasmodium growth impairment at all 
stages of development compared to normal control blood. Further work in this 
thesis provided evidence that the parasite growth inhibitory effect in EPP cells 
was due to FECH deficiency, irrespective of protoporphyrin substrate levels. An 
important role for host FECH in malarial infection was also confirmed in a mouse 
model of FECH deficiency, demonstrated by the severe growth impairment of P. 
chabaudi in Fech-1- (with 5% residual FECH activity) compared to normal wild-
type control mice. Results were irrespective of sex, with both male and female 
Fech-1-mice demonstrating resistance. A similar level of resistance was observed 
on both isogenic and mixed backgrounds, demonstrating parasite growth 
impairment in Fech-1- mice is irrespective of the genetic background of the host. 
Furthermore, host ALAD was shown to be essential for normal parasite growth, 
as pharmacological inhibition of the host enzyme inhibited both parasite 
invasion and growth. A final question remains if the absence or inhibition of the 
host enzyme is having a direct effect on the mature red cell, making it 
inhospitable for parasite growth. This may be independent of, or in addition to 
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the host enzyme being scavenged by the parasite. Overall, this work has 
confirmed that host FECH, UROS and ALAD are vital for normal parasite growth, 
indicating they play an important functional role. 
Implications of targeting host haem enzymes 
Current antimalarials target parasite specific enzymes or processes, but many of 
these parasite-directed drugs still exhibit toxic side effects to the host. A host-
directed therapy has been proposed here, as a novel antimalarial strategy to 
potentially avoid parasite resistance, however the potential side effects of 
targeting host enzymes must also be considered. Most of the enzymes in the 
mature red cell are purely residual, left over from development (i.e. the red cell is 
not actively synthesizing the target enzymes). Other cells that may be affected by 
a HDT, like hepatocytes and erythroblasts, are continually synthesising new 
enzymes, meaning the largest impact of such a therapy will be felt by the mature 
red cells. This is exemplified by griseofulvin, which inhibits FECH as a side effect 
to its normal antifungal activity. Human patients taking griseofulvin to treat 
dermatophyte skin infections can take up to one gram per day for up to several 
months at a time and do not display porphyric symptoms due to impaired FECH 
( except if patients already have a FECH deficiency). This indicates that other sites 
of haem synthesis, such as the liver and erythropoietic progenitor cells are not 
affected by griseofulvin treatment. While griseofulvin is not an irreversible 
inhibitor, this thesis has shown that it accumulates in red cells over a course of 
500mg per day and also after a once-off 2000 mg dose. This compound has 
sustained activity in the red cell, as shown by the antimalarial effects still evident 
48 h after the once-off dose was taken by human volunteers. This provides 
further evidence that a HDT targeting haem synthetic enzymes is a feasible 
approach to antimalarial treatment without severe side effects to the host. 
Irreversible inhibitors of haem synthetic enzymes (such as SA) could also be 
useful antimalarials. An irreversible inhibitor will permanently inactivate its 
target enzyme in the red cell, meaning the red cell may be refractory to infection 
for its lifespan (about 120 days). This could lead to a HDT being used 
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intermittently (perhaps weekly or biweekly), which would mean fewer side 
effects, better compliance and a lower cost to the patient. In the case of SA, the 
potential side effects may be anticipated from people with hereditary 
tyrosinemia. These patients have abnormal tyrosine metabolism and produce 
excessive SA, resulting in ALAD inhibition. While this is an extreme example, 
there are side effects due to the sustained ALAD inhibition over the life of the 
patient. Intermittent antimalarial treatment with SA would not result in severe 
side effects as seen in hereditary tyrosinemia and combined with correct dosing 
and drug design modifications, could ideally eliminate potential side-effects. 
A potential role for host haem enzymes in the liver stage of malarial infection 
Apart from red cells, the liver is the other site of Plasmodium infection in the 
human host. Coincidently, the liver is also the other main site of haem synthesis, 
where haem is required as a cofactor for several cytochromes. Like in the red 
cell, the parasite may also scavenge and use the host haem synthetic enzymes to 
supplement its own metabolic pathways during exoerythrocytic development. 
While P. chabaudi was used in this study to investigate in vivo blood stage 
infection, another murine model of malaria, P. berghei, may serve as a useful tool 
to investigate the potential role host haem enzymes play in the liver stage of 
infection. P. berghei is widely used as a rodent model of the liver stage in malaria. 
Future experiments using both P. berghei and the variety of available haem 
deficient mouse models and inhibitors described in this thesis may open up a 
new line of investigation into the importance of host haem enzymes in the liver 
stage of malarial infection. If the parasite relies on scavenging host haem 
enzymes during the liver stage of infection, targeting host enzymes in this stage 
may eliminate the progression of infection prior to the symptomatic red cell 
stage. 
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Over 700 other potential red cell targets for a host-directed therapy 
Alongside the haem synthetic enzymes investigated in this thesis, there are a 
multitude of other potential HDT candidates in the red cell. Several other red cell 
proteins have been demonstrated to be required for parasite invasion, growth or 
egress. These include superoxide dismutase, peroxiredoxin-2, calpain-1, 
erythrocyte G protein, host protein kinases and basigen (Fairfield et al., 1983, 
Koncarevic et al., 2009, Chandramohanadas et al., 2009, Murphy et al., 2006, 
Crosnier et al., 2011, Sicard et al., 2011). Any of these proteins could be potential 
host-targets for a novel antimalarial therapy. Additionally, several proteomic 
studies have predicted around 700 other enzymes (Alvarez-Llamas et al., 2009, 
Goodman et al., 2007, Kakhniashvili et al., 2004, Pasini et al., 2006, Roux-Dalvai 
et al., 2008) in the mature red cell. Future work could take a candidate approach 
to investigate the importance of other host red cell enzymes in malarial infection. 
In a technique recently described, each of these proteins in mature red cells 
could be systematically immunodepleted, resealed and infected in vitro with P. 
falciparum, with subsequent growth kinetics investigated (Chandramohanadas 
et al., 2009, Murphy et al., 2006). Further investigations into the role of host red 
cell enzymes may reveal new insights into host-parasite biology in addition to 
the identification of potential new antimalarial targets. 
An additional technique to investigate novel potential host targets is that of 
chemical mutagenesis screens. N-ethyl-N-nitrosurea (ENU) is a chemical agent 
inducing random mutations in the germ-line of mice. Progeny of END-treated 
mice may be screened for malaria susceptibility (to P. chabaudi) and red cell 
phenotype. Mice that demonstrate malarial resistance can be sequenced to 
identify the responsible gene. This is a powerful unbiased approach currently 
being undertaken in the Foote laboratory that may be useful in identifying new 
host targets for a novel HDT. 
Conclusions 
Work described in this thesis has demonstrated that the host haem synthetic 
enzymes ALAD, UROS and FECH are localised in the Plasmodium parasite during 
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intraerythrocytic growth. Genetic knockdown of enzyme activity and 
pharmacologic targeting of the host haem synthetic enzymes resulted in 
impaired Plasmodium growth, indicating their requirement as essential host 
factors during intraerythrocytic parasite development. This work has also 
identified griseofulvin as a potential new antimalarial compound. Griseofulvin is 
an FDA and TGA-approved drug that may be a useful new generation "off the 
shelf' antimalarial agent. Overall, this work has validated a host-directed therapy 
as a novel antimalarial strategy, paving the way for host-directed antimalarial 
treatments as a new therapeutic field, which may avoid parasite resistance 
common to the current range of antimalarials. 
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